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Abstract
Purpose: Refractory temporal lobe epilepsy associated w ith hippocampal sclerosis 
(TLE-HS) affects about 30% of TLE patients, where antiepileptic drugs are not effective 
in controlling seizures. These patients become candidates for surgical treatm ent which 
is effective in only 60-70% of cases. In addition, surgical treatm ent causes memory and 
cognitive impairments as well as psychopathological disturbance. Therefore, the aim of 
this study is to investigate potential biomarkers in surgically resected sclerotic TLE-HS 
(n = 49) and non-spiking superior temporal gyrus samples (TLE-STG; n = 25) from TLE 
patients and post-mortem  hippocampi (PMC; n = 10), in order to increase our 
understanding of refractory TLE pathophysiology and help in identifying new potential 
drug targets for treatm ent of TLE patients. Methods: GABAb receptor subunits were 
investigated in TLE-HS, TLE-STG and PMC tissue by quantitative real time polymerase 
chain reaction (qRT-PCR) and quantitative western blot (WB) techniques. Alterations in 
expressions of SGK1, SCN4B, IP3R1 and SYNPR were investigated in TLE-HS, TLE-STG 
and PMC specimens by qRT-PCR and WB. The transcriptome profiling of TLE-HS, TLE- 
STG and PMC samples was done by microarray analysis (MA). MA was followed by 
functional annotation clustering analysis (FAC) of the MA differentially expressed 
genes (DEGs). Genes from FAC analysis were further investigated by qRT-PCR. MA 
Aquaporin (AQP1, 3, 4, 5, 8, 9, 11) expressions were further validated by qRT-PCR. 
Results: Expression of the inhibitory GABAB2 receptor subunit was significantly up 
regulated in TLE-HS compared to PMC but its expression was reduced in TLE-HS 
compared to TLE-STG.The expression of SCN4B, IP3R1 and SYNPR, which are involved 
in regulating neuronal excitability, were significantly reduced in TLE-HS compared to 
TLE-STG and were significantly increased compared to PMC. The expression of SGK1 
mRNA was significantly increased in TLE-HS compared to both TLE-STG and PMC. MA 
analysis revealed 1821 genes were significantly up regulated and 1511 genes were 
significantly down regulated in TLE-HS compared to TLE-STG and PMC. The first cluster 
from FAC analysis of DEGs showed that the up regulated inflammatory genes such as 
cytokines had the highest enrichment score. The qRT-PCR data showed tha t expression 
of IL-lp, IL-18, Fas, ICAM-1, CCL2, CCL4, CXCL1, CXCL2, CXCL12, CXCR4 and CX3CR1 
were significantly higher in TLE-HS compared to TLE-STG and PMC therefore validating 
MA data. AQP1 and -4, which are involved in water homeostasis, were significantly up 
regulated in TLE-HS compared to TLE-STG. AQP11 expression was significantly reduced 
in TLE-HS while AQP3, -5, -8 and -9 were not significantly altered in TLE-HS compared 
to TLE-STG and PMC. Discussion: The significant dysregulation of biomarker expression 
investigated in this study indicate that d ifferent biological processes such as neuronal 
excitability, neuronal and astrocytic energy metabolism, neurogenesis, apoptosis, 
neuroinflammation, intracellular calcium and water homeostasis are affected in the 
epileptogenic TLE-HS tissue. These biomarkers seem to be associated w ith TLE-HS 
pathophysiology. Furthermore, they highlight the role of neuronal, astrocytic, 
microglia and endothelial cell dysfunction in TLE-HS pathology. In conclusion, the 
biomarkers investigated increased our understanding of biological processes affected 
in TLE-HS pathophysiology and they represent potential drug targets for refractory TLE- 
HS. However, further research is still needed to understand the temporal and spatial 
changes of those genes and their proteins during TLE.
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1 General Introduction
1.1 Epilepsy
Epilepsy is a common neurological condition that is defined by a tendency to have 
recurrent unprovoked seizures. The International League Against Epilepsy (ILAE) 
defines epilepsy as "Epilepsy is a disease o f the brain defined by any o f the fo llow ing  
conditions: (1) A t least two unprovoked (or reflex) seizures occurring >24 h apart. (2) 
One unprovoked (or reflex) seizure and a probability o f fu rthe r seizures sim ilar to the 
general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the 
next 10 years. (3) Diagnosis o f an epilepsy syndrome" (Fisher et a!., 2014).
Epilepsy affects about 0.8 % of the human population and its prevalence in the UK is 
estimated to be about 0.5 -  1 % of the population (Pitkanen and Sutula, 2002; 
Smithson and Walker, 2012; Rang et al., 2014; Johnson et a!., 2015). According to 
Epilepsy Action; in the UK, 600,000 or one in every 103 people have epilepsy 
(www.epilepsy.org.uk).
An important concept that must be clarified is the difference between epilepsy and 
acute symptomatic seizures. In epilepsy the seizures are frequent and unprovoked 
while acute symptomatic seizures are triggered and provoked by a specific cause such 
as hypoglycaemia, fever or head injury. Epileptic seizures are brief w ith a sudden onset 
and normally are divided into phases; the pre-ictal, ictal, post-ictal and inter-ictal 
phases (Rang et al., 2014). The epileptic seizure is caused by synchronised excessive 
discharge of action potentials or impulses from a group of neurons in the brain. This is 
due to abnormal neuronal firing from excitatory neurons, reduced inhibition or both.
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The underlying mechanism of epileptic seizure is still poorly understood (Smithson and 
Walker, 2012; Rang et al., 2014).
The prognosis of epilepsy depends upon many factors such as gender, age, genetic 
background and the cause of epilepsy. A study done on the population of Rochester, 
Minnesota, USA, found that the risk of developing epilepsy increased w ith age in both 
males and females. It also found that males had higher risk of developing epilepsy 
compared to females in the same age group (Hesdorffer et al., 2011).
In addition to the fact that epilepsy has a significant negative effect on individuals' 
social lives, it has a high m ortality rate due to accidents, suicides and sudden 
unexpected death in epilepsy (SUDEP) (Smithson and Walker, 2012).
1.2 Classification of epilepsy
The classification of epilepsy is d ifficult and complicated. However, it has been 
clinically classified into two broad categories partial and generalized seizures based on 
the origin of seizure in the brain, and the speed and distance over which it spreads. 
Some seizures start as partial then become generalized seizures as in tonic-clonic 
seizures (Berg and Scheffer, 2011; Smithson and Walker, 2012).
1.2.1 Partial or focal seizures
Partial seizures originate from a localized cortical area in the brain and they normally 
affect one hemisphere. They account for 60 % of all adult epilepsy cases. Partial 
seizures are further divided into:
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•  Simple partial seizures: they are brief, intense, stereotypical, and there is no 
loss of consciousness.
•  Complex partial seizures: there is loss of consciousness in addition to confusion 
after the seizure.
•  Secondary generalized seizures begin as partial and then spread to both 
hemispheres (Berg and Scheffer, 2011; Smithson and Walker, 2012; Tellez- 
Zenteno and Hernandez-Ronquillo, 2012).
1.2.2 Generalized seizures
Generalized seizures originate from a local brain area, then they spread to both 
hemispheres and they normally affect the whole brain. The two most common types of 
generalized seizures are tonic- clonic seizure and absence seizures (Berg and Scheffer, 
2011).
1.3 Temporal lobe epilepsy
Temporal lobe epilepsy (TLE) is one of the most common partial seizures as 60% of all 
partial seizures originate from the temporal lobe. TLE often starts as a simple partial 
seizure that extends to become a complex partial seizure (Smithson and Walker, 2012; 
Tellez-Zenteno and Hernandez-Ronquillo, 2012). According to the ILAE (2010), TLE is 
classified into 3 main types:
1. Mesial temporal lobe epilepsy (MTLE): seizures start from
amygdalohippocampal area (hippocampus, parahippocampal gyrus and 
amygdala).
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2. Lateral temporal lobe epilepsy (LTLE): seizures start from the neocortex lateral 
to the temporal area.
3. Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS): it is one 
of the most common types of epilepsy referred to surgery and it is often 
refractory to antiepileptic drugs (Bliimcke et a!., 2012; Tellez-Zenteno and 
Hernandez-Ronquillo, 2012).
The common symptoms in TLE include m otor arrest followed typically by chewing, lip 
smacking and swallowing, fiddling with the hands, illusions, auditory hallucinations and 
complex visual hallucinations (Smithson and Walker, 2012).
1.4 Temporal lobe epilepsy pathogenesis
In most patients w ith symptomatic TLE, the epileptic process includes three phases: 
the epileptogenic lesion, the latent period and the development of seizures and 
epilepsy as in figure 1.1. In the epileptogenic lesion phase there is an identifiable 
brain-damaging insult that is thought to underlie the cause of seizures. This brain 
injury could be a brain infection, a stroke, a head trauma or status epilepticus (SE). SE 
is a life threatening condition characterized by a continuous seizure activity w ithout 
recovery of consciousness (Pitkanen and Sutula, 2002; Kuruba et a!., 2009).
Following the epileptogenic lesion comes the latent period where there are no 
seizures. The epileptogenesis process starts when the epileptogenic lesion triggers a 
cascade of neurobiological events leading to the development of spontaneous seizures 
and the diagnosis of epilepsy. A fter the diagnosis of epilepsy patients are treated w ith 
antiepileptic drugs (Pitkanen and Sutula, 2002; Kuruba et al., 2009).
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Figure 1.1 TLE pathogenesis
TLE pathogenesis includes an epileptogenic lesion, latent period and development of 
spontaneous seizures. Adapted from Pitkanen and Sutula (2002).
1.5 Temporal lobe epilepsy drug treatment
1.5.1 Neuronal action potential:
Epileptic seizures are caused by excessive discharge of action potentials. Therefore to 
treat epileptic seizures, it is vital to understand what a neuronal action potential is and
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how it is generated. An action potential is a pulse of electrical activity which is very 
important in neuronal communication. It starts at the axon initial segment then 
propagates along the axon to the nerve terminal. At the nerve term inal it activates 
voltage-gated calcium channels, which play a major role in the release of synaptic 
vesicles containing neurotransmitters into the synapse (Lai and Jan, 2006).
Normally at resting potential - 70 mV there are: high extracellular sodium ion (Na+) 
concentration and high intracellular potassium ion (K+) concentration, which is 
maintained by Na+/K+ ATPase activity. At this stage both voltage-gated Na+ and K+ 
channels are closed as in figure 1.2. When a stimulus is strong enough to reach the 
threshold (- 50 mV), it opens the voltage-gated sodium channels (Nav) allowing the 
influx of Na+ inside the cell. This results in membrane depolarization. The sodium ions 
will continue flowing into the cell until the membrane potential reaches +40 mV. Then 
the Nav channels become inactive and the voltage-gated potassium channels (Kv) open 
allowing the flux of K+ ions outside the cell. This results in the membrane repolarisation 
and leading to hyperpolarisation. The hyperpolarisation stage is also known as 
refractory period (Na channels are inactive) where the cell can not fire another action 
potential. Then the Na+/K+ ATPase will help in returning the membrane to its resting 
potential and Nav channels will return to the ir closed position (Namadurai et ol., 2015)
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Figure 1.2 Schematic presentation of the main events in a neuronal action potential
The neuronal action potential phases include: (a) Resting potential, where both Nav 
and Kv channels are closed, (b) Depolarization following a stimuli, where Nav channels 
open causing the influx of Na+ in the cell, (c) Repolarisation, where Nav channels 
become inactive and Kv channels open allowing the flux o f K+ ions, (d) Return to resting 
potential after hyperpolarisation, Nav channels change into the ir closed conformation. 
Adapted from Namadurai et al. (2015).
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1.5.2 Antiepileptic drugs (AEDs)
The purpose of giving antiepileptic drugs (AEDs) is to reduce the synchronised 
excessive discharge of impulses firing from the neurons during seizures w ithout 
affecting the normal non-epileptic impulses. This is achieved by acting on one or many 
molecular targets such as ion channels, neurotransm itter transporters and metabolic 
enzymes at the same time (Rogawski and Loscher, 2004). The AEDs available on the 
market today work with a diverse mechanism of actions that can be summarised as:
•  Modulation of voltage-gated ion channels such as voltage-gated sodium, 
potassium and calcium channels.
•  Enhancement of synaptic inhibition: drugs act on y-amino butyric acid (GABA) 
receptors (the main inhibitory neurotransm itter in the brain).
•  Inhibition of synaptic excitation: drugs that block glutamate receptors 
(excitatory neurotransmitter).
1.5.2.1 Voltage-gated sodium channel modulators
The voltage-gated sodium channels (VGSCs) are responsible for the depolarisation 
phase in the neuronal action potential. They are composed of a main a-subunit and 
two auxiliary 3 subunits as in figure 1.3 (Namadurai et a i, 2015). There are four 3 
subunits 3 1  - 34, that play an important role in modifying voltage dependence and 
gating kinetics of VGSC (Cannon and Bean, 2010; Catterall et a i,  2010). The presence 
o f 3 subunits w ith sodium channel a subunits accelerates the activation and 
inactivation rate of the channel. While, 31 arid 33 favour the Na+ channel inactivation, 
the 34 subunit favours Na+ channel activation and makes neurons more susceptible to 
excitation (Yu et a i,  2003).
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Figure 1.3 Schematic diagram of voltage-gated sodium channel subunits
VGSCs are composed of a main a subunit associated w ith two auxiliary p subunits (P l- 
p4). The a subunit consists of 4 homologous domains (I, II, III and IV) and each domain 
has 6 transmembrane segments (S1-S6). The pore of the channel is formed by S5 and 
S6 from each domain and the channel's voltage sensor segment is S4. The fast 
inactivation gate that closes the channel in a hinge-like mechanism located between 
Dill and DIV. Sodium channel modulating drugs such as lamotrigine stabilizes the 
inactive form by binding to S6 in domain III and IV. Adapted from Yarov-Yarovoy et al. 
(2001) and Namadurai et al. (2015).
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The VGSCs undergo three conformational changes (closed, open and inactive forms) 
w ith in milliseconds (ms) range during the action potential. In the depolarisation phase 
the sodium channels change from closed state to the open conducting state. The 
channels then change to the inactive form and when repolarisation is reached the 
channel changes back to the resting closed state (Kuo and Bean, 1994; Cannon and 
Bean, 2010).
The sodium channel inactivation process is very im portant as it determines the 
frequency of action potential firing. There are two main types o f inactivation, fast and 
slow. The fast inactivation occurs via the inactivation particle which is a short loop of 
amino acid residues between a subunit domain III and IV. It occludes the channel like a 
hinged lid. The slower inactivation is associated w ith the pathological prolonged 
depolarization such as seen in epileptic activity. The channel pore undergoes molecular 
rearrangement to stop the sodium flux (Goldin, 2003).
As mentioned previously the voltage-gated sodium channels are responsible fo r the 
depolarization phase in the action potential. Thus, voltage-gated sodium channel 
blockers protect against seizures by inactivating sodium channels and subsequently 
blocking the depolarization in the high-frequency repetitive action potential (which 
happens during the spread of the seizure). On the other hand, they do not interfere in 
the physiological generation of action potentials; as they bind slowly to  sodium 
channels and will only affect the long pathological depolarization events that are 
associated w ith the epileptic activity. Examples of AEDs that stabilize fast inactivation 
state of VGSCs are: phenytoin, carbamazepine, lamotrigine, oxcarbazepine and 
rufinamide (Rogawski and Loscher, 2004; Brodie et a i,  2011). A recently developed
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AEDs, lacosamide and eslicarbazepine acetate, act via selective enhancement of the 
slow inactivation state of VGSCs (Perucca et al., 2008; Park et al., 2013).
1.5.2.2 Voltage-gated potassium channel modulators
The voltage-gated potassium (K+) channels (VGKCs) are responsible fo r the 
repolarization phase in the neuronal action potential and thus they stabilize the 
membrane potential by controlling the neuronal excitability. The M-type potassium 
channels are low-threshold voltage-gated channels that are widely distributed in the 
central and peripheral neurons including hippocampal and cortical pyramidal cells. 
They are heterotetramers composed of 4 a subunits; two Kv7.2 subunits and two 
Kv7.3 subunits that are products o f KCNQ2 and KCNQ3 genes respectively as in figure 
1.4. (Telezhkin et al., 2012).
Many studies found that mutations in KCNQ2 and KCNQ3 genes caused a familial 
neonatal convulsion which is a form of congenital epilepsy (Tatulian et al., 2001) and 
thus came the idea behind developing an anti-epileptic drug that enhances the M 
channel activity. Accordingly retigabine, an anticonvulsant drug, was developed; it 
activates Kv7.2 and Kv7.3 and enhances the opening of the M type potassium channel 
causing hyperpolarization o f the membrane and longer refractory period tha t reduces 
the number of firing action potentials (Wickenden et al., 2000; Tatulian et al., 2001).
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Figure 1.4 Schematic diagram of voltage-gated M-type potassium channel
M-type potassium channel is composed of 4 a subunits, (a) each a subunit consists of 6 
transmembrane domains (S1-S6). S4 is the voltage-sensing domain. S5 and S6 are the 
pore-forming domains, (b) M-type potassium channel is composed of two Kv7.2 and 
two Kv7.3 subunits that are arranged in an alternative manner. Adapted from 
Telezhkin et al. (2012).
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1.5.2.3 Calcium channel modulators
There are two broad groups of voltage-gated calcium channels: the high-voltage 
activated (HVA) calcium channels (P/Q type) and the low-voltage activated calcium 
channels (T type). The HVA calcium channels are a potential AED target as they 
regulate the neurotransmitter release from presynaptic nerve terminals. AEDs such as 
gabapentin and pregabalin act in part by blocking HVA calcium channels (Rogawski and 
Loscher, 2004; Bialer and White, 2010).
The low-voltage activated calcium channels regulate neuronal firing. AED ethosuximide 
blocks the T-type calcium channels in the thalamic neurons and it is effective in the 
treatm ent of absence seizures (Rogawski and Loscher, 2004).
1.5.2.4 GABA mediated AEDs
Most of the broad spectrum antiepileptic drugs act by mechanisms that influence 
GABA, which is the main inhibitory neurotransm itter in the brain. GABA acts on two 
types of receptors: GABAa receptors are ligand-gated chloride channels (ionotropic 
receptors) and GABAb receptors are G-protein- coupled metabotropic receptors (Jacob 
et al., 2008).
GABAa receptor
GABA causes a fast post synaptic inhibition upon its binding to GABAa receptor. It 
opens the chloride channel allowing the Cl" anion influx. This will result in a 
hyperpolarized membrane potential that stops the firing o f the next action potential. 
The GABAa receptor is composed of 5 subunits (2a, 2(3 and y) that are assembled to 
from a chloride channel. Each subunit is composed of 4 transmembrane domains
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(TM1-TM4); TM2 domain forms the chloride channel pore. The ligand binding site is at 
the large N-terminal extracellular domain as in figure 1.5 (Jacob et al., 2008).
GABAb receptors
GABAb receptors are G-protein coupled receptors that are responsible fo r the slow 
synaptic inhibition and prolonging inhibitory postsynaptic potentials (IPSP) (Benarroch, 
2012). It was found that mice which are lacking functional GABAb receptors developed 
epileptic activity and spontaneous seizures supporting the inhibitory role of GABAb 
(Schuler et al., 2001).
GABAb receptors are present on both the pre- and postsynaptic membranes in the 
neuronal synapses. The activation of presynaptic GABAb receptor inhibits the release 
of GABA by the inhibition of voltage-gated Ca2+ channels. The activation of 
postsynaptic GABAb receptor activates the K+ channels causing hyperpolarisation and 
prolonged IPSP (Benarroch, 2012).
Drugs acting on GABAergic system
The AEDs that enhance GABA inhibition either act as GABA agonists or inhibitors of 
GABA transaminase enzyme and GABA transporters to increase GABA levels in the 
synaptic cleft. Barbiturates and benzodiazepines are GABA agonists tha t bind to  
allosteric sites in GABAa receptor potentiating the effect of GABA. While, the 
barbiturates prolong the channel opening time; the benzodiazepines increase the 
number of channels opening resulting in more hyperpolarized membrane potential. 
The barbiturates also act on sodium and calcium ion channels (Rogawski and Loscher, 
2004; Johnston, 2005).
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aFigure 1.5 Ligand-gated GABAa receptor structure
(a) The four transmembrane domains (TM1-4) of a single GABAa subunit. TM2 domains 
line the chloride channel pore. The large N-terminal extracellular domain is the site for 
binding neurotransmitters and AEDs such as benzodiazepines (BZs). (b) 
GABAa receptor is composed of five subunits to from a heteropentameric chloride 
channel. The most common type of GABAa receptor found in the brain consists o f 2a, 
2p, and ly  subunits. Adapted from Jacob et al. (2008).
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The AED vigabatrin increases GABA levels via inhibition of GABA degradation. It 
irreversibly inhibits GABA transaminase enzyme (GABAT) that is responsible for 
converting GABA to succinic semi-aldehyde (SSA) as in figure 1.6. Tiagabine increases 
GABA concentration by inhibiting its reuptake by neurons and astrocytes. It is a potent 
selective inhibitor of GABA transporter 1 (GAT1), which is the most abundant GABA 
transporter that reuptakes GABA and terminates its action. Tiagabine binds to GAT1 
w ith high affin ity slowing the reuptake of GABA. Therefore, it prolongs the inhibitory 
postsynaptic potential (Sills et al., 1999; Brodie et al., 2011; Besag and Patsalos, 2012).
It was found that gabapentin and pregabalin also have a GABA-mediated action. It is 
thought that gabapentin and pregabalin increase cellular GABA levels by enhancing 
GABA transporter GAT1 (W hitworth and Quick, 2001; Errante et al., 2002; Sills, 2006). 
In addition, valproate also increases GABA synthesis and turnover (Rogawski and 
Loscher, 2004).
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Figure 1.6 GABA-mediated antiepileptic drugs
In the presynaptic terminal GABA is synthesized from Glutamate (Glu) by glutamate 
decarboxylase (GAD). GABA is released in the synapse where it acts on the 
postsynaptic GABAa receptor. The action of GABA is term inated by its reuptake by 
GABA transporter 1 (GATl) into presynaptic neurons and astrocytes; where it is 
degraded into succinic semi-aldehyde (SSA) by the GABA transaminase (GABAT). 
GABA-mediated AEDs: phenobarbital and benzodiazepines are allosteric GABAa
receptor agonists. Tiagabine inhibits GABA reuptake by selective inhibition of GATl 
and Vigabatrin inhibits GABA degradation by irreversible inhibition of GABAT. Adapted 
from Rogawski and Loscher (2004).
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1.5.2.5 Inhibitors of synaptic excitation
Glutamate is the main excitatory neurotransm itter that mediates most of the fast 
excitatory neurotransmission in the brain. There are 3 families of ionotropic glutamate 
receptors: A/-methyl-D-aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPA) and kainate receptors. In epilepsy there is an 
over excitation state, theoretically glutamate receptor blockers make ideal drugs in 
treatm ent of TLE (Rogawski and Loscher, 2004). However, the results of preclinical and 
clinical trials of selective NMDA antagonists were disappointing and so far there are no 
marketed AEDs that act predominantly on the NMDA receptors (Rogawski, 2011; 
Besag and Patsalos, 2012). Nevertheless, some of the available AEDs do act partly on 
glutamate receptors such as: felbamate that acts partly by blocking NMDA receptors 
(Kuo et al., 2004) and topiramate that acts partly by blocking kainate and AMPA 
receptors (Gryderand Rogawski, 2003).
Recently a new AED perampanel was introduced to the market fo r treatm ent of partial 
seizures that significantly reduced seizure frequencies in patients. Perampanel acts as 
a highly selective non-competitive AMPA antagonist that was well tolerated in epilepsy 
patients (Besag and Patsalos, 2012; Trinka et al., 2016).
1.5.2.6 Synaptic vesicle modulators
Synaptic vesicles play a major role in regulating neurotransm itter release. They are 
responsible fo r neurotransmitter exocytosis and endocytosis and therefore are very 
important in regulating the efficiency of synaptic transmission (Casillas-Espinosa et al., 
2012 ).
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The synaptic vesicle glycoprotein 2A (SV2A), found in presynaptic terminals in neurons, 
has a regulatory role in synaptic vesicle exocytosis and calcium-dependent 
neurotransm itter release. SV2A down regulation was reported in both animal models 
and refractory TLE patients. Its dysfunction was associated w ith increased 
neurotransm itter via the presynaptic calcium accumulation (Bialer and White, 2010; 
Sills, 2010).
It was found that there is strong correlation between the binding affin ity to SV2A and 
anticonvulsant potency of AEDs in animal models. The AED levetiracetam binds to 
SV2A w ith high affinity, inhibiting the recycling of SV2A neurotransm itter vesicles and 
thus decreasing the vesicular release. In addition, levetiracetam also blocks the HVA 
calcium channels (Rogawski and Loscher, 2004; Bialer and White, 2010).
Brivaracetam is a selective SV2A ligand that binds to SV2A with high affinity. It is about 
6 to 12 times more potent and has more rapid brain penetration compared to 
levetiracetam. The preclinical trials suggest that it may provide an effective treatm ent 
fo r refractory epilepsy (Bialer and White, 2010; Klitgaard et al., 2016). Brivaracetam is 
one of the newest AEDs to be approved fo r treatm ent of epilepsy (Zaccara, 2016).
The presynaptic vesicle protein synaptoporin (SYNPR) is highly expressed in adult 
hippocampus and it plays a vital role in regulating synaptic transmission in both 
physiological and pathological conditions (Singec et al., 2002; Sun et al., 2006).
Neurotransmitter release via presynaptic vesicle proteins such as S2VA and SYNPR is a 
calcium dependent process that is affected by intracellular Ca2+ level (Chen et al., 
1996; Matsumoto and Nagata, 1999). Inositol 1, 4, 5-trisphosphate receptor 1 (IP3R1)
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is one of the main IP3 receptors in neurons that is found on the endoplasmic reticulum. 
IP3R1 regulates intracellular Ca2+ levels, neuronal excitability and neurotransm itter 
release (Nicolay et al., 2007).
1.5.2.7 AEDs that act on multiple targets
The mechanism of action of some AEDs is not fully understood and some others are 
complex and acting on many targets such as valproate, felbamate, topiramate, 
zonisamide and acetazolamide. Valproate is thought to block HVA calcium channels, 
fast and slow voltage-gated sodium channels in addition to its role in increasing GABA 
turnover (Rogawski and Loscher, 2004). Felbamate multiple mechanisms of action 
include possible actions on both GABA and NMDA receptors in addition to its actions 
on fast VGSCs and HVA calcium channels. Topiramate acts as sodium channel and 
kainate/AMPA receptor blocker, it enhances GABAergic transmission and inhibits 
carbonic anhydrase. Zonisamide anticonvulsant activity is thought to act mainly by 
blocking of VGSCs and HVA calcium channels (Rogawski and Loscher, 2004; Baulac and 
Leppik, 2007; Besag and Patsalos, 2012).
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1 .5 .2 .8  S um m ary  o f a n tie p ile p tic  drugs
The main issue with the present AEDs, summarized in table 1.1, is that they only treat 
the symptoms and do not reverse or stop the progression o f epilepsy (Brodie et al., 
2011). Therefore, the ultimate goal of epilepsy treatm ent should be to prevent and 
reverse the progression of epilepsy. In order to achieve that, understanding the 
epileptogenic process that underlines the mechanism of enhanced seizure 
susceptibility, is vital to develop anti-epileptogenic drugs. Those drugs will inhibit and 
stop the process of epileptogenesis. In addition, AEDs are only effective in controlling 
seizures in about 70 % of TLE patients and the remaining 30 % of patients are 
refractory to AEDs. For these patients, the uncontrolled recurrent seizures contribute 
to the severity of TLE as well as the deterioration of the patient's cognitive functions 
(Pitkanen and Sutula, 2002).
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T ab le  1 .1  S um m ary  o f a n tie p ile p tic  drugs and th e ir  targe ts
1. Sodium channel actions
• Blockade by stabilizing fast-inactivated 
state
• Blockade by stabilizing slow-inactivated 
state
Phenytoin, carbamazepine, 
lamotrigine, oxcarbazepine, 
rufinamide.
Lacosamide, eslicarbazepine
2. Potassium channel actions
•  Opens Kv7 potassium channels Retigabine
3. Calcium channel actions
• Blockade of high voltage-activated channel 
(P/Q type)
•  Blockade of low voltage-activated channel 
(T type)
Gabapentin, pregabalin 
Ethosuximide
4. GABA-mediated actions
•  GABAa receptor agonists
•  Blockade of GABA transporter GATl
•  Inhibition of GABA transaminase
Phenobarbital
Benzodiazepines
Tiagabine
Vigabatrin
5. AMPA receptor action
•  selective AMPA receptor antagonist Perampanel
6. Synaptic vesicle protein 2A actions
•  Modulation of SV2A Levetiracetam, brivaracetam
7. Multiple actions
•  Various actions on multiple targets
Valproate, felbamate, 
topiramate, zonisamide,
Adapted from (Brodie et al., 2011)
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1.6 Pathogenesis of refractory temporal lobe epilepsy associated with 
hippocampal sclerosis (TLE-HS)
According to ILAE drug resistant or refractory epilepsy is defined as "failure o f 
adequate trials o f two tolerated, appropriately chosen and used antiepileptic drug 
schedules (whether as monotherapies or in combination) to achieve sustained seizure 
freedom " (Kwan et al., 2010).
Since the 19th century epilepsy has been associated w ith brain damage and 
hippocampal sclerosis especially the drug refractory TLE. About 30% of epilepsy 
patients are drug resistant and the majority of those patients have hippocampal 
sclerosis (Blumcke et al., 2012). Hippocampal sclerosis is a lesion characterised by 
neuronal loss in the main cornu ammonis (CA) CA1 - CA4 and the dentate gyrus regions 
of the hippocampus as in figure 1.7 (Pitkanen and Sutula, 2002; Coras and Blumcke, 
2015).
In refractory TLE associated with hippocampal sclerosis (TLE-HS), there is continuous 
seizure-induced plasticity in neural circuits as part of the epileptogenic process. There 
is also a continuous seizure-induced neuronal loss, neurogenesis, axonal and dendritic 
plasticity, gliosis and molecular reorganization (Pitkanen and Sutula, 2002; Coras and 
Blumcke, 2015).
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Figure 1.7 Hippocampal sclerosis in TLE-HS
(a) The anatomically normal hippocampus showing the staining of pyramidal neurons 
in cornu ommonis (CA) CA1 - CA4 subregions. It also shows the staining of granular 
neurons in external and internal limbs of dentate gyrus (DGext, DGint). (b) Sclerotic 
hippocampus from TLE patient showing the significant neuronal loss in the pyramidal 
neurons of CA1 - CA4 areas (indicated by black arrows). In addition, it shows the 
significant neuronal density reduction and dispersion in both external and internal DG 
hippocampal areas (indicated by red arrows). NeuN immunohistochemistry w ith 
hematoxylin counterstaining using 4 pm thin paraffin embedded sections. CA: cornu 
ommonis. DGext: External limb of dentate gyrus. DGint: Internal limb of dentate gyrus. 
Scale bar = 2000 pm. Adapted from Coras and Blumcke (2015).
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1.6.1 Neuronal loss and damage in TLE-HS
Many histological studies have been undertaken on brain tissue resected from TLE 
patients undergoing surgical treatment. These studies indicated the association of 
recurrent seizures and long duration of epilepsy with the severity of neuronal loss in 
different hippocampal subregions (Mathern et al., 1995; Yilmazer-Hanke et al., 2000; 
Pitkanen and Sutula, 2002). According to Mathern et al. (1995) the type of neuronal 
damage in TLE depends on age of the patient at the initial epileptogenic lesion and the 
age of developing epilepsy. The hippocampal damage was greater in patients where 
the initial epileptogenic lesion occurred in childhood.
Many animal model experiments were performed to assess the effect of seizure on 
hippocampal neuronal loss. Those studies showed that hippocampal neuronal loss 
was induced by brief seizures and as the number of seizures increased, the neuronal 
loss also increased in a pattern similar to hippocampal sclerosis seen in TLE patients 
(Cavazos and Sutula, 1990; Cavazos et al., 1994). It was suggested that the primary 
cause of seizure-induced neuronal death is glutamate excitotoxicity. The over­
activation of the glutamate gated ion channels leads to the neurons being flooded w ith 
sodium and calcium ions. This leads to the neurone swelling and membrane rupture. 
Some animal studies showed that the administration of glutamate receptor-blocker 
(such as NMDA antagonists) had a neuroprotective effect. They reduced the 
hippocampus damage after status epilepticus but the rats still developed epilepsy later 
due to the disruption of normal brain function (Engel and Henshall, 2009).
The neuronal loss in TLE-HS is caused by cellular mechanisms such as apoptosis (Xu et 
al., 2007). Many studies indicated that the seizure-induced neuronal death may involve
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the activation of apoptosis, probably the intrinsic pathway. The intrinsic pathway is 
activated by internal changes w ith in a cell such as DNA damage and calcium overload. 
Studies on the human hippocampi obtained from patients w ith refractory TLE, found 
an alteration in expression of Bcl-2 (pro-apoptotic) and caspase family genes. There 
was evidence of up-regulation of anti-apoptotic genes (Bcl-2, Bcl-xL and Bcl-w) as well 
as pro-caspases genes (2, 6, 7, 8 and 9) in TLE patients. This indicated tha t apoptosis 
seem to be contributing to the neuronal loss seen in TLE-HS (Henshall et al., 2000; 
Engel and Henshall, 2009; Thompson et al., 2011).
Neuroinflammation mediated by the pleiotropic cytokine tum our necrosis factor alpha 
(TNF-a), also has a role in seizure-induced neuronal loss and damage. Data from both 
animal and human studies showed that seizures induce TNF-a that activates TNF 
receptor 1 (TNFR1). The prolonged activation of TNFR1 (that contains a death domain) 
will activate apoptosis via caspase 8 (Thompson et al., 2011). In addition, Fas-mediated 
neuronal loss was also reported in resected sclerotic hippocampi obtained from TLE 
patients. This further implicates the role of extrinsic apoptotic pathway in TLE-HS 
neuronal loss (Xu et al., 2007).
1.6.2 Gliosis in TLE-HS
In the sclerotic hippocampus there is a prominent proliferation of glial cells such as 
astrocytes, microglia, and oligodendrocytes. Alterations in glial cell functions such as 
growth-factor production, pH regulation and transm itter uptake may play a major role 
in hippocampal circuit excitability and seizure susceptibility (Pitkanen and Sutula, 2002; 
Lee et al., 2004; Verkhratsky et al. 2013; Steinhauser et al., 2016).
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1.6.2.1 Role of astrocytes in TLE-HS
TLE-HS is characterized by reactive astrogliosis (Lee et al., 2004; Verkhratsky et al. 
2013; Steinhauser et al., 2016). Astrocytes are important in maintaining brain 
physiological function. They maintain extracellular K+ homeostasis by K+ uptake and 
spatial buffering. The control of K+ homeostasis is very im portant fo r maintaining 
normal brain function as high extracellular K+ concentrations can cause a significant 
increase in neuronal excitability (Steinhauser et al., 2016).
Unlike normal neuronal activity, where there is a transient increase in K+ concentration, 
in epilepsy there is an excessive accumulation of extracellular K+ concentration tha t is 
cleared by the astrocytic inward rectifier K+ channels (Kir4.1). However in epileptic 
tissue from TLE-HS patients; there is a down-regulation in astrocytic Kir4.1 channels. 
This causes an impaired K+ buffering and contributes to increased seizure susceptibility 
in TLE-HS (Lee et al., 2004; Binder et al., 2012; Heuser et al., 2012). In addition, the 
down regulation of perivascular aquaporin 4 (AQP4) in TLE-HS is accompanied by 
impaired extracellular K+ homeostasis that caused prolonged and aggravated epileptic 
seizures (Eid et al., 2005).
Astrocytes also play a critical role in maintaining extracellular glutamate levels. High 
level of extracellular glutamate causes glutamate neurotoxicity and increased seizure 
susceptibility. At excitatory terminals, astrocytes are responsible for glutamate 
reuptake via the excitatory amino acid transporters (EAAT) EAAT1-EAAT2. Therefore, 
they reduce extracellular glutamate levels and lim it activation o f extrasynaptic 
glutamate receptors. Serum- and glucocorticoid-inducible kinase-1 (SGK1) up-regulates 
glutamate EAAT transporters in astrocytes and induces the clearance of accumulated
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glutamate in the synaptic space (Rothstein et al., 1996; Boehmer et al., 2006). The 
glutamate in astrocytes is converted into glutamine by glutamine synthetase enzyme. 
The glutamine is taken up by neurons and used as a precursor fo r the synthesis of both 
glutamate and GABA (Steinhauser et al., 2016).
In sclerotic hippocampi obtained from TLE patients, there were high levels of 
extracellular glutamate (Cavus et al., 2005). This was accompanied with the down 
regulation of EAAT-1 and EAAT-2 glutamate transporters (Proper et al., 2002; Sarac et 
al., 2009) and astrocytic glutamine synthetase (Eid et al., 2004; van der Hel et al., 2005). 
In addition, there is an up-regulation of ionotropic and metabotropic glutamate 
receptors in astrocytes from epileptic tissues that contribute to increased seizure 
susceptibility (Verkhratsky et al. 2013; Steinhauser et al., 2016). Therefore, reactive 
astrogliosis seen in TLE-HS appears to play a vital role in epileptogenesis and 
pathophysiology of TLE-HS (Steinhauser et al., 2016).
1.6.2.2 Role of activated microglia in TLE-HS
One of the characteristics of TLE-HS epilepsy is microglia activation (Kang et al., 2006; 
Shapiro et al., 2008; Yeo et al., 2011; Xu et al., 2015; Abiega et al., 2016). Microglia are 
the main immune cells in the CNS that play a central role in mediating immune 
responses and maintaining homeostasis (Xu et al., 2015). Activated microglia have a 
phagocytic function, they engulf and degrade apoptotic cells and damaged cell debris. 
I t  They also have the ability to release inflammatory mediators such as interleukin-1 
beta (IL-1(3) and TNF-a as well as matrix metalloproteinases (Felderhoff-Mueser et al., 
2005; Xu et al 2015; Abiega et al., 2016).
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In patients w ith intractable epilepsy, there is a significant elevation in the number of 
activated microglia in the epileptogenic tissue indicating neuroinflammation (Choi et 
al., 2009). Following SE in animal models, rapid microglial activation in the 
hippocampus preceded the SE-induced neuronal damage, suggesting a possible role in 
the epileptogenesis process (Kang et al., 2006; Shapiro et al., 2008).
In physiological conditions there is coupling between apoptosis and phagocytosis in 
the hippocampus. In TLE there is an increase in the number of apoptotic cells that 
need to be phagocytosed by microglia. A recent study that investigated the role of 
microglia phagocytic ability in human and experimental TLE found that the activated 
microglia had an impaired phagocytic function that caused uncoupling between 
apoptosis and phagocytosis. It also found that the loss of coupling was correlated to 
high expression of pro-inflammatory cytokines such as IL-lp in the epileptogenic tissue 
(Abiega et al., 2016). Therefore, microglial activation seems to plays a vital role in TLE 
epileptogenesis (Kang et al., 2006; Abiega et al., 2016).
In summary, gliosis in TLE-HS is involved in the TLE epileptogenic process and 
developing drugs that target activated microglia or reactive astrocytes in early stages 
of epilepsy could have an anti-epileptogenic effect.
1.6.3 Mossy fibre sprouting in TLE-HS
The mossy fibres are the axons of the granule cells in the dentate gyrus (DG). They 
project through the dentate hilus (DH) to CA3, where they make synaptic contacts w ith 
hilar and CA3 pyramidal cells. Normally the majority of mossy fibres project towards 
the inhibitory GABAergic interneurons rather than the excitatory cells (Frotscher et al., 
2006).
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The mossy fibres sprouting is a phenomenon seen in both human and animal models 
o f TLE. It is a form of synaptic reorganization in the DG where the mossy fibres develop 
collaterals that project into abnormal locations to form new functional synapses on 
neurons that they do not normally innervate (Koyama and Ikegaya, 2004; Ben-Ari and 
Dudek, 2010). These mossy fibres form new excitatory synapses on the dendrites of 
granule cells in the inner third of the DG molecular layer, CA1 and CA3 pyramidal 
neurons as in figure 1.8 (Ben-Ari and Dudek, 2010).
Some studies suggested that the mossy fibres sprouting has a role in developing the 
epileptiform activity during and after the latent period of epileptogenesis as the 
majority of these new synapses are excitatory. Therefore there is an increase in 
number of excitatory synapses in granular cells and CA3 pyramidal neurons that are 
innervated by sprouting mossy fibres as in figure 1.9 (Bragin et al., 2000; Scharfman et 
al., 2003; Koyama and Ikegaya, 2004; Ben-Ari and Dudek, 2010).
On the other hand, some studies suggested that sprouting mossy fibres form  synapses 
w ith inhibitory interneurons in DG, inhibit the excitability of granule cells and lead to 
hyper-inhibition state that resist the generation of epileptiform discharges (Frotscher 
et al., 2006; Sloviter et al., 2006). Hence, the role of mossy fibre sprouting in 
epileptogenesis needs to be further investigated.
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DGCA3
Figure 1.8 Mossy fibre sprouting in TLE-HS
The normal mossy fibres (black) are the axons of the granule cells in the dentate gyrus 
(DG) and they project through the dentate hilus (DH) to CA3. They make new synaptic 
contacts w ith hilar cells, CA3 pyramidal cell layer (PCL) and interneurons. In TLE the 
new sprouting mossy fibres (Red) will arise from dentate hilus (arrowhead) and run 
across the granule cell layer (GCL). They will also project to the inner th ird molecular 
layer (ML) (arrow). They will contact other granule cell's dendrites and form  excitatory 
synapses. Adapted from Koyama and Ikegaya (2004).
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Before epileptogenesis
Normal recurrent excitation 
After epileptogenesis
Increased recurrent excitation
Figure 1.9 Schematic representation of mossy fibre sprouting in the CA3 area of the 
hippocampus before and after epileptogenesis
The numbers of excitatory synapses in CA3 pyramidal cells formed by mossy fibre 
sprouting are increased after epileptogenesis leading to an increased excitation. 
Adapted from Ben-Ari and Dudek, (2010).
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1.6.4 Neurogenesis in TLE-HS
Neurogenesis in the hippocampus is seen in all mammals throughout life. It has an 
important role in cognitive functions such as learning and memory. It also has a 
reparative function, as neurogenesis is increased after an acute cerebral injury to  help 
in neuronal recovery. The rate of neurogenesis declines with age (Kuruba et al., 2009). 
Neurogenesis occurs w ithin the subgranular zone (SGZ) of the hippocampal dentate 
gyrus. The progenitor cells mature into granule neurons then migrate into the granule 
cell layer and send their axons to the hilus and CA3 subfield (Engel et al., 2011).
Many animal studies reported that acute seizures were associated w ith an increase in 
hippocampal neurogenesis. In contrast, chronic seizures were associated w ith severe 
reduction in hippocampal neurogenesis. Human studies also showed a decrease in the 
sclerotic hippocampal neurogenesis that supports the finding from chronic seizures 
animal studies (Engel, et al., 2011). However, the functional significance of 
neurogenesis is still poorly understood, as some studies suggest that the new neurons 
that migrate to  the granular cell layer may have a pro-epileptogenic effect (Kuruba et 
al., 2009).
1.6.5 Neuroinflamm ation in TLE-HS
Many experimental and clinical studies highlighted the role of inflammatory pathways 
in epilepsy pathogenesis. Many cells such as infiltrated leukocytes, endothelial cells of 
the blood brain barrier (BBB), activated microglia, astrocytes and neurons, contribute 
to neuroinflammation in TLE-HS by the synthesis and secretion of high levels of pro- 
inflammatory cytokines (Maroso et al., 2011).
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In an experimental model of acute TLE, there was an induction of pro-inflammatory 
cytokines such as interleukin-1 beta (IL-1(3) and TNF-a in glia and neurons after acute 
seizures (Ravizza and Vezzani, 2006). In addition, in a chronic model of TLE the IL-1(3 
expression showed persistent up regulation in astrocytes and activated microglia. 
While the chronic up regulation of astrocytic IL-ip  did not depend on the frequency of 
seizures, microglial IL-1(3 up regulation was dependent on frequency of seizures and 
was only found in areas w ith high seizure frequency (Ravizza et al., 2008). Furthermore, 
there was up regulation of IL-1(3 and TNF-a as well as their downstream inflammatory 
mediators such as prostaglandins and complement in the epileptogenic tissue from TLE 
patients (Ravizza et al., 2008; Maroso et al., 2011).
Many studies found that lnterleukin-1 type 1 recepto r/To ll-like  receptor (IL-1R1/TLR) 
signalling pathways contribute to seizure activity in epilepsy. The IL-1(3 that is released 
from astrocytes and activated microglia in response to seizures, acts on neuronal IL1- 
R1 and increase the NMDA-mediated Ca2+ influx. Hence leads to increase in neuronal 
excitability. The High-mobility group box 1 (HMGB1) is a danger molecule that is 
released from injured neurons following a seizure. It acts on TLRs and increases 
neuronal excitability also via increasing the NMDA-mediated Ca2+ influx (Maroso et al., 
2011). Therefore, drugs targeting (IL-1R1/TLR) signalling will help reduce inflammatory 
processes in the epileptic brain as well as counteracting the neuronal hyperexcitability 
(Maroso et al., 2011).
Recent evidence also highlighted the role of up regulated pro-inflam m atory 
chemokines such as CCL2, CCL3 and CCL4 in TLE neuropathology (Van Gassen et al., 
2008; Kan et al., 2012; Arisi et al., 2015). Activated microglia and astrocytes are
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primary sources of chemokines following CNS injury. Chemokines are a class of 
cytokines that play an im portant role in neuroinflammation. They are leukocyte 
chemoattractants; they facilitate leukocyte infiltra tion across BBB. Once leukocytes are 
w ithin the brain, together w ith microglia and astrocytes, they accelerate the 
inflammatory process by inducing the release of pro-inflammatory cytokines, cytotoxic 
substances and proteolytic enzymes (Mantovani et al., 2006; Louboutin et al., 2011).
In summary, TLE-HS prolonged chronic inflammation appears to participate in its 
pathophysiology and targeting inflammation provides a new therapeutic approach in 
TLE treatm ent that may have an anti-epileptogenic effect (Vezzani et al., 2013).
1.6.6 W ater homeostasis in TLE-HS
Water and ion homeostasis are important factors that modulate seizure susceptibility 
(Andrew, 1990; Schwartzkroin et al., 1998; Lee et al., 2012). It was found that 
hippocampus excitability is affected by alteration in water movement and osmotic 
changes as hypotonic solutions promoted epileptiform  activity in hippocampal brain 
slices (Andrew, 1990). Magnetic resonance imaging in TLE-HS patients shows water 
accumulation in sclerotic hippocampi, compared to non-sclerotic ones and indicates 
impaired water homeostasis in TLE-HS (Bronen et al., 1991; Dawe et al., 2014).
Aquaporins (AQPs) are membrane transporter proteins that mainly regulate the 
bidirectional water movement across cell membranes in response to osmotic gradients 
(Amiry-Moghaddam and Ottersen, 2003). A few studies on human TLE-HS specimens 
reported dysregulation in AQP4 and AQP1 expression in HS. They also suggested that 
AQPs are implicated in water accumulation seen in TLE-HS (Lee et al., 2004; Eid et al.,
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2005; Bebek et al., 2013). However little  is known about the expression of other AQPs 
such as AQP3, AQP5 AQP8, AQP9 and AQP11 in TLE-HS.
1.7 Surgical treatment of refractory TLE-HS
The TLE-HS patients that are refractory to the available AEDs become candidates for 
surgical treatm ent where the epileptogenic focus is resected. They either undergo 
selective amygdalohippocampectomy or temporal lobectomy. The surgical treatm ent 
is effective in controlling seizures in 60 - 70% of patients. It also stops the cognitive 
decline associated w ith recurrent and uncontrolled seizures (Blumcke et al., 2012; 
Coras and Blumcke, 2015). However, TLE surgery does have many complications; it 
causes memory and cognitive impairments such as verbal memory decline. It also 
increases patient's risk of accelerated mental ageing compared to medically treated 
patients (Helmstaedter et al., 2008). Another significant complication follow ing surgery 
is the worsening of previously existing psychiatric disorders, in addition, it causes the 
development of de novo psychopathological disorder in patients such as depression, 
anxiety and to less extent psychosis (Cleary et al., 2012).
Nevertheless, 40% of TLE patients suffer from surgery failure (Blumcke et al., 2012). So 
in addition to their uncontrolled seizures, patients still suffer from the surgery 
complications which could be very distressing to them and their families (Cleary et al., 
2012).
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1.8 Aims and objectives
Refractory TLE is a common adult epilepsy where antiepileptic drugs are not effective 
in controlling seizures. Those patients become candidates for surgical treatm ent which 
is effective in only 60 - 70% of TLE patients. Although surgical treatm ent can control 
recurrent seizures and halt cognitive decline, it causes memory and cognitive 
impairments as well as psychopathological disturbance. Therefore, further research is 
needed to  further understand the pathophysiology of refractory TLE in order to 
develop effective drug treatments for refractory TLE-HS. Consequently, the objective 
of this study is to investigate potential biomarkers, which will increase our 
understanding of refractory TLE pathophysiology and help in the identification of new 
potential drug targets. Thus, the aims of this study are to do:
1. Quantitative investigation of inhibitory GABAb receptor expression in sclerotic 
hippocampi obtained from TLE patients undergoing surgical resection.
2. Quantitative investigation of IP3R1, SGK1, SCN4B and SYNPR biomarkers, which 
are involved in regulating neuronal excitability, in sclerotic hippocampi 
obtained from TLE patients undergoing surgical resection.
3. Transcriptome analysis of sclerotic hippocampi obtained from  TLE patients 
undergoing surgical resection and further validating microarray expression data 
of inflammatory cytokines by qRT-PCR.
4. Quantitative investigation of AQP1, AQP3, AQP4, AQP5, AQP8, AQP9 and 
AQP11 biomarkers, which are involved in water homeostasis, in sclerotic 
hippocampi obtained from TLE patients undergoing surgical resection.
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2 Materials and Methods
2.1 Human sample collection and patients' clinical data
2.1.1 Surgical samples
All surgical samples were obtained from the Royal Hallamshire Hospital (Sheffield, UK). 
The research was approved by South Yorkshire Research Ethics Committee 
(08/H1310/49) and it followed the Code of Ethics o f the World Medical Association 
(2001). The samples were obtained with the understanding and the w ritten consent of 
each patient.
We recruited patients w ith pharmacoresistant TLE associated w ith unilateral HS. The 
diagnosis o f TLE-HS was made by the treating clinician based on brain MRI scan and 
inter-ictal and ictal EEG characteristics being consistent with a seizure focus in the 
hippocampus w ithin the temporal lobe. The patients' relevant clinical data are shown 
in Table 2.1. These patients underwent a therapeutic selective
amygdalohippocampectomy. After surgery two samples were obtained; sclerotic 
hippocampi (TLE-HS, n = 49), which are the epileptogenic and seizure focus specimens 
and superior temporal gyrus specimens (TLE-STG, n = 25), which are the part of the 
temporal lobe that showed no ictal or inter-ictal activity.
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Tab le  2 .1  P a tie n t clinical d a ta
Patient
No
Sex
Family
history
Age at 
surgery 
(yrs)
Epilepsy
duration
(yrs)
samples
(side)
Current
AED
previous
AEDs
P t.O l M No 59 15
TLE-HS (Rt) 
TLE-STG (Rt)
PGB LMT, LEV, CBZ
Pt. 02 M No 40 32
TLE-HS (Rt) 
TLE-STG (Rt)
PHT PHT, LEV,CBZ
Pt. 03 M No 37 12
TLE-HS (Lt) 
TLE-STG (Lt)
CBZ, LEV VPA
Pt. 04 M No 50 48.5
TLE-HS (Lt) 
TLE-STG (Lt)
LEV, 
ZNS,PGB
CBZ, TPM, PB, VPA, 
GBP, PHT
Pt. 05 F NA 34 NA TLE-HS (Rt) NA NA
Pt. 06 F NA 44 28
TLE-HS (Rt) 
TLE-STG (Rt)
TPM LMT, CBZ, LEV, CLB
Pt. 07 F No 39 26
TLE-HS (Lt) 
TLE-STG (Lt)
None CBZ, PHT, LEV, LMT
Pt. 08 F No 26 18 TLE-HS (Lt)
LEV, PHT, 
CLB
CBZ,LMT
Pt. 09 F No 34 33.5
TLE-HS (Rt) 
TLE-STG (Rt)
LMT, LEV PB, PHT, CBZ, VPA
Pt. 10 F No 36 32 TLE-HS (Lt) PHT,VPA
PGB, LEV, LMT, CBZ, 
TPM, ZNS
Pt. 11 M No 42 40 TLE-HS (Lt)
CBZ,ZNS, 
PHT
PB,VPA, GBP,LEV
Pt. 12 M NA 54 NA TLE-HS (Rt) CBZ, ZNS
PB, PHT, PGB, 
CNP, LEV
Pt. 13 F No 24 23 TLE-HS (Lt) LCS, LEV CBZ, LMT
Pt. 14 M NA 42 NA
TLE-HS (Lt) 
TLE-STG (Lt)
CBZ,CNP, 
ZNS
NA
Pt. 15 F Yes 32 13
TLE-HS (Rt) 
TLE-STG (Rt)
LMT, CBZ, 
GBP
LEV
Pt. 16 M No 25 23 TLE-HS (Lt)
ZNS, TPM CBZ, VPA, GBP
Pt. 17 M NA 61 NA
TLE-HS (Lt) 
TLE-STG (Lt)
NA NA
Pt. 18 M Yes 48 47
TLE-HS (Rt) 
TLE-STG (Rt)
PER,CBZ
PHT, LEV,LMT,GBP, 
TPM,PGB,ZNS
Pt. 19 F No 51 11
TLE-HS (Lt) 
TLE-STG (Lt)
LCS, LEV CBZ, LMT, VPA
Hippocampal sclerotic specimens (TLE-HS) and superior tem pora l gyrus specimens (TLE-STG) obtained 
from  tem pora l lobe epilepsy patients. A ntiep ilep tic  drugs (AEDs): CBZ, Carbamazepine; CLB, Clobazam; 
CNP, Clonazepam; GBP, Gabapentin; LCS, Lacosamide; LEV, Levetiracetam; LMT, Lam otrigine; OXC, 
Oxcarbazepine; PB, Phenobarbital; PER, Perampanel; PGB, Pregabalin, PHT, Phenytoin; TGB, Tiagabine; 
TPM, Topiram ate; VGB, Vigabatrin; VPA, Valproate; ZNS, Zonisamide. NA: no t available.
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Tab le  2 .1  P a tie n t clinical d a ta  (co n tin u ed ):
Patient
No
Sex
Family
history
Age at 
surgery 
(yrs)
Epilepsy
duration
(y s )
samples
(side)
Current
AED
previous
AEDs
Pt. 20 M No 30 2 TLE-HS (Lt)
LEV, TPM, 
LCS
LMT
Pt. 21 M Yes 32 3
TLE-HS (Rt) 
TLE-STG (Rt)
LMT, OXC CBZ, LEV
Pt. 22 M No 51 6
TLE-HS (Lt) 
TLE-STG (Lt)
NA NA
Pt. 23 M No 35 18
TLE-HS (Lt) 
TLE-STG (Lt)
CBZ, LEV TPM, LMT, VPA
Pt. 24 F No 54 53
TLE-HS (Lt) 
TLE-STG (Lt)
LMT, PGB
GBP,VPA,PHT,CBZ,PB, 
LEV, CNP,LCS
Pt. 25 M No 41 29
TLE-HS (Lt) 
TLE-STG (Lt)
NA NA
Pt. 26 F No 22 13
TLE-HS (Rt) 
TLE-STG (Rt)
LCS, LMT, 
TPM, PB
VPA
Pt. 27 F No 25 6
TLE-HS (Lt) 
TLE-STG (Lt)
NA NA
Pt. 28 F No 44 22
TLE-HS (Rt) 
TLE-STG (Rt)
LMT,VPA, 
PHT
CBZ,LEV,TPM
Pt. 29 F No 24 20
TLE-HS (Rt) 
TLE-STG (Rt)
LMT VPA, TPM, CBZ
Pt. 30 M NA 35 NA
TLE-HS (Rt) 
TLE-STG (Rt)
NA NA
Pt. 31 F NA 44 10 TLE-HS (Lt)
LCS, LEV, 
PHT
OXC, LMT
Pt. 32 M NA 32 NA TLE-HS NA NA
Pt. 33 M NA 35 14 TLE-HS (Lt) LMT, CLB VPA, ZNS, CBZ
Pt. 34 F NA 31 NA
TLE-HS
TLE-STG
NA NA
Pt. 35 M NA NA NA
TLE-HS
TLE-STG
NA NA
Pt. 36 M NA 42 NA
TLE-HS
TLE-STG
NA NA
Pt. 37 F No 45 16 TLE-HS (Lt) None CBZ,LEV,PGB,CLB
Pt. 38 M NA 33 24 TLE-HS (Lt) None CBZ,VPA, LEV
Hippocampal sclerotic specimens (TLE-HS) and superior tem pora l gyrus specimens (TLE-STG) obtained 
from  tem pora l lobe epilepsy patients. A n tiep ilep tic  drugs (AEDs): CBZ, Carbamazepine; CLB, Clobazam; 
CNP, Clonazepam; GBP, Gabapentin; LCS, Lacosamide; LEV, Levetiracetam; LMT, Lamotrigine; OXC, 
Oxcarbazepine; PB, Phenobarbital; PER, Perampanel; PGB, Pregabalin, PHT, Phenytoin; TGB, Tiagabine; 
TPM, Topiram ate; VGB, Vigabatrin; VPA, Valproate; ZNS, Zonisamide. NA: no t available.
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T ab le  2 .1  P a tie n t clinical d a ta  (co n tin u ed ):
Patient
No
Sex
Family
history
Age at 
surgery 
(yrs)
Epilepsy
duration
(yrs)
samples
(side)
Current
AED
previous
AEDs
Pt. 39 M No 33 31 TLE-HS (Lt) LEV, LMT CBZ,VPA, CLB
Pt. 40 F NA 22 NA TLE-HS (Lt) CBZ, LMT CNP,LEV,ZNS
Pt. 41 F No 39 37 TLE-HS (Rt) None GBP,LEV, LMT
Pt. 42 F No 29 28 TLE-HS (Lt) CBZ, LMT
CLB, LCS,
LEV,PGB,VPA, ZNS
Pt. 43 M No 23 16 TLE-HS (Lt) LMT CLB, LEV, TPM
Pt. 44 F No 27 9 TLE-HS (Rt) CBZ, LEV CLB,LMT, TPM
Pt. 45 M No 31 20 TLE-HS (Rt)
CBZ, LEV, 
LCS
PGB, VGB
Pt. 46 M No 48 41 TLE-HS (Rt) None
CBZ, LMT, VPA, PHT, 
VGB, CLB, TPM,TGB
Pt. 47 M NA 48 NA TLE-HS (Lt) LEV, VPA OXC
Pt. 48 F NA 44 NA TLE-HS (Lt) PGB,VPA LEV, LMT
Pt. 49 M No 63 46 TLE-HS (Lt) LEV,CLB VPA,VGB, PB,ZNS
Total
M=27 
F =22
TLE-HS (49) 
TLE-STG (25)
Hippocampal sclerotic specimens (TLE-HS) and superior tem pora l gyrus specimens (TLE-STG) obtained 
from  tem pora l lobe epilepsy patients. A ntiep ilep tic  drugs (AEDs): CBZ, Carbamazepine; CLB, Clobazam; 
CNP, Clonazepam; GBP, Gabapentin; LCS, Lacosamide; LEV, Levetiracetam; LMT, Lam otrig ine; OXC, 
Oxcarbazepine; PB, Phenobarbital; PER, Perampanel; PGB, Pregabalin, PHT, Phenytoin; TGB, Tiagabine; 
TPM, Topiram ate; VGB, Vigabatrin; VPA, Valproate; ZNS, Zonisamide. NA: not available.
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2.1.2 Post-mortem hippocampi samples
The post-mortem hippocampi samples were obtained from UCL Brain Bank 
(08/H0718/54). They were from individuals w ith no previous medical history of 
neurological or psychiatric disease (Table 2.2). At autopsy the hippocampi were 
dissected, pH was checked to be between 6 and 7 (optimal for RNA stability), and then 
they were snap frozen and stored at - 80°C (Kingsbury et a!., 1996).
Table 2.2 Post-mortem hippocampi samples
Sample Gender
Age
(yrs)
PMI
(hrs)
Cause of death Method
PMC 1 F 64 79 Bowel cancer RT-PCR
PMC 2 M 38 80.35 Gastric cancer RT-PCR
PMC 3 M 63 42 Congestive Heart Failure RT-PCR
PMC 4 M 43 15 Heart attack RT-PCR
PMC 5 F 53 29.5 Intra-cerebral haemorrhage RT-PCR
PMC 6 M 71 38.5 Mesothelioma RT-PCR /  MA
PMC 7 F 78 23.3 Endometrium cancer RT-PCR/W B/M A
PMC 8 F 80 49.1 Pancreas cancer RT-PCR/ W B /M A
PMC 9 M 85 51.3 M ultip le organ failure RT-PCR/ W B /M A
PMC 10 F 78 51.3 Colon cancer RT-PCR/W B/M A
PMC: Post-mortem control sample. PMI: Post-mortem Interval in hours. qRT-PCR: 
Quantitative real- time polymerase chain reaction. WB: Quantitative Western blot. MA: 
Microarray analysis.
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2.2 Experimental design
The human samples obtained were used to investigate both mRNA and protein levels 
of potential biomarkers involved in TLE-HS pathophysiology. The mRNA levels were 
investigated by quantitative real-time polymerase chain reaction (qRT-PCR) and 
microarray analysis technique, while protein expression was investigated by two- 
colour quantitative western blot (WB) as in figure 2.1.
Protein extraction 
Protein quantification
Investigating mRNA 
expression
qRT-PCR 
Microarray analysis
RNA extraction 
cDNA synthesis
Investigating protein 
expression
Quantitative western blot
Human samples:
Sclerotic hippocampi obtained from TLE-HS surgery (n = 49) 
Superior temporal gyrus obtained from TLE-HS surgery (n = 25) 
Post-mortem control (n = 10)
Figure 2.1 Experimental design of the study
Potential biomarkers involved in TLE-HS pathophysiology were investigated by 
techniques such as quantitative real-time polymerase chain reaction (qRT-PCR), 
microarray analysis and quantitative western blot.
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2.3 RNA extraction
2.3.1 RNA extraction protocol
RNA extraction: The SV Total RNA Isolation System (Promega, Z3100) was used to 
extract the total RNA from samples according to the manufacturer's instructions. The 
hippocampus tissue lysate was prepared by adding 1ml of RNA lysis buffer to 342 mg 
of tissue, and then homogenized using a manual homogenizer. 175pl o f tissue lysate 
was diluted with 350pl SV RNA dilution buffer before it was incubated at 70°C fo r 3 
minutes. The lysate was then centrifuged at 13,000 xg for 10 minutes at 25°C and the 
clear lysate solution was transferred to a fresh microcentrifuge tube w ithout disturbing 
the pelleted debris. All centrifugation steps were done at 13,000 xg unless they are 
stated.
RNA purification by centrifugation: the clear lysate was mixed w ith 200pl 95% ethanol 
and then transferred to the Spin Column Assembly (Promega, Z3100) before it was 
centrifuged for 1 minute. The liquid in the collection tube was discarded and 600pl of 
SV RNA wash solution was added to the spin basket and centrifuged fo r 1 minute 
followed by emptying the collection tube.
DNase treatment: 50pl of freshly prepared DNase incubation mix (40pl Yellow Core 
Buffer, 5pl 0.09M MnCI2 and 5pl of DNase I enzyme) was added directly to the 
membrane of spin basket where it was then incubated for 15 minutes at room 
temperature (RT). Following DNase incubation, 200pl of SV DNase stop solution was 
added to the spin basket and then centrifuged for 1 minute.
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RNA washing and elution: The RNA adsorbed on the spin basket membrane was 
washed by adding 600jj.I of SV RNA wash solution followed by centrifugation for 1 
minute. The collection tube was emptied and 250pl o f SV RNA wash solution was 
added to the spin basket before it was centrifuged again for 2 minutes. The spin basket 
was then transferred to a sterile elution tube and RNA was eluted in lOOpI of nuclease- 
free water by centrifugation fo r 1 minute. The basket was discarded and the purified 
RNA solution collected in the elution tube was stored at - 80°C.
RNA quantification and purity: the NanoDrop-1000 spectrophotometer was used to 
determine RNA concentration (ng/pl), yield and purity. A pure RNA sample has 
A260/A280 ratio o f (1.8 - 2.0) and A260/A230 ratio of (1.8 - 2.2) to dismiss any protein 
and guanidine contamination respectively.
2.3.2 Ethanol precipitation of RNA
If an RNA sample was very dilute or inadequately pure (A260/A280 and A260/A230 
ratios lower than 1.8), it underwent a further ethanol precipitation step to concentrate 
and purify it. For lOOpI RNA sample, lOpI of sodium acetate (3M, pH 5-5.2) and 250pl 
of 100 % ethanol were mixed gently w ith the RNA sample and then incubated 
overnight at -20°C. The sample was then centrifuged at 12,000 xg fo r 30 minutes at 4°C 
and the supernatant was removed carefully w ithout disturbing the RNA pellet (gel-like 
pellet). The RNA pellet was resuspended in 250pl of 70% ethanol and then centrifuged 
at 12,000 xg fo r 15 minutes at 4°C. The supernatant was removed carefully and the 
RNA pellet was air-dried fo r 10 minutes at RT. The RNA was resuspended in 20pl 
nuclease-free water and RNA concentration and purity were checked by NanoDrop- 
1000 spectrophotometer as in figure 2.2.
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2.3.3 Agarose gel electrophoresis o f to ta l RNA
The overall RNA quality and integrity was checked by running the sample on 1% 
agarose gel electrophoresis. The pre-stained agarose gel was prepared by adding 1 g of 
agarose (A9537, Sigma-Aldrich) to  100ml IX  Tris acetate EDTA (TAE) buffer (40mM 
Tris-acetate, Im M  EDTA, pH 8.2 - 8.4). The agarose was dissolved by heating the 
mixture in a microwave for about 2 minutes. The solution was then allowed to cool for 
a few minutes before adding 7.5pl of ethidium bromide (5mg/ml). The solution was 
poured into a sealed gel tray w ith an 8-well comb and it was allowed to set fo r about 
40 minutes. The gel was transferred to an electrophoresis tank after removing the 
comb. The tank was filled w ith IX  TAE buffer until the gel was completely submerged. 
The RNA samples were mixed w ith a loading dye (5pl RNA sample and lp l  loading dye) 
then they were loaded into the wells (wells at negative electrode side). The 
electrophoresis was run at 90 volts for 45 minutes then the gel was visualized using a 
UV transilluminator. The images were captured on Labworks software version 4. A 
good RNA sample with no degradation or contamination should have 2 bands fo r 28S 
and 18S ribosomal RNAs in a 2:1 ratio approximately shown in figure 2.3.
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Figure 2.2 RNA sample purity assessment by NanoDrop-1000 spectrophotometer
RNA sample purity assessed by NanoDrop-1000 spectrophotometer before and after 
ethanol precipitation. (A) RNA extraction of C28 RNA sample concentration was 101.4 
ng/pl, 260/280 ratio was 2.10 and 260/230 ratio was 1.78. (B) C28 RNA sample 
concentration after ethanol precipitation was increased to 425.9 ng/pl. 260/230 ratio 
was increased to 1.92 and 260/280 ratio decreased to 1.96 indicating a more pure RNA 
sample.
Figure 2.3 RNA sample integrity assessed by 1 % agarose gel electrophoresis
The RNA samples showed 2 clear bands fo r 28S and 18S ribosomal RNA in a 2:1 ratio 
indicating no degradation of the RNA.
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2.4 Complementary DNA (cDNA) synthesis
The mRNA was reverse transcribed to cDNA using Superscript™ III first strand 
synthesis system (Life Technologies, 18080-051). Starting from 1 pg of total RNA, lp l of 
50 pM oligo (dT)2o primer and lp l  of 10 mM deoxyribonucleotide triphosphate (dNTPs) 
mix were added to 8pl of total RNA before they were incubated at 65°C for 5 minutes 
and then placed on ice. A cDNA synthesis mix (lOpI) was then prepared in the 
following o rd e r: 2pl of 10X RT buffer, 4pl of 25 mM MgCI2 , 2pl of 0.1 M dith iothre ito l 
(DTT), lp l of RNaseOUT™ (40 U/pl) and lp l o f Superscript™ III RT®. The lOpI cDNA 
synthesis mix was added to RNA, oligo (dT)20 primer and dNTP mix, before it was mixed 
gently and incubated at 50°C for 50 minutes. The reaction was term inated by 
incubation at 85°C for 5 minutes then it was placed on ice.
The cDNA was then purified using a QIAquick PCR purification kit (Qiagen, 28104) 
according to the manufacturer's instructions. The cDNA sample (20pl) was mixed 
gently w ith lOOpI of buffer PB before it was transferred to a QIAquick spin column and 
then centrifuged at 13,000 xg for 1 minute. The collection tube was emptied and 750pl 
of Buffer PE was added to column and centrifuged at 13,000 xg for 1 minute. The 
collection tube was emptied and the column was centrifuged again at 13,000 xg fo r 1 
minute. The spin column was then transferred to a sterile elution tube and cDNA was 
eluted by adding 30pl of nuclease-free water and centrifuged at 13,000 xg for 1 minute. 
The cDNA was quantified using NanoDrop-1000 spectrophotometer and stored at - 
80°C.
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2.5 Quantitative real-time polymerase chain reaction (qRT-PCR)
2.5.1 Principle of qRT-PCR using TaqMan© gene expression assays
qRT-PCR is one of the most powerful and sensitive techniques used for investigating 
gene expression. Some of the advantages of qRT-PCR include: it collects the data in 
real time as amplification and detection are done simultaneously and it does not need 
post amplification processing; it is very accurate and can detect small changes in gene 
expression between samples; it needs small amounts of starting cDNA and is more 
accurate and sensitive than end point PCR (Wong and Medrano, 2005).
qRT-PCR phases: The PCR process is divided into 4 phases: linear ground, early 
exponential, log-linear, and plateau phases as shown in figure 2.4. The Linear ground 
phase is the first few cycles of PCR where the fluorescence baseline is being calculated. 
The early exponential phase is the starting point in which the gene of interest is first 
detected and threshold cycle (Ct) is determined. The Ct is the cycle in which the 
fluorescence becomes higher than the background level. The Ct value is inversely 
proportional to cDNA quantity in the samples. In log-linear phase the PCR products are 
doubling w ith every cycle and when PCR components are depleted the PCR reaches 
the plateau phase.
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Figure 2.4 qRT-PCR amplification plot phases
There are 4 phases: In linear ground phase the baseline fluorescence is measured. In 
the early exponential phase, the threshold cycle (Ct) is the intersection between an 
amplification curve and a threshold line. The target Ct is the cycle tha t target 
fluorescence exceeds the background signal and it reflects the relative target 
concentration in the sample. The log-linear phase shows the optimal amplification as 
PCR product is doubled w ith every cycle. In the plateau phase the PCR component 
starts to be depleted. The ARn signal is fluorescence of sample minus background 
fluorescence. This graph was generated on StepOnePlus™ Real-Time PCR System 
(Applied Biosystems).
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TaqMan® Gene Expression Assays consists of 2 unlabelled PCR primers specific to 
target sequence and a TaqMan® minor groove binder (MGB) probe that is designed to 
anneal specifically to a sequence between forward and reverse primer. This gives 
further specificity to TaqMan assays compared to  non-probe SYBR Green I dye 
chemistry. The TaqMan probe is a double-dye oligonucleotide hydrolysis probe that 
contains fluorescent reporter fluorochrome (FAM™ dye) at the 5' end, MGB and non- 
fluorescent quencher (NFQ) fluorochrome at the 3' end of the probe as in figure 2.5. In 
the intact probe, NFQ supresses the reporter dye fluorescence due to proxim ity 
distance between the 2 fluorochrome. However during the PCR amplification, the 
reporter dye is hydrolysed by 5' exonuclease activity of Taq DNA polymerase enzyme 
and the reporter dye fluorescence is em itted and detected. The FAM reporter 
fluorescence is increased with every PCR cycle providing real time measurement of 
target gene (Van der valden et al., 2003).
There is no non-specific amplification detected when using TaqMan MGB probes for 
many reasons: (1) the probe is specifically designed to anneal to complementary 
sequence in the target gene. (2) The MGB in the probe increases the melting 
temperature and allows the design of shorter more specific primers. (3) The probe is 
conjugated w ith non-fluorescent quencher making it more accurate to measure the 
reporter fluorescence. (4) The reporter dye fluorescence is only detected when it is 
separated from the quencher. (5) Taq DNA polymerase cleaves only probes that are 
annealed to target gene. (6) The 3' end of the probe is locked so the probe doesn't 
extend and cause any non-specific amplification (Van der valden et al., 2003).
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Figure 2.5 Principle of qRT-PCR using TaqMan® MGB probes
a) In polymerization forward and reverse primers anneal to specific sequences in 
target gene. TaqMan® Minor grove binder (MGB) probe binds specifically down steam 
of the primer. At this stage the probe is intact and there is no em itted fluorescence 
from the reporter dye (R) due to close distance to non-fluorescent quencher (NFQ). b) 
During the extension of the primers, the Taq DNA polymerase (P) in itia lly displaces the 
probe, c) The 5' exonuclease activity of DNA polymerase cleaves the reporter dye 
separating it from NFQ allowing R fluorescence to be detected, d) The polymerization 
of the strand continues until the first cycle is complete and then this process is 
repeated in the following PCR cycles (Adapted from TaqMan® gene expression assays 
protocol, Applied Biosystems™, PN 4333458N).
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2.5.2 RT-PCR Relative quantification using the comparative CT method
There are two ways of analysing RT-PCR data, absolute and relative quantification 
methods. In the absolute quantification method, the transcript of interest absolute 
copy number is determined by a standard curve. In the comparative Ct (2~AACt) method, 
relative change in gene expression in tested sample is determined as a fold change 
compared to the control sample. For each sample, the gene of interest expression is 
first normalised to a stable housekeeping gene that acts as an internal control (Linvak 
and Schmittgen, 2001; Wong and Medrano, 2005).
The raw data obtained at the end of the qRT-PCR experiment is Ct values fo r genes in 
diseased and control sample. The RT-PCR assay fo r target and housekeeping gene are 
done in triplicates and therefore, the first step in data analysis is to average Ct values 
for each gene to account fo r any inter-assay variability. Then the target gene 
expression in different samples is normalized to  housekeeping gene and ACt calculated 
as following:
The ACt in diseased sample:
ACt (Dis) = Housekeeping gene Ct (D-.s) - Target gene Ct (DiS)
The ACt in control sample:
ACt (cont) = Housekeeping gene Ct (C0nt) - Target gene Ct (Cont)
The 2'AACt method is calculated as following:
AACt = ACt (Dis) ” ACt (cont)
Fold-change ratio = 2'AACt
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The qRT-PCR data could then be presented as fold-change compared to control sample 
(2'AACt), where control equals 1. However, data can also be presented as gene 
expression normalized to housekeeping gene (2‘ACt), showing the actual expression of 
gene in both control and diseased samples (Linvak and Schmittgen, 2001).
2.5.3 Selection o f stable housekeeping genes
The qRT-PCR is an outstanding accurate and sensitive method fo r mRNA quantification 
but it critically depends on the selection of a good stable internal control or a 
housekeeping gene (HKG). The first step in data analysis by ACt method (section 1.6.2) 
is to normalise target gene expression to a stable HKG, to elim inate any variation 
between samples that may be caused by different amount or quality of starting RNA or 
cDNA. Therefore in relative qRT-PCR quantification, it is vital to evaluate and select the 
most stable HKGs that are not affected by experimental and pathological conditions 
(Radonic et al., 2004; Wierschke et al., 2010). It is also recommended to use 2 or more 
HKGs as normalization factor, rather than just one, as this provides the most accurate 
method for gene expression determination (Vandesompele et al., 2002).
The selection o f stable housekeeping genes was done using Fast 96 -well TaqMan® 
Express Human Endogenous Control plates (Life technologies,4426700). Those plates 
contained dried-down TaqMan® assays specific for 32 housekeeping genes in 
triplicates, the HKG TaqMan®assay IDs are in table 2.3 and plate layout in figure 2.6. 
Those candidate HKGs were selected from literature search and whole genome 
microarray analysis as they were constitutively expressed at moderate abundance.
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Tab le  2 .3  TaqM an® assay IDs in T aqM an®  express hum an  endogenous co n tro l p lates■
1 18S Eukaryotic 18S rRNA Hs99999901_.s i
2 GAPDH Glyceraldehyde-3-phosphate dehydrogenase Hs99999905_.m l
3 HPRT1 Hypoxanthine phosphoribosyltransferase 1 (Lesch- 
Nyhan syndrome)
Hs99999909_ m l
4 GUSB Glucuronidase, beta Hs99999908_.m l
5 ACTB Actin, beta Hs99999903_.m l
6 B2M Beta-2-microglobulin Hs99999907_ m l
7 HMBS Hydroxymethylbilane synthase Hs00609297_.m l
8 IP08 Importin 8 Hs00183533_.m l
9 PGK1 Phosphoglycerate kinase 1 Hs99999906_.m l
10 RPLPO Ribosomal protein, large, P0 Hs99999902_.m l
11 TBP TATA box binding protein Hs99999910_ m l
12 TFRC Transferrin receptor (p90, CD71) Hs99999911_.m l
13 UBC Ubiquitin C Hs00824723_.m l
14 YWHAZ Tyrosine 3-monooxygenase/tryptophan 5- 
monooxygenase activation protein, zeta polypeptide
Hs00237047_ m l
15 PPIA Peptidylprolyl isomerase A (cyclophilin A) Hs99999904_ m l
16 POLR2A Polymerase (RNA) II (DNA directed) polypeptide A, 
220kDa
Hs00172187_.m l
17 CASC3 Cancer susceptibility candidate 3 Hs00201226_ m l
18 CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cipl) Hs00355782_.m l
19 CDKN1B Cyclin-dependent kinase inhibitor IB (p27, Kipl) Hs00153277_.m l
20 GADD45A Growth arrest and DNA-damage-inducible, alpha Hs00169255_ m l
21 PUM1 Pumilio homolog 1 (Drosophila) Hs00206469_ m l
22 PSMC4 Proteasome (prosome, macropain) 26S subunit, 
ATPase, 4
Hs00197826_.m l
23 EIF2B1 Eukaryotic translation initiation factor 2B, subunit 1 
alpha, 26kDa
Hs00426752_ m l
24 PES1 Pescadillo homolog 1, containing BRCT domain Hs00362795_gl
(zebra fish)
25 ABL1 V-abl Abelson murine leukemia viral oncogene 
homolog 1
Hs00245445_.m l
26 ELF1 E74-like factor 1 (ets domain transcription factor) Hs00152844_.m l
27 MT-ATP6 Mitchondrially encoded ATP synthase 6 Hs02596862_gl
28 MRPL19 Mitochondrial ribosomal protein L19 Hs00608519_ m l
29 POP4 Processing of precursor 4, ribonuclease P/MRP 
subunit (S. cerevisiae)
Hs00198357_.m l
30 RPL37A Ribosomal protein L37a Hs01102345_.m l
31 RPL30 Ribosomal protein L30 Hs00265497_.m l
32 RPS17 Ribosomal protein S17 Hs00734303_gl
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Protocol: for every sample the PCR reaction mix (10pl final volume), per well, was 
prepared by adding 5pl of cDNA template (lOng cDNA in RNase-free water) and 5pl of 
2X TaqMan® fast universal PCR master mix (Life Technologies,4352042). The TaqMan® 
express human endogenous control plate was centrifuged briefly at 1000 xg fo r 1 min 
and then lOpI PCR reaction mix was added to each well. The plate was covered by 
MicroAmp® optical adhesive film  and centrifuged at 1000 xg for 1 min. The plate was 
loaded in StepOnePlus™ Real-Time PCR instrument (Applied Biosystems) and fast 
thermal cycling conditions were set on the instrument (polymerase activation 95°C for 
20 sec, 40 cycles of denaturing at 95°C for 3 sec, and annealing and extension at 60°C 
for 30 sec).
The data analysis: was done according to Applied Biosystems Application Note 
(127AP08) and Radonic et al. (2004). For every gene, the average Ct values and 
standard deviation (Stdev) were calculated using Microsoft® Excel 2010 software and 
data plotted using GraphPad Prism 6 software for Windows, version 6.05 
(www.graphpad.com). The genes with lowest variability were selected as internal 
controls for data analysis.
2.5.4 Determination of primer efficiencies
The comparative Ct method (section 1.6.2) used for qRT-PCR analysis, is based on the 
assumption that the amplification efficiencies of both target and housekeeping genes 
are 100% and within 5% of each other. The ideal 100% amplification efficiency means 
that PCR products are doubling with each PCR cycle during the exponential phase. 
Therefore it is essential to validate this assumption by determining primer efficiencies 
of all genes prior to data analysis (Wong and Medrano, 2005).
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The primer efficiencies are assessed by using 5 different dilutions of cDNA samples 
starting from 100 ng concentration. The average Ct value was plotted against Log 10 
cDNA concentration. The linear regression (R2) and linear equation were determined 
and plotted on graph. The slope of the standard curve is obtained from the linear 
equation and primer efficiency was calculated using the following equation:
Primer efficiency E = [10 1/slope] - i
Primers efficiency ranging from 90 -110% within 5% of each other is considered 
acceptable and could be used fo r comparative Ct data analysis (Wong and Medrano, 
2005).
2.5.5 qRT-PCR protocol
For all investigated genes, lOng of sample cDNA and final PCR reaction volume of lOpI 
were used (2pl of cDNA and 8pl of PCR reaction mix). For every sample tested, the 2 
HKGs and investigated genes were run on the same PCR plate in duplicate.
The PCR mix, per well, was prepared by adding 0.5pl of 20X TaqMan® gene expression 
assay (Assay IDs for investigated genes are in table 2.4), 2.5pl RNase-free water and 
5pl 2X TaqMan® fast universal PCR master mix (Life technologies, 4352042). To each 
well of 96-well PCR plate, 2pl of sample cDNA template was loaded followed by 
addition of 8pl of PCR mix. The plate was then sealed by MicroAmp® optical adhesive 
film  (Life technologies, 4360954) and centrifuged at 1000 xg fo r 1 min. The qRT-PCR 
was run on StepOnePlus™ Real-Time PCR instrument (Applied Biosystems) using fast 
thermal cycling conditions (polymerase activation 95°C for 20 sec, 40 cycles of 
denaturing at 95°C for 1 sec, and annealing and extension at 60°C for 20 sec).
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2.5.6 qRT-PCR data statistical analysis
The data obtained from RT-PCR is average Ct values; these were exported to 
Microsoft® Excel (2010) software. The data was analysed by calculating 2~ACt (fully 
described in section 2.5.2). Relative mRNA expression was normalised to cyclophilin A 
(PPIA) and cyclin-dependent kinase inhibitor IB  (CDKN1B) housekeeping genes as they 
were among most stably expressed genes in our samples (fully described in section 
2.5.3) and Wierschke et al., (2010).
The StatsDirect statistical software (www.statsdirect.co.uk) and GraphPad Prism 6 
software for Windows, version 6.05 (www.graphpad.com) were used for the statistical 
analysis and data presentation. The Shapiro-Wilk test was performed to test the 
normality of the data and Kruskall—Wallis w ith Conover-lnman post hoc analysis test 
was then used to identify significant differences between samples (P < 0.05).
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2.6 Protein extraction
Protein extraction from human hippocampal specimens was done using CelLytic™MT 
mammalian tissue Lysis/Extraction reagent (Sigma-Aldrich, C3228) and protease 
inhibitor cocktail (Sigma-Aldrich, P8340). The cocktail contains inhibitors w ith a broad 
specificity for serine, cysteine, and acid proteases, and aminopeptidases. For every 1 
gram of tissue, 10ml of CelLytic™ lysis buffer and 10pl of protease inhib itor cocktail 
were added to the sample in a pre-chilled manual homogenizer. The sample was then 
homogenized at 4°C and the lysate was centrifuged twice at 500 xg fo r 15 minutes at 
4°C. The pellet was discarded and the collected supernatant was centrifuged at 20,000 
xg for 40 minutes at 4°C. The pellet was washed twice with 50mM TrisHCI, pH 7.5 
(TBS) and was then re-suspended in TBS according to the original 1 : 10 ratio. The 50pl 
resuspended pellet aliquots were then stored at - 20°C until further use.
2.7 Total protein determination by BCA assay
The concentration of total proteins extracted from hippocampal specimens were 
determined by bicinchoninic acid (BCA) assay. The principle of the assay relies on the 
formation of a stable purple-blue complex between BCA and Copper I (Cu1+) in an 
alkaline environment. The protein's peptide bond reduces Cu2+ to Cu1+ and the Cu1+ 
produced from this reaction then forms the stable coloured complex w ith  BCA. 
Therefore the colour produced is directly proportional to protein concentration 
(Brown et al., 1989; Walker, 2009).
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The BCA reagent was freshly prepared by mixing 50 parts of bicinchoninic acid solution 
(Sigma-Aldrich, B9643) w ith 1 part o f 4% copper (II) sulphate pentahydrate solution 
(Sigma-Aldrich, C2284). Bovine serum albumin (BSA) standards were then prepared by 
making serial dilutions of the stock BSA solution (lOpg/pl). The BSA standards 
concentration were (1, 2, 3, 4, 5, 6, 7, 8, 9, 10) pg/pl. In a 96 well plate, the protein 
sample (10pl) at a 1:20 dilution was added to  the BCA reagent (200pl); every sample 
was tested in triplicate. The plate was incubated for 1 hour at room tem perature on a 
shaker. The absorbance was measured at 562 nm on a Tecan-Control 
spectrophotometer. The standard curve was then generated by plotting absorbance 
against concentration of BSA standards. The protein concentration of unknown sample 
was calculated from the linear equation of the standard curve with regression (R2) > 
0.95.
2.8 Quantitative two colour western blot analysis (WB)
Western blotting also known as protein blotting or imm unoblotting is a powerful 
technique used to identify, quantify and determine the size of specific proteins. The 
proteins are separated, based on their size, by polyacrylamide gel electrophoresis then 
they are transferred to a membrane. The target proteins are then identified by using 
primary antibody, specific to the target, and secondary labelled-antibodies that allow 
visualization and quantification of target proteins (Kurien and Scofield, 2006; Jensen, 
2012). The advantage of WB is that the membrane is easily handled and the proteins 
transferred on to a membrane, unlike in a gel, are more accessible to many probes 
(Kurien and Scofield, 2006).
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There are many methods of protein detection by WB depending on the secondary 
antibody used. In the colorimetric method, the secondary antibody is conjugated to an 
enzyme that produces colour when it reacts w ith its substrate. In the fluorescence 
detection method the secondary antibody is labelled w ith fluorophores. Recently a 
new method of detection was developed, it involved the use of near-infrared (IR) 
fluorophores directly conjugated to the secondary antibodies. Those fluorophores 
need to be excited by a laser beam before they can em it fluorescence such as IRDye™ 
800 labelled antibodies (excitation at 778 nm and emission at 800 nm) and IRDye™ 
680 labelled (excitation at 680 nm and emission at 700 nm) antibodies (Schutz- 
Geschwender et al., 2004).
The use of (IR) fluorophores in WB provide many advantages to the technique; it 
provides a highly sensitive and accurate method fo r quantifying proteins, low 
abundant proteins from as small as 1 pg can be accurately quantified, very low 
background auto fluorescence is detected in the near-IR spectrum, and it allows two - 
colour WB detection method (Schutz-Geschwender et al., 2004; Ambroz 2006).
The quantitative two-colour WB, provides the detection and quantification of two 
target proteins simultaneously on the same blot by hybridizing them w ith two different 
IR labelled antibodies (700 nm and 800 nm) at the same time. This is a fast and more 
precise quantification of protein expression as it eliminates the variability due to 
stripping or comparing separate blots. It also enables more accurate normalization of 
target protein to a housekeeping control (Picariello et al., 2006).
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2.8.1 Protein sample preparation fo r loading into gels
The proteins were extracted from the samples and quantified by BCA assay (described 
in sections 1.7 and 1.8). For all proteins investigated by WB, the same amount of total 
protein (20pg) was loaded in each gel well. The protein samples were prepared by 
adding lOpI o f 2X sample buffer [20% Glycerol, 4.6% SDS, 0.02% Bromophenol blue, 
2% DTT and 130 mM Tris-CI, pH 6.8] to lOpI of protein sample (20pg). The proteins in 
the mixture were denatured and reduced by incubation at 72°C for 4 minutes, then 
samples were placed on ice until loaded onto the gel.
2.8.2 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
The SDS-polyacrylamide gel (8%) was placed in the BIO-RAD Mini-protean®Tetra 
electrophoresis tank filled w ith 1 X Tris-glycine SDS running buffer (10X running buffer: 
0.25 M Tris,1.92 M glycine and 1% SDS in 1 L deionized water). Then 2pl of ColorPlus 
prestained protein marker (New England BioLab, P7711S) and 20pl protein samples 
were loaded into the wells. The proteins were then separated by electrophoresis at 
120 volts for about 1 hour or until the dye front reached the bottom of the gel.
2.8.3 Protein electro-blotting
Following electrophoresis the SDS-PAGE gel, sponges, blotting paper and Hybond-C 
Extra nitrocellulose (NC) membrane (Fisher Scientific, 10564755) were submerged in 
cold Tris-glycine transfer buffer (100 ml 10X transfer buffer, 200 ml methanol and 700 
ml water; 10X transfer buffer: 0.25 M Tris and 1.92 M glycine in 1 L deionized water). 
The WB sandwich was prepared and placed in the BIO-RAD Mini-protean® II cell 
transfer tank filled with pre-chilled transfer buffer. The proteins were electro­
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transferred onto the NC membrane at 100 volts for one hour at 4°C. The membrane 
was washed briefly in phosphate buffer saline (PBS) fo r a few minutes then it was 
blocked with 5% w /v non-fat dry milk (5% NFDM) in PBS and 0.1% Tween 20 (PBST) for 
one hour at room temperature.
2.8.4 Incubation w ith  antibodies
The primary antibodies were diluted w ith 0.1% PBST according to table 2.5. The NC 
membrane was incubated over night at 4°C w ith gentle shaking and sufficient volume 
of antibody to completely cover the membrane. Then it was washed 4 times w ith 0.1% 
PBST for 5 minutes. The IRDye* secondary antibodies were diluted w ith 0.1% PBST 
according to table 2.5 and were incubated w ith the NC membrane fo r 1 hour at room 
temperature. The NC membrane was incubated w ith both IRDye® 680LT goat anti­
mouse IgG (for (3-actin detection) and IRDye® 800CW goat anti-rabbit IgG (for target 
detection) at the same time. Following the incubation time, NC membrane was 
washed four times w ith PBS for 5 minutes.
The NC membrane was scanned on an Odyssey infrared imaging system (LI-COR, 
Biosciences, NE, U.S.A). Typically fo r each membrane, the instrument "Preset" is set to 
membrane, 169mm resolution, medium quality and 0 focus offset. Then scanning 
intensity for both 700 and 800 nm channels are adjusted to get the optimal image of 
the blot. The band quantification was done on the Odyssey software version 1.2, and 
Image studio™ lite 4 software (LI-COR, Biosciences). The band signal of target protein 
was normalized to p-actin band in the same lane, to eliminate any loading variation, as 
following:
Normalized intensity = Target protein signal /  P-actin signal
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Tab le  2 .5  P rim ary  and secondary an tib o d ies  and th e ir  d ilu tions  used in w e s te rn  b lo t
ACTB
Mouse monoclonal 
P-actin antibody
(S3700, Cell Signaling 
Technology®)
1 :1000
IRDye* 680LT goat 
anti-mouse IgG
(926-68020, LI-COR* 
Bioscience)
1 :10 ,000
GABAgi
Rabbit polyclonal 
GABAbi antibody 
(S3835, Cell Signaling 
Technology® )
1 :500
IRDye 800CWgoat 
anti-rabbit IgG
(926-32211, LI-COR* 
Bioscience)
1 :5 0 00
GABAb2
Rabbit monoclonal 
GABAb2 antibody 
(ab75838, Abeam®)
1 :5 0 0
IRDye 800CWgoat 
anti-rabbit IgG 
(926-32211, LI-COR* 
Bioscience)
1 :10 ,000
NF-L
Rabbit monoclonal 
Neurofilament-L 
antibody
(S2837, Cell Signaling 
Technology®)
1 :5 0 0
IRDye* 800CW goat 
anti-rabbit IgG
(926-32211,LI-COR* 
Bioscience)
1 :10 ,000
NeuN
Rabbit polyclonal 
Anti-NeuN antibody
(ABN78, M erck Millipore®)
1 :2000
IRDye 800CW goat 
anti-rabbit IgG
(926-32211,LI-COR* 
Bioscience)
1 :5 0 00
SGK1
Rabbit monoclonal 
Anti-SGK1[Y238] 
antibody
(Abeam, ab32374)
1 :5 0 0
IRDye* 800CW goat 
anti-rabbit IgG
(926-32211,LI-COR* 
Bioscience)
1 :10 ,000
SYNPR
Rabbit polyclonal 
Synaptoporin (H-60)
(sc-99075, SANTA CRUZ 
BIOTECHNOLOGY)
1 :2 0 0
IRDye 800CW goat 
anti-rabbit IgG 
(926-32211,LI-COR* 
Bioscience)
1 :5 0 00
SCN4B
Rabbit polyclonal 
Anti-SCN4B antibody
(Abeam,ab80539)
1 :5 0 0
IRDye 800CW goat 
anti-rabbit IgG
(926-32211,LI-COR* 
Bioscience)
1 :5 0 00
Antibodies were diluted w ith 0.1% PBST
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2.8.5 Western blot statistical analysis
The Shapiro-Wilk test was performed to test the normality of the data and Kruskall- 
Wallis w ith Conover-lnman post hoc analysis test was then used to identify significant 
differences between samples (P < 0.05). StatsDirect statistical software
(www.statsdirect.co.uk) and GraphPad Prism 6 software for Windows, version 6.05 
(www.graphpad.com) were used for the statistical analysis and data presentation.
2.9 Microarray analysis
DNA microarrays consist of complementary DNA strands called probes which are 
chemically bound to a solid surface such as a glass slide. The glass slides, unlike nylon 
membranes, are insensitive to light and provide excellent support to the DNA probes 
while allowing the use of smallest amount of sample (Stekel, 2003; Trevino et al., 
2007).
The probes can be single stranded PCR products or oligonucleotides depending on the 
type of microarray. The probes can either be ink-jet printed or microspotted on the 
microarray glass surface. The oligonucleotide microarrays are high quality arrays that 
have thousands of single-stranded nucleotide probes complementary to target genes 
in a test sample. Arrays are designed species-specific and they could cover the whole 
genome or a group of selected genes (Stekel, 2003)
Microarray analysis (MA) is a hybridization-based technique that allows the testing of
thousands of genes simultaneously. It has many applications in biomedical and clinical
research such as transcriptome profiling in physiological and disease conditions. This
helps in understanding the underlying cause of a disease and the identification of new
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drug targets. The oligo-based microarrays are the most common arrays used in 
biomedical research (Trevino et al., 2007; Lemuth and Steffen, 2015).
The Agilent SurePrint microarrays are high quality arrays that are prepared by applying 
a thin film  of an activated monolayer substrate to the glass slide which tightly binds to 
nucleic acids that are printed on its surface. The oligonucleotide probes are printed by 
an inkjet method. The probes are synthesized directly on the glass microarray surface 
via base-by-base repetitive printing rather than printing the full probe. Once the probe 
is printed it is called a feature. The inkjet printing undergoes multiple real-time 
monitoring to make sure that features present, size, shape and location are all 
consistent. Following the probe printing, the glass surface around the feature is 
deactivated to minimize the background signal (Agilent technologies, 5988-8171EN).
2.9.1 M icroarray analysis experimental design
There are many microarray platforms in order to investigate gene expression. Here the 
two SurePrint G3 Human Gene Expression 8x60K Microarrays (Agilent technologies, 
Cat. number: G4851A, design ID: 028004) were used; the eight 60K microarrays were 
printed on 1-inch x 3-inch glass slides. The first microarray slide was used for the 
transcriptome analysis of TLE-STG and TLE-HS surgical samples. The second slide was 
used for transcriptome analysis of sclerotic TLE-HS and post-mortem  hippocampi 
samples as shown in figure 2.7.
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M A I MA2
TLE-HS (E)/TLE-STG (C) TLE-HS (E) /Post-m ortem  (PM) samples
E l/P M l E2/PM2
E3/PM3 E4/PM4
E5/PM5 E6/PM3
E7/PM2 E l/P M l
E l/C l E2/C2
E3/C3 E4/C4
E5/C5 E6/C6
E7/C7 E3/C3
Figure 2.7 Experiment design of microarray analysis
The SurePrint G3 Human gene expression Microarrays (8x60K) slides were used to 
investigate hippocampal gene expression in sclerotic TLE-HS, TLE-STG and post­
mortem samples. E: sclerotic hippocampi from TLE patients (n = 7). C: Non-spiking 
superior temporal gyrus TLE-STG from TLE patients (n = 7). PM: post-mortem  
hippocampi (n = 5). MA: Microarray analysis slide.
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2.9.2 M icroarray analysis w orkflow
The standard workflow of a two-colour based microarray gene expression analysis 
shown in figure 2.8; is based on RNA extraction, cDNA and cRNA synthesis, and 
labelling the target and control samples with fluorescent dyes, cyanine 3 (Cy3) and 
cyanine 5 (Cy5). Then an equal amount of both labelled samples are hybridized to the 
microarray at 65°C for 17 hours. This is followed by washing steps, scanning and 
feature extraction. A fter RNA extraction, the following steps of RNA amplification, 
labelling, hybridization and microarray scanning were done in the Centre for Genomic 
research (CGR), University of Liverpool, UK.
2.9.3 Sample preparation fo r m icroarray analysis
2.9.3.1 RNA extraction
The RNA was extracted from samples by SV Total RNA Isolation System (Promega, 
Z3100) as described in section 2.3. The RNA concentration (ng/pl) and purity were 
checked by NanoDrop-1000 spectrophotometer and its integrity was checked by 1% 
agarose gel electrophoresis. Only high quality total RNA samples w ith A260/A280 ratio 
of 1.8 to 2.0 and an A260/A230 ratio o f > 2.0 were used for microarray study. The RNA 
concentrations and integrity were also checked on Agilent 2100 Bioanalyzer in CGR.
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Amplified cRNA
RNA 
from 
Sample A
AAAA 3‘ mRNA
RNA 
from 
Sample B
AAAA? mRNA
1 1 RNA Polymerase
Aflm tyScript*RT 
01 go dT-Promoter Primer
r n r n  fptoTo^e^ s' 1st strand cDNA
AAAAI Antons* r 
I Promote* I
13 2nd strand 5‘ 
cDNA
AfRnityScrip!.RT
T7 RNA Polymerase 
Cy3*CTP. NTPs
AffimtvScnpt*RT 
Ofigo dT-Promotcr Primer
r^-ir=n «• IZ"‘
A A A a |a » » !w « iq Q  3 2nd strand 
I Promoter Y-V cDNA
A f f  r  r y S tr ip ’ -R I
T7 RNA Polyrrerase 
Cy5-CTP. NTPs
i
r<&
T7 RNA Polymerase
c uuuu | \
AAAA
6 cRNA 3‘
Antksense
Promoter
Purify cRNA
2nd strand 
cDNA
- □  5 cRNA
AAAA K T - r h  strand 
I  Promoter I cONA
Purify cRNA
I II I
Q .___ .Q ^U U W  —  □  b’ cRNA
(antisense)
UUUll [  5 ‘ cRNA
(aotisensej
0 |igo Microarrays
Figure 2.8 Workflow in two-colour microarray gene expression analysis
Adapted from Agilent technologies protocol, G4140-90050.
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2.9.3.2 Preparation of spike-in Mix A and B
The RNA Two colour spike-in kit (Agilent technologies, 5188-5279) contains spike-in 
mix A and B. The spike-in mixes are positive controls that are added to the target RNA, 
in order to monitor microarray workflow such as amplification, labelling and 
hybridization. The spike-in is a mixture o f 10 in vitro  synthesized, polyadenylated 
transcripts (E1A transcripts) which are premixed at various ratios. The spike-in mix A is 
always labelled w ith Cy3 while spike-in mix B is labelled with Cy5. For each of the E1A 
transcripts, the calculated Log ratio of Cy5/Cy3 is plotted against the expected Log 
ratio and a correlation coefficient > 0.9 demonstrates a high quality microarray data.
The spike-in mix A and B were pre-heated at 37°C for 5 minutes and then mixed well. 
For each spike-in mix, starting from 2pl of stock solution, four serial dilutions were 
done according to  manufacturer's instructions and in the following order 1:20, 1:40, 
1:16 and 1:4. From the fourth dilution 2pl were added to 50 ng of target RNA sample.
2.9.3.3 The cRNA amplification and labelling
RNA samples were processed by using the Two-colour Low Input Quick Amp Labelling 
Kit (Agilent technologies, 5190-2306). The starting RNA input that could be used is 
between 10 - 200 ng. The kit uses T7 RNA polymerase to simultaneously amplify and 
label the target mRNA (with Cy3 or Cy5) w ith about a 100-fold amplification. In our 
experiment there are three types of samples that are investigated: the TLE-HS 
hippocampi samples were labelled with Cy5, while TLE-STG and PMC samples were 
labelled with Cy3.
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cDNA synthesis: 2pl of diluted spike-in mix were added to 50 ng of RNA sample (1 .5p l). 
Spike-in mix A was added to TLE-STG and PMC samples, while spike-in mix B was 
added to TLE-HS samples. Then 1.8|il o f T7 oligo dT primer and 3.5|il target RNA 
sample (contain spike-in mix) were mixed and incubated at 65°C for 10 minutes and 
then they were placed on ice for 5 minutes. The 5X first strand buffer was incubated at 
80°C for 4 minutes and was then allowed to cool to room temperature before it was 
added to the cDNA master mix. The cDNA master mix (4.7pl) was prepared by adding; 
2pl of pre-heated 5X first stand buffer, lp l of 0.1M DTT, 0.5pl of lOmM dNTPs mix, 
1.2pl of A ffin ity Script RNase Block Mix. To each sample, a 4.7pl of cDNA master mix 
was added and reaction was incubated at 40°C for 2 hours then at 70°C for 15 minutes 
to stop the reaction. The cDNA samples synthesized (lOpI) were then placed on ice for 
5 minutes.
cRNA synthesis and labelling: two transcription master mixes were prepared as in 
table 2.6 , one with Cy3-CTP and the other w ith Cy5-CTP depending on the sample. 
Then to lOpI o f cDNA samples previously synthesised, 6pl of transcription master mix 
were added and the reaction was incubated at 40°C for 2 hours, followed by placing 
the sample on ice.
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Tab le  2 .6  T ranscrip tion  m as te r m ix  co m p on en ts
Nuclease-free water 0.75 0.75
5x transcription buffer 3.2 3.2
0.1 M DTT 0.6 0.6
NTPs Mix 1 1
T7 RNA polymerase blend 0.21 0.21
Cyanine 3-CTP - 0.24
Cyanine 5-CTP 0.24 -
Total volume 6 6
The labelled cRNA purification was purified by RNeasy Mini Kit (Qiagen, 74104). 84pl 
nuclease-free water was added to the 16pl of labelled cRNA. First 350pl o f buffer RLT 
and then 250pl o f 96% ethanol were mixed w ith the diluted cRNA. The mixture was 
transferred to an RNeasy Mini Spin Column and was then centrifuged at 4°C for 30 sec 
at 13,000 xg. The RNeasy column was then transferred to a new collection tube and 
500pl o f buffer RPE were added to the column and then centrifuged at 4°C for 30 sec 
at 13,000 xg. The collection tube was emptied and another 500pl of buffer RPE was 
added to the column and then it was centrifuged at 4°C for 60 sec at 13,000 xg. The 
collection tube was emptied and the column was centrifuged again at 4°C for 30 sec at 
13,000 xg to remove any traces of Buffer RPE. The column was transferred to  a sterile 
collection tube and the pure cRNA was eluted by adding 30pl RNase-Free water 
directly onto the RNeasy filte r membrane. After waiting fo r 1 minute the column was 
centrifuged at 4°C for 30 sec at 13,000 xg. The cRNA sample was stored at - 80°C.
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2 .9 .3 .4  The lab e lled  cRNA q u a n tific a tio n
The cRNA concentration (ng/M.1), the Cy3 and Cy5 concentrations (pm ol/|il) were all 
determined using the NanoDrop ND-1000 UV Spectrophotometer. The cRNA yield and 
Cy3 and Cy5 specific activity were calculated according to the following formulas: 
cRNA Cone, (ng/pl) X 30 pi (elution volume)
pg of cRNA =
1000
Cy3 or Cy5 Cone, (pmol/pl)
pmol of Cy3 or Cy5 /pg  cRNA = --------------------------------------------- X 1000
cRNA Cone, (ng/pl)
For optimal microarray hybridization the cRNA yield should be at least 0.825 pg and 
Cy3 or Cy5 specific activity should be at least 6 pmol /pg  cRNA.
2.9.3.5 Microarray hybridization
The hybridization was done using the Gene Expression Hybridization Kit (Agilent 
technologies, 5188-5242). For each microarray, equal amounts of the two samples 
were mixed gently w ith 10x gene expression blocking agent and 25x fragmentation 
buffer as in table 2.7. The mix was incubated at 60°C for 30 minutes to fragment the 
RNA and was then placed on ice fo r 1 minute. 25pl of 2x Hi-RPM hybridization buffer 
was mixed gently with the cRNA sample w ithout introducing bubbles then it was 
centrifuged at room temperature for 1 min at 13,000 xg.
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T ab le  2 .7  S am ple  p re p a ra tio n  fo r  h ybrid iza tio n
Volume/MassComponents
Cy3 labelled cRNA (TLE-STG or PMC) 
Cy5 labelled cRNA (TLE-HS)
10x gene gxpression blocking agent 
Nuclease-free water 
25x fragmentation buffer 
Total volume
bring volume to 24pl
300 ng 
300 ng 
5pl
lp l
25pl
The hybridization sample was then loaded onto the microarray by slowly dispensing 
40pl o f the sample onto the gasket well, w ithout introducing any air bubbles. Then 
samples were hybridized at 65°C for 17 hour by placing the assembled slide chamber 
into a rotating hybridization oven. Following hybridization, the microarray 
hybridization chamber was disassembled at room temperature in gene expression 
wash buffer 1 (Agilent Technologies, 5188-5327). The microarray slide was placed into 
the slide rack and was washed with gene expression wash buffer 1 fo r 1 minute at 
room temperature. Then it was washed for another minute with the pre-warmed gene 
expression wash buffer 2 (warmed overnight to 37°C). The microarray slide was placed 
in a slide holder ready for scanning.
2.9.3.6 Microarray scanning and feature extraction
Following the washing steps, the microarrays were scanned immediately on Agilent 
Technologies SureScan Microarray Scanner and data was extracted using Agilent 
feature extraction software version 10.7.1. The features background signal was 
subtracted by local subtractions method. The raw data obtained was Log2 ratio of 
Cy5/Cy3. The analysis of microarray data is fully described in chapter 5 (section 5.2.4).
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Chapter 3
Expression of GABAb receptor in 
sclerotic hippocampi from refractory
TLE-HS patients
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3 Expression of GABAb receptor in sclerotic hippocampi from  
refractory TLE-HS patients
3.1 Introduction
In the brain y-amino butyric acid (GABA) is the main inhibitory neurotransmitter. It acts 
on 2 types of receptors: ionotropic and metabotropic. The ionotropic GABAa and 
GABAC receptors are responsible for fast synaptic inhibition. The metabotropic GABAb 
receptors are G-protein-coupled receptors that are present on pre- and postsynaptic 
membranes in neuronal synapses (Jacob et al., 2008; Benarroch, 2012). They are 
responsible fo r the slow and prolonged inhibitory postsynaptic potential (IPSP). GABAb 
receptors are also expressed in astrocytes and microglia (Charles et al., 2003; Oka et al., 
2006). Many studies suggested that GABAb receptor could be implicated in TLE-HS 
pathophysiology (Billinton et al., 2001a; 2001b; Munoz et al., 2002; Princivalle et al., 
2002 ; 2003; Benke eta!., 2012).
3.1.1 GABAb receptors subunits
3.1.1.1 Principal or core subunits
The functional GABAb receptor is an obligatory heterodimer composed of two principal 
subunits, GABABi and GABAb2. The core subunits are seven-transmembrane domain 
(7TM) subunits that have large extracellular N-terminal domains known as 'venus 
flytrap domain' (VFTD) and a large intracellular C-terminal domain that forms the 
coiled-coil dimerization domain. The GABAb1 extracellular N-terminal domain contains 
the GABA binding site and its C-terminal domain contains the endoplasmic reticulum
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(ER) retention/retrieval signal. The GABAB2 N-terminal domain does not have a ligand 
binding site but the transmembrane-domain has an allosteric binding site, which 
influences the GABA binding affin ity to GABABi (Billinton et al., 2000; Benarroch, 2012; 
Benke et al., 2012; Gassmann and Bettler, 2012). The GABAB1 subunit has two isoforms, 
GABABia and GABABlb which are splice variants from the GABABi  gene. The GABABi a 
differs from GABABib by having an additional two protein-protein domains at the 
extracellular N-terminal known as sushi domains as in figure 3.1 (Bettler et al., 2004).
3.1.1.2 Auxiliary subunits
Recent research found that the GABAb receptor is also composed of auxiliary subunits. 
The C-terminus of GABAB2is tightly associated w ith those auxiliary subunits which are 
potassium channel tetramerization T1 domain-containing (KCTD) protein members as 
in figure 3.1. Those protein members are KCTD8, KCTD12, KCTD12b and KCTD16 and 
they bind to the receptor in tetramers to form a stable receptor complex at the cell 
membrane (Gassmann and Bettler, 2012; Turecek et al., 2014; Xu et al., 2014; Rajalu et 
al., 2015).
The KCTD auxiliary proteins could influence the GABA binding-affinity of the receptor, 
KCTD8 and 16 were found to slightly increase the GABA binding-affinity (Rajalu et al., 
2015). KCTD could also bind to the G-protein at the receptor and differentially regulate 
the G-protein signalling. KCTD12 reduced the receptor internalization and therefore 
increasing the magnitude of receptor signalling (Turecek et al., 2014; Xu et al., 2014; 
Rajalu et al., 2015).
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Figure 3.1 GABAb receptor principal and auxiliary subunits
GABAb is composed of 2 seven-transmembrane-domain (7TM) principal subunits: 
GABAbi and GABAB2- The N-terminal venus flytrap domain (VFTD) of GABAbi subunit 
contain GABA binding site. GABABi a isoform has two additional protein domains at the 
extracellular N-terminal known as sushi domains. The GABAB2 7TM domain has an 
allosteric binding site and its C-terminal binds to potassium channel tetramerization 
domain-containing protein (KCTD) auxiliary subunits. Adapted from Benke et ol. (2 0 1 2 ).
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3.1.2 GABAb receptor assembly and trafficking
The GABAbi with GABAB2 subunits are synthesized in the endoplasmic reticulum from 
GABBR1 and GABBR2 genes respectively, where they are assembled into a complex by 
the coiled-coil interaction between the 2 subunits. This assembly will mask the 
endoplasmic reticulum-retention signal (ER retention signal), in the GABAbi C- terminal 
domain, ensuring that only the heteromeric GABAbi and GABAB2 receptor could be 
exported from the ER as in figure 3.2. Therefore, heteromeric assembly of GABAbi 
with GABAB2 subunits is vital for the receptor trafficking to the cell surface (Benke et al., 
2012; Valenzuela et al., 2014).
3.1.3 GABAb receptors mechanism of action
GABAb receptors are responsible for slow synaptic inhibition as they prolong the late 
inhibitory postsynaptic potential (IPSP) (Billinton et al., 2001a; Benarroch, 2012). The 
activation of presynaptic GABAb receptors inhibits the release of neurotransmitters 
such as GABA and glutamate, while the activation of postsynaptic GABAb causes 
prolonged IPSP (Benke et al., 2012).
The GABAb receptor is activated by binding of GABA to GABAbi subunit and this will 
lead to the recruitment and activation of the G-protein (GcXj/0) by GABAB2 subunit. The 
activated G-protein will act on three targets; adenylyl cyclase, voltage-gated calcium 
channels (VGCCs) and G protein-activated inwardly rectifying potassium channels 
(GIRKs) as in figure 3.3.
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Figure 3.2 GABAb receptor assembly and trafficking to cell membrane
The heteromeric assembly of GABAbi and GABAB2 subunits hides the endoplasmic 
reticulum-retention signal in GABAbi subunit and allows the receptor to be exported 
from the endoplasmic reticulum and trafficked to the cell membrane. Adapted from 
Valenzuela et al. (2014).
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Figure 3.3 GABAb receptor activation and mechanism of action
The binding of GABA to GABABi  subunit leads to the activation of the G-protein which 
subsequently acts on three targets; adenylyl cyclase, voltage-gated calcium channels 
(VGCC) and G protein-activated inwardly rectifying potassium channels (GIRKs). 
Adapted from Gassmann and Bettler (2012).
The a-subunit of the activated G protein will inhibit adenylyl cyclase and lowers the 
level of cyclic adenosine monophosphate (cAMP). In pre-synapse, the reduced cAMP 
levels will hinder synaptic vesicle fusion and reduce the spontaneous neurotransm itter 
release. In postsynapse, the low cAMP levels will reduce cAMP dependent protein 
kinase A (PKA) activity and inhibit the calcium permeability of NMDA glutamate 
receptor (Skeberdis et al., 2006; Gassmann and Bettler, 2012).
The (3y dimer subunits of the activated G protein reduce calcium dependent 
neurotransm itter release by inhibiting presynaptic VGCCs and by interacting directly 
w ith SNARE (soluble A/-ethylmaleimide-sensitive factor attachment protein receptor) a 
synaptic vesicle fusion complex (Yoon et al., 2007). The (3y dimer also activates the 
postsynaptic GIRKs causing an outward K+ current and hyperpolarized membrane that 
leads to prolonged IPSP and the subsequent inhibition of back propagating action 
potentials (Benarroch, 2012; Benke et al., 2012).
In addition to GABAb inhibition function, it was reported that GABAb receptors in 
hippocampal neuronal cultures promoted GABAa receptor surface expression via 
increasing the secretion of endogenous brain-derived neurotrophic factor (BDNF). The 
(3y subunits released from Gi/o proteins leads to the activation of phospholipase C, 
generation of diacylglycerol, and activation of protein kinase C (PKC). PKC mediates the 
phosphorylation of L-type VGCCs and subsequent secretion of BDNF (Kuczewski et al., 
2011).
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3 .1 .4  6ABAb receptors  in TLE-HS
GABAb receptors were hypothesised to have an important role in the pathophysiology 
of TLE associated w ith HS. Many studies suggested that there was a reduction in the 
GABA-mediated inhibition in the neurons of the sclerotic hippocampus of temporal 
lobe epilepsy (Mangan and Lothman, 1996; Billinton et al., 2001a; Princivalle et al., 
2003). Electrophysiological studies also showed a reduction in the inhibitory 
postsynaptic potential in sclerotic hippocampal neurons (Mangan and Lothman, 1996; 
Teichgraber et al., 2009).
The distribution and expression levels of GABABi a, GABABlb and GABAB2 mRNA were 
studied in human TLE-HS samples by in situ hybridisation; neuronal loss was evident 
compared to the control hippocampi and there were alterations in the expression 
levels of GABAb subunits in the different subregions of the hippocampus. However, 
when the expression level was calculated per neuron to normalize for the neuronal 
loss, it showed that expression levels of GABABi a, GABABlb and GABAb2 were 
significantly higher in the surviving neurons (Billinton et al., 2001a; Princivalle et al., 
2003).
The investigation of protein expression level is required to extend our understanding 
of the role o f the GABABin TLE-HS. The GABAb receptor distribution was studied in the 
animal models of TLE (Benke et al., 1999; Straessle et al., 2003) and in human TLE-HS 
specimens (Munoz et al., 2002). However, so far no quantitative studies o f GABABi a, 
GABABib and GABAB2 subunits were performed in human TLE-HS specimens.
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3.1.5 Aims of the study
The aim of this study was to do: 1) Quantitative analysis of GABAbsubunits transcript 
levels in TLE-HS and PMC samples to further corroborate the in situ hybridisation data 
(Billinton et al., 2001a; Princivalle et al., 2003). 2) mRNA quantitative analysis of GABAb 
subunits in the TLE-STG samples. 3) Quantitative analysis o f GABAb subunits protein 
level in TLE-HS, TLE-STG and PMC. This will lead to further understanding of the role of 
GABAb receptor in refractory TLE-HS pathophysiology.
3.2 Materials and methods
3.2.1 Patient clinical inform ation
Clinical information for TLE-HS, TLE-STG and PMC samples investigated in this chapter 
is described in Appendix I.
3.2.2 Study design
The selection of a stable housekeeping gene was followed by the investigation of 
mRNA levels o f PPIA, CDKN1B, GABAb1, GABAb2 and NeuN by qRT-PCR in TLE-HS (n = 
26), TLE-STG (n = 11) and PMC (n = 10) samples. The protein expression of GABABi a, 
GABABi b, GABAb2, NeuN, NF-L and (3-actin (ACTB) were investigated by two-colour 
quantitative western blot in TLE-HS (n = 9), TLE-STG (n = 6) and PMC (n = 4) samples. 
Significant difference between the samples was identified by Kruskal-Wallis w ith 
Conover-lnman post hoc analysis test.
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3.2.3 Methods
qRT-PCR: In brief, the total RNA was extracted by SV Total RNA Isolation System 
(section 2.3.1) and then was reverse transcribed using Superscript™ III first strand 
synthesis system (section 2.4). Stable housekeeping genes were selected fo r the 
normalization of target gene expression (section 2.5.3). The TaqMan® primers 
amplification efficiency of housekeeping and target genes was assessed first (section
2.5.4) prior to performing the qRT-PCR using TaqMan® gene expression assays (section
2.5.5).
WB: Briefly the total proteins were extracted from hippocampi samples using 
CelLytic™MT mammalian tissue extraction reagent (section 2.6).Then total protein 
determination was assessed by the BCA assay (section 2.7). Quantitative two colour 
western blotting was done for all samples by electrophoresis of lOpg protein followed 
by electro-transfer onto a nitrocellulose membrane. The membrane was then blocked, 
incubated w ith primary and secondary antibodies before it was scanned on the 
Odyssey infrared imaging system (section 2.8).
3.3 Results
3.3.1 RNA purity and integrity
High quality and pure RNA is essential fo r an effective and good reverse transcription 
reaction and qRT-PCR analysis. The extracted total RNA purity was assessed by the 
NanoDrop-1000 spectrophotometer, A260/A280 ratio indicated the presence of 
protein contamination and A260/A230 ratio indicated the presence of guanidine 
thiocyanate and alcohol contamination.
90
Only RNA samples w ith A260/A280 ratio of 1.8 - 2.0 and A260/A230 ratio of 2.0 - 2.2 
as in figure 3.4 were considered free of contaminants and were used fo r qRT-PCR 
analysis. The integrity of total RNA extracted was also assessed by running 1% agarose 
gel electrophoresis. An intact RNA sample w ith no degradation should have 2 distinct 
bands for 28S and 18S ribosomal RNAs in an approximately 2:1 ratio as in figure 2.5.
Sample Type RNA-4Q jOverlay control Cleat graph each Sample v
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Sample ID H37 RNA after ppt7 00-
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Figure 3.4 RNA sample purity assessed by the NanoDrop-1000 spectrophotometer
The RNA samples 260/280 ratio was 1.97 and 260/230 ratio was 2.00 indicating a pure 
RNA sample suitable for further investigations such reverse transcription, RT-PCR and 
MA analysis.
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3.3.2 Selection of stable housekeeping genes fo r qRT-PCR analysis
In the relative qRT-PCR analysis, the expression of target gene is normalized to HKGs 
and thus it is vital to select the most stable HKGs that are not affected by experimental 
and pathological conditions (Radonic et al., 2004; Wierschke et al., 2010). Therefore in 
our study, 32 HKGs were tested in 6 samples, in triplicates, to check their stability. The 
analysis was done according to Applied Biosystems Application Note (127AP08) and 
Radonic et al. (2004). For every gene, the average Ct values and standard deviation 
(Stdev) were calculated and then plotted as in figure 3.5. The gene variability fo r each 
HKG was determined and plotted as in figure 3.6, and PPIA and CDKN1B were selected 
as normalization genes for subsequent qRT-PCR analysis as they were most stable. The 
Ct values of PPIA and CDKN1B in all the samples used were determined and plotted as 
in figure 3.7 to ensure their stability in all samples.
3.3.3 Primer efficiency
Once the HKGs were selected the primer efficiency for each gene was determined. For 
every gene the standard curve was done by plotting the average Ct value against Logio 
cDNA concentration as in figure 3.8. The standard curve slope was used to calculate 
primers efficiency. The resulting primer efficiencies ranged from 96 % to 99.6 % and 
were within 5% of each other (table 3.1), making them very suitable fo r comparative 
qRT-PCR analysis.
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Figure 3.5 Threshold cycle (Ct) of 32 housekeeping genes in 6 samples
The Ct is the cycle number at which the target fluorescence exceeds the threshold 
fluorescence. Refer to table 2.3 in section 2.5 fo r HKGs names. Data presented as the 
Ct mean ± StDev (n = 6). CT: Threshold cycle (Ct).
Housekeeping genes
3.0-1
2.5-
£
!5 2.0-
.2c<0 1.5-
>
<D
C 1.0-a>
O
0.5-
0.0-
Less stable
More stable
U r**1**1
Figure 3.6 Variability of 32 housekeeping genes in 6 samples
The variability of each gene in the 6 samples is Ct standard deviation. The PPIA and 
CDKN1B were selected as normalizing genes as they were 2 of the most stable genes. 
Refer to table 2.3 in section 2.5 for HKGs names.
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Figure 3.7 PPIA and CDKN1B gene variability
The Ct values of PPIA and CDKN1B obtained from RT-PCR were determined in all TLE- 
HS, TLE-STG and PM control samples. Data presented as Ct mean ± standard deviation. 
Number of samples: TLE-HS (n =26), TLE-STG (n = 11) and PM control (n = 10). CT: 
Threshold cycle (Ct).
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Figure 3.8 Standard curves for primer efficiency determination
PPIA, CDKN1B, GABAbi and GABAB2 primers had good linear regression R2 = 0.95-0.98
Table 3.1 TaqMan© assay primer amplification efficiency for all housekeeping and 
target genes used for qRT-PCR
PPIA -3.4 0.97 96.84
CDKN1B -3.33 0.97 99.66
GABAbi -3.36 0.95 98.03
GABAb2 -3.41 0.98 96.45
NeuN -3.42 0.98 96.06
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3.3.4 Relative GABABi and GABAB2 mRNA expression
The data from qRT-PCR show a very similar trend for both GABAbi and GABAB2 subunits. 
Comparing TLE-HS to PMC sample it can be seen that GABAB1 mRNA is not varying 
whereas GABAB2 mRNA level demonstrated an increased expression in TLE-HS. On the 
contrary, comparing TLE-HS to TLE-STG, both subunits mRNA level showed a reduced 
level of expression in TLE-HS. However, only GABAB2 mRNA expression was significantly 
decreased in TLE-HS compared to TLE-STG as shown in figure 3.9.
3.3.5 Relative Neuronal nuclei (NeuN) mRNA expression
The neuronal marker NeuN mRNA expression obtained from qRT-PCR analysis showed 
a significant decrease in TLE-HS tissue compared to PMC. It also showed a decreased 
expression in TLE-HS tissue compared to TLE-STG, thought it was not significant as in 
figure 3.10.
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Figure 3.9 qRT-PCR data showing the relative mRNA expression of GABAbi and 
GABAb2 in TLE-HS, TLE-STG and PMC
The GABAbi mRNA level in TLE-HS was not significantly altered compared to PMC and 
was decreased compared to TLE-STG. The GABAB2 mRNA level in TLE-HS was increased 
compared to PMC but was significantly reduced compared to TLE-STG. qRT-PCR data 
analysis was done by 2"ACT method. Statistical analysis: Kruskal-Wallis w ith Conover- 
Inman post hoc analysis test was used to identify significant differences between 
samples (* P < 0.05). Number of samples: TLE-HS (n =26), TLE-STG (n = 11) and PMC (n 
= 10). Data presented as mean ± S.E.M.
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Figure 3.10 qRT-PCR data showing the relative mRNA expression of NeuN in TLE-HS,
TLE-STG and PMC
The NeuN mRNA was significantly reduced in TLE-HS compared to PMC. The TLE-HS 
NeuN mRNA level was slightly decreased compared to TLE-STG. The qRT-PCR data 
analysis was done by 2~ACT method. Statistical analysis: Kruskal-Wallis w ith Conover- 
Inman post hoc analysis test was used to identify significant differences between 
samples (* P < 0.05). Number of samples: TLE-HS (n =26), TLE-STG (n = 11) and PMC (n 
= 10). Data presented as mean ± S.E.M.
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3.3.6 Total protein quantification in hippocampi samples
The extracted total proteins were quantified by the bicinchoninic acid (BCA) assay to 
ensure the same amount of proteins was loaded for WB analysis. A standard curve was 
generated by plotting bovine serum albumin (BSA) concentrations against their 
absorbance at 562 nm as in figure 3.11. The protein concentration of unknown 
samples were calculated using linear equation of the standard curve y = 0.2766 x + 
0.3757, where y = absorbance and x = protein concentration.
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Figure 3.11 BSA standard curve for protein determination
The protein concentration of unknown sample was determined from the curve linear 
equation X = (y - 0.375)/0.2766, where x = protein concentration and y = unknown 
sample absorbance at 562 nm.
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3.3.7 Western b lo t quantification o f GABABi and GABAB2 receptor subunits
The double-labelled western blots in TLE-HS, TLE-STG and PMC samples demonstrated 
an alteration in expression of GABAb isoforms and subunits compared to the consistent 
expression of (3-actin. In all samples GABAbi subunit showed a distinct 2 bands at 130 
and 95 KDa fo r GABABia and GABABi b isoforms respectively. The GABAb2 subunit 
showed one distinct band at 106 KDa as in figure 3.12a. The densitometric analysis of 
the WB bands showed that, the expression of GABAb isoforms and subunit follows the 
same trend as in figure 3.12b. The results demonstrated that GABABla, GABABlb and 
GABAb2 protein levels in TLE-HS samples showed a significant up regulation compared 
to  PMC samples. On the other hand, they showed a decreased protein levels compared 
to TLE-STG samples although only GABAB2 subunit was significantly down regulated.
3.3.8 Western blot quantification o f NeuN and NF-L200
The double-labelled western blots of neurofilament-light (NF-L) in TLE-HS and TLE-STG 
samples, showed as expected 2 bands specific to NF-L at about 60 and 70 kDa and 
band specific to ACTB at about 45 kDa as in figure 3.13a. The WB also showed 
nonspecific band at about 50 kDa in the TLE-STG samples. The double-labelled western 
blots of NeuN protein in TLE-HS and TLE-STG samples, showed multiple bands, a band 
specific to NeuN at about 48 kDa, a band specific to ACTB at about 45 kDa and 
nonspecific band at about 50 kDa as in figure 3.13b. The WB quantification analysis of 
the bands intensities showed a significant reduction of both NF-L and NeuN protein 
levels in TLE-HS compared to TLE-STG samples, indicating neuronal loss in TLE-HS 
specimens as in figure 3.13c.
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Figure 3.12 Quantitative western blotting of GABABi a/ GABABib and GABAb2 subunits
in TLE-HS, TLE-STG and PMC
(a) Two-colour WBs showing expression of GABABi a, GABABi b, GABAb2 and ACTB and 
the negative control fo r IRDye 680 and 800 secondary antibodies, (b) Quantitative 
expression of GABABi a, GABABlb and GABAB2 relative to ACTB expression. All GABAb 
subunits were significantly up regulated in TLE-HS compared to PMC and only GABAb2 
subunits was significantly down regulated in TLE-HS compared to  TLE-STG. The band 
quantification was done by Odyssey (1.2) and Image Studio Lite (4.0) software. 
Statistical analysis: Kruskal-Wallis w ith Conover-lnman post hoc analysis test was used 
to identify significant differences between samples (* P < 0.05, * *  P < 0.01). Number of 
samples: TLE-HS (n =9), TLE-STG (n = 6) and PMC (n = 4). Data presented as mean ± 
S.E.M.
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Figure 3.13 Quantitative western blotting of NF-L and NeuN in TLE-HS and TLE-STG
Two-colour WB using IRDye 680 and 800 secondary antibodies showing bands for (a) 
NF-L (~ 70 KDa) and p-Actin (~ 45 KDa) (b) NeuN (~ 48 KDa) and and (3-Actin. (c) 
Quantitative expression of NF-L and NeuN was normalized to ACTB. The NF-L and 
NeuN expression were significantly reduced in TLE-HS indicating a degree of neuronal 
loss compared to TLE-STG. Statistical analysis: Kruskal-Wallis w ith Conover-lnman post 
hoc analysis test was used to identify significant differences between samples (* P < 
0.05, * * *  P < 0.001). Number of samples: TLE-HS (n =9), and TLE-STG (n = 6). Data 
presented as mean ± S.E.M.
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3.3.9 Neuronal GABABi and GABAB2 protein expression
The relative protein level of neuronal GABAB subunits was determined in TLE-HS and 
TLE-STG samples by normalizing GABAe subunit expression against two neuronal 
markers which are NF-L and NeuN to give us an indication of GABAb neuronal 
expression. The GABAb subunit, NF-L and NeuN expression values obtained from the 
two-colour western blot analysis were used to calculate the neuronal expression as a 
ratio o f GABAb to NF-L or NeuN.
The neuronal protein expression of GABAb subunits followed the same trend when 
normalized against both NF-L and NeuN. The neuronal GABABi aand GABABi b protein 
level was slightly increased in TLE-HS compared to TLE-STG samples. While the 
neuronal GABAb2 expression showed a reduction in GABAB2 protein level in TLE-HS 
specimens compared to TLE-STG as in figure 3.14.
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Figure 3.14 Neuronal GABAgi and GABAB2 protein expression in TLE-HS and TLE-STG
determined by western blotting.
The WB densitometic analysis values of GABAbsubunits were expressed as a ratio to 
NeuN protein level (a) and as a ratio to NF-L protein level (b). The neuronal GABAbi 
expression was increased while GABAB2 was decreased in TLE-HS but they were not 
significant. Statistical analysis: Kruskal-Wallis w ith Conover-lnman post hoc analysis 
test was used to identify significant differences between samples. Number of samples: 
TLE-HS (n = 9), and TLE-STG (n = 6). Data presented as mean ± S.E.M.
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3.4 Discussion
Previous studies indicated that changes in GABAb receptor subunits could be 
implicated in the pathophysiology of pharmacoresistant TLE associated w ith HS 
(Billinton et al., 2001a; 2001b; Munoz et al., 2002; Princivalle et al., 2003). In summary 
the novel contributions of this study were: 1) the determination of both mRNA and 
protein levels of GABABi and GABAb2 subunits in TLE-HS and PMC hippocampal 
homogenates, which contain neurons, microglia and astrocytes from all hippocampal 
subregions: 2) the quantification of mRNA and protein levels of both GABABi and 
GABAb2 subunits in TLE-STG samples, which are non-spiking, non-sclerotic surgical 
specimens: 3) the determination of relative neuronal protein level of GABABi and 
GABAb2 subunits in TLE-STG and TLE-HS.
3.4.1 Expression o f GABAb receptor in TLE-HS compared to  post-m ortem  control
Quantifying mRNA and proteins in post-mortem  brain tissue has the frequent problem 
of confounding factors such as gender, age at death, post-mortem interval and agonal 
state. Those factors influence the quantification and they need to be considered in 
studies using post-mortem  tissues (Preece and Carins, 2003; Tomita et al., 2004). In the 
present study there was no regression between the age at death, post-mortem  interval 
and mRNA expression (Appendix II).
The qRT-PCR results obtained in this study showed that the overall GABABi mRNA 
expression in TLE-HS hippocampi, compared to PMC, was not significantly altered. This 
was the same trend demonstrated by Billinton et al., (2001a) in situ hybridization data. 
The GABAB2 mRNA expression in this study was increased in TLE-HS compared to  PMC,
105
though it was not significant. The in situ hybridization data (Princivalle et al., 2003) of 
GABAb2 mRNA expression also demonstrated an overall increase in GABAB2 mRNA in 4 
out o f 6 hippocampal subregions supporting our data. An important point that needs 
to be considered, is that hippocampi specimens used in our study were homogenates 
of all hippocampal subregions rather than neuronal expression of an individual 
hippocampal area. Therefore it was challenging comparing GABAb subunits mRNA level 
of our qRT-PCR to in situ hybridization data of Billinton et ol. (2001a) and Princivalle et 
al. (2003). However, both techniques did show the same overall trend which is a higher 
expression of GABAB2 mRNAs in TLE-HS compared to PMC.
There are not many studies that investigated the protein level o f GABAb subunit in 
human TLE-HS. The expression of GABABi a-b subunit was investigated by semi- 
quantitative immunohistochemistry and its expression was significantly reduced in 
TLE-HS dentate gyrus granular cells compared to post-mortem controls (Munoz et al., 
2002). The WB protein quantification obtained in our study demonstrated that, the 
overall protein expression of GABABi isoforms (la  and lb )  and GABAb2 were 
significantly up regulated in TLE-HS compared PM control. The GABAb2 protein level 
reflects the increased mRNA levels obtained from qRT-PCR. The increased GABAb 
protein expression could be a compensatory mechanism to the hyperexcitability in 
TLE-HS tissue. However there seem to  be an imbalance in expression o f GABABi to 
GABAb2 ratio in TLE-HS samples.
The GABAb receptor autoradiography binding assays using both agonist and antagonist
showed a significant reduction in receptor density in the overall TLE-HS tissue
compared to PM control (Billinton et al., 2001b; Princivalle et al., 2002). It may be
106
argued that these finding contradict our results however, it is vital to point out that we 
investigated the protein levels of GABAb receptor subunits separately not knowing if 
these subunits are part of a functional receptor. While autoradiography binding assays 
done by Billinton et al., (2001b) and Princivalle et al. (2002) investigated the functional 
heterodimeric receptor. Therefore even though both GABAb receptor subunits were 
significantly increased in TLE-HS compared to PM control It is hard to know what 
proportion of those subunits actually heterodimerize to form the full receptor.
Recent evidence show that GABAb receptor subunits are also expressed in 
hippocampal astrocytes and activated microglia (Charles et al., 2003; Oka et al., 2006; 
Huyghe et al., 2014). In this study mRNA and proteins levels of GABAb receptor 
subunits represent the overall total GABAb expression including astrocytic expression 
however the astrocytic expression of GABAb receptors needs to be further explored.
3.4.2 Expression of GABAb receptor in TLE-HS compared to  TLE-STG
In recent years many studies investigating the TLE pathophysiology have started 
comparing their results to surgically resected control samples to overcome agonal and 
post-mortem  factors (Lee et al., 2006; Ravizza et al., 2008; Teichgraber et al., 2009; 
Rocha et al., 2015). In the present study for the first time, GABAb expression was 
investigated in TLE-STG surgically resected samples as well as in TLE-HS. The mRNA and 
protein levels of GABABi subunit and its isoforms were decreased in TLE-HS compared 
to TLE-STG though the reduction was not significant. On the other hand, mRNA and 
protein levels of GABAb2 subunit were significantly reduced in TLE-HS compared to TLE- 
STG specimens. The relative neuronal protein level of GABAb2 subunit was also reduced 
in TLE-HS compared to TLE-STG.
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It is now well recognised that heterodimeric GABAb receptor composed of GABABiand 
GABAb2 subunits is vital fo r trafficking of receptor complex to  cell surface and G-protein 
activation. Therefore a fully functional receptor needs to be composed of GABABiand 
GABAb2 subunits (Kaupmann et al., 1998; Gassmann and Bettler, 2013). The reduction 
in GABAB2 subunit compared to GABABi will lead to a decrease in formation of a 
functional heterodimeric receptor and the reduction in the density of functional GABAb 
receptor in TLE-HS patients. This supports the hypothesis of a compromised GABAb 
function in drug resistant TLE-HS pathophysiology.
Electrophysiological studies done on neurons from drug resistant TLE-HS patients, 
showed an impaired function of both pre- and post- synaptic GABAb receptor 
compared to neurons from TLE-STG tissue (Teichgraber et al., 2009). Those findings 
support our results and indicate an altered GABA receptor function in TLE-HS patients.
3.5 Conclusion
In summary, there was an apparent increase in the total GABABiand  GABAb2 subunits 
expression in TLE-HS compared to PM controls but there was an imbalance in the 
expression ratio of GABABi  to GABAb2 subunit in TLE-HS cases. On the other hand, 
there was a persistent significant reduction in TLE-HS GABAb2 subunits compared to 
TLE-STG which seems to contribute to reduction in functional GABAb receptor density 
and therefore, contribute to the increased excitatory hyperactivity in TLE-HS patients. 
This supports the role of a compromised GABAb function in drug resistant TLE-HS 
pathophysiology and suggests that GABAb receptor should be further investigated as a 
potential drug target fo r those patients w ith drug resistant TLE-HS.
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Chapter 4
Expression of serum- and 
glucocorticoid-inducible kinase-1 
(SGK1), Sodium channel p4 subunit 
(SCN4B), Inositol 1,4,5-trisphosphate 
receptor 1 (IP3R1) and Synaptoporin 
(SYNPR) in sclerotic TLE-HS hippocampi 
from refractory TLE-HS patients
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4 Expression of SKG1, SCN4B, IP3R1 and SYNPR in sclerotic 
hippocampi from refractory TLE-HS patients
4 .1  In troduction
A vast amount of research has been done on experimental animal models of status 
epilepticus (SE) to try  and understand TLE-HS pathophysiology and to discover new 
drug targets. The microarray analysis data obtained from an animal model o f status 
epilepticus (Borges et al., 2007) was analysed by the GALGO multivariate method 
(Trevino and Falciani, 2006), it suggested that SCN4B, SGK1, IP3R1 and SYNPR genes 
could be indicators o f seizures in epileptic hippocampi. Many other studies also 
suggested that those genes could be implicated in TLE-HS pathophysiology (Singec et 
al., 2002; Cai et al., 2004; Lang et al., 2006; Lee et al., 2013; Miyazaki et al., 2014).
4.1.1 Serum- and glucocorticoid-inducible-kinase-1 (SGK1)
The serum- and glucocorticoid-inducible kinase-1 (SGK1) is a member o f the 
serine/threonine protein kinase family. It was identified as SGK1 because its 
transcription was highly induced by serum and glucocorticoids in a mammary tum our 
cell line (Webster et al., 1993). SGK1 plays a vital role in neuronal functions; it is a 
potent regulator of ion channels activity as it activates certain potassium, sodium, and 
chloride channels and therefore it regulates neuronal excitability and cell survival (Lang 
et al., 2006; 2010). The SGK1 up-regulates glutamate transporters (EAAT1- EAAT4) that 
help clear the accumulated glutamate in the synaptic space and therefore protects 
neurons from excitotoxicity and neuronal death (Rothstein et al., 1996; Boehmer et al.,
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2006). On the other hand, SGK1 increases the abundance of kainate receptor GluR6 
protein in the plasma membrane and therefore contributes to the excitatory 
postsynaptic potentials (Strutz-Seebohm et al., 2005; Wang et al., 2010).
The SGK1 activates the voltage-gated potassium channels (VGKCs). The VGKCs 
participate in maintaining the neuronal membrane potential as they are responsible 
fo r the repolarization phase in the neuronal action potential. Therefore the ir activation 
will lead to  prolonged IPSP and the subsequent reduction of back propagating action 
potentials. It was also found that SGK1 up regulation causes the increased expression 
of VGKCs (Gamper et al., 2002a; 2002b; Lang et al., 2006). Therefore, due to the role 
of SGK1 in regulating neuronal excitability any alterations in its expression could be 
involved in pathophysiology of TLE.
4.1.2 Sodium channel beta 4 subunit (SCN4B)
The voltage-gated sodium channels (VGSCs) are very im portant in neuronal action 
potential generation and propagation. They are responsible fo r the depolarisation 
phase and therefore play a critical role in controlling neuronal excitability. They are 
composed of a-subunits that are associated w ith auxiliary 3 subunits. The a subunit 
forms the ion-conducting pore and it contains the voltage sensors segments. The 
auxiliary 3 subunits modify the gating kinetics and voltage dependence of the VGSCs. 
They are also adhesion molecules that interact w ith the extracellular matrix and the 
cellular cytoskeleton (Cannon and Bean, 2010; Catterall et al., 2010).
There are four known 3 subunit genes (SCN1B-4B) tha t encode 31-34  proteins. The 3 
subunits are intrinsic membrane proteins that belong to immunoglobulin (Ig) domain
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family of cell adhesion molecules. They have a large extracellular N - term inal domain 
which contains a single immunoglobulin (Ig) domain, a single transmembrane domain 
and an intracellular C - terminal domain (Liu et al., 2014; Namadurai et al., 2015). In 
neurons the presence of 3 subunits w ith sodium channel a subunits shifts the VGSCs 
gating properties from slow to  fast mode and thus accelerating the rate of channel 
activation and inactivation (Yu et al., 2003).
The novel p4 subunit is widely distributed in neurons of the brain. In the hippocampus, 
(34 was found to be expressed in the pyramidal cells and in the hilar neurons in the 
dentate gyrus. The 34 subunit has molecular mass of 38 kDa and it is covalently bound 
to a-subunits of VGSCs and therefore it is likely that it has an effect on the 
physiological function of multiple sodium channels (Yu et al., 2003).
The 34 subunit favours the Na+ channel activation and it causes a significant negative 
shift in the voltage dependence activation of Na+ channel. Subsequently this will allow 
sodium channel to be activated at more negative voltages, resulting in the generation 
of an action potential in response to milder depolarizing stimuli. This will make the 
neurons more sensitive to excitatory inputs and hence making them more susceptible 
to excitation (Yu et al., 2003). On the other hand, 31 and 33 subunits have opposite 
effect to 34, they favour the Na+ channel inactivation and they cause positive shifts in 
the voltage dependence of activation making neurons less susceptible to excitation. 
However, the presence of 34 subunit overrides the effect of 31 and 33 subunits 
leading to a facilitated action potential firing in the neurons tha t express the 34 
subunit (Amen et al., 2009).
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In addition, (34 subunit is responsible for resurgent kinetics of Na+ channels that occurs 
during repolarization phase of the membrane after action potentials. A major site of 
resurgent Na+current is the hippocampus where about ~60% of DG granule cells and 
~35% of CA1 pyramidal cells show those resurgent currents. The resurgent Na+ 
currents significantly enhance firing frequency of action potential in response to 
depolarizing stimuli that is slightly above-threshold (Grieco et al., 2005; Castelli et al., 
2007; Zhou et al., 2012). The (34 subunit is necessary for generating those resurgent 
currents which in turn influence the action potential firing of the neurons (Grieco et al., 
2005; Zhou et al., 2012). Therefore, alteration in 34 subunit expression could play a 
role in seizure susceptibility and TLE-HS pathophysiology.
4.1.3 Inositol 1, 4, 5-trisphosphate receptor 1 (IP3R1)
IP3R1 is the main inositol trisphosphate (IP3) receptor in neurons. It is a ligand-gated 
calcium channel that is found on the endoplasmic reticulum. Its main function is to 
regulate the intracellular calcium (Ca2+) concentrations. It is widely expressed in CA 
and DG subregions in the hippocampus (Nicolay et al., 2007).
The IP3 acts as a second messenger that is released in response to the binding of
neurotransmitters such as glutamate to the ir metabotropic receptors (mGluRs). The
activated coupled G-proteins subsequently lead to the activation of phospholipase C
(PLC). PLC will cause the hydrolysis of the membrane phosphatidylinositol 4, 5-
bisphosphate (PIP2) to diacylglycerol (DAG) and IP3. Then the generated IP3 could act
on its receptors (Taylor and Tovey, 2010; Kuczewski et al., 2011). The activation of
IP3R1 by IP3 and cytosolic Ca2+ will lead to the mobilization of Ca2+ from  the
endoplasmic reticulum into the cytoplasm and this will lead to increase in the
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intracellular Ca2+concentrations (Matsumoto and Nagata, 1999). The intracellular Ca2+ 
acts as a second messenger playing an important role in neuronal functions such as 
gene transcription, neuronal excitability and neurotransm itter release (Nicolay et al.,
2007). The Ca2+ can regulate neuronal excitability by binding to ion channels and 
modulating the ir activity such as activation of calcium-dependent potassium channels 
or by inactivation of voltage-dependent calcium channels (Steinlein, 2014).
Many studies indicate that the calcium signalling pathway has a major role in the 
generation of seizures and epilepsy (Matsumoto and Nagata, 1999; Pal et al., 2001; Cai 
et al., 2004; Steinlein, 2014). An increased level of intracellular Ca2+ is cytotoxic to 
neurons and is believed to be the cause of many types of seizures. This increased 
intracellular Ca2+ is caused by defects in the mechanisms that regulate the intracellular 
Ca2+homeostasis (Matsumoto and Nagata, 1999; Cai et al., 2004; Steinlein, 2014). In 
neurons there are 2 major sources of calcium, external and internal, Ca2+ entering cells 
through VGCCs and NMDA receptors and the intracellular Ca2+ released from ER. The 
later was suggested to be responsible for most of the neurotoxic Ca2+ in neurons (Pal 
et al., 2001). IP3R1 is very im portant in regulating the intracellular released calcium 
and therefore alteration in IP3R1 expression seems to be implicated in TLE-HS 
pathophysiology.
4.1.4 Synaptoporin (SYNPR)
Synaptoporin is a highly conserved synaptic vesicle membrane protein tha t belongs to
synaptophysin family. The major members of the synaptic vesicle synaptophysin fam ily
are synaptophysin, synaptoporin, synaptogyrin, pantophysin and mitsugumin29 (Dai et
al., 2003). Synaptoporin is a glycoprotein that is specifically expressed in the brain and
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it is composed of 4 transmembrane domains and C- and N-terminals (Cowan et al., 
1990). Synaptoporin is highly expressed in granule cells, CA3 pyramidal cells and it is 
also found in various interneurons in adult hippocampus (Grabs et al., 1994; Singec et 
al., 2002). Synaptoporin expression co-localized w ith GAD65 (GABA synthesizing 
enzyme), indicating that it is expressed in the inhibitory GABAergic nerve terminals in 
the different hippocampal layers (Singec et al., 2002).
In the brain, synaptic vesicles play a major role in regulating neurotransm itter release 
as they are responsible fo r the neurotransm itter storing, exocytosis and endocytosis. 
Therefore they are very important in regulating the efficiency of synaptic transmission 
(Casillas-Espinosa et al., 2012). Synaptophysin is a membrane protein associated w ith 
presynaptic vesicles that is vital for the calcium dependent neurotransm itter release 
(Chen et al., 1996). It is found in synaptic terminals in all regions of the hippocampus 
and was found to be down regulated in sclerotic hippocampi obtained from  drug 
resistant TLE patients (Grabs et al., 1994; Davies et al., 1998). There was also a reduced 
expression of synaptophysin in the hippocampi of spontaneous recurrent seizures in a 
rat model, indicating that the loss in synaptic vesicles seems to be involved in the 
pathogenesis of TLE (Zhang et al., 2014).
The novel presynaptic synaptoporin expression, was found to be increased in response
to nerve injury in the peripheral nervous system indicating its role in regulating
synaptic transmission in both physiological and pathological conditions (Sun et al.,
2006). In the hippocampus, Grabs et al. (1994) suggested that synaptoporin seems to
have a distinct function in the mossy fibre terminals that needs to be further explored.
Recently Lee et al. (2013) found that the presynaptic synaptoporin at the mossy fibre-
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CA3 synapse is crucial for maintaining homeostatic synaptic plasticity in hippocampus, 
which is important for regulating neuronal activity. Therefore changes in synaptoporin 
expression in the hippocampus could play an important role in refractory TLE-HS 
pathophysiology.
4.1.5 Aims of the study
SGK1, SCN4B, IP3R1 and SYNPR are potential biomarkers in TLE, they all play a role in 
regulating neuronal excitability and so far their expression has not been investigated in 
hippocampi from TLE-HS patients. Therefore the aim of this study was to do 
quantitative analysis of these potential biomarkers; in sclerotic TLE-HS and non- 
sclerotic TLE-STG tissue obtained from TLE patients and in post-mortem hippocampi, 
as this will also provide an insight into their roles in the pathophysiology of refractory 
TLE-HS.
4.2 Materials and methods
4.2.1 Patient clinical inform ation
Clinical information for TLE-HS, TLE-STG and PMC samples investigated in this chapter 
is described in Appendix I.
4.2.2 Study design
The mRNA level of SGK1, SCN4B, IP3R1 and SYNPR was investigated by qRT-PCR in TLE- 
HS (n = 10), TLE-STG (n = 5) and PMC (n = 8) samples. The protein expression of SGK1, 
SCN4B, SYNPR and ACTB was investigated by two-colour quantitative western blot in
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TLE-STG (n = 4) and TLE-HS (n = 7) samples. Significant difference between the samples 
was identified by Kruskal-Wallis w ith Conover-lnman post hoc analysis test.
4.2.3 Methods
qRT-PCR: In brief, the total RNA was extracted by SV Total RNA Isolation System 
(scetion 2.3.1) and then was reverse transcribed using Superscript™ III first strand 
synthesis system (section 2.4). Stable housekeeping genes were selected for the 
normalization of target gene expression (section 2.5.3) which was then followed the 
qRT-PCR using TaqMan® gene expression assays (section 2.5.5).
WB: Briefly the total proteins were extracted from hippocampi samples using 
CelLytic™ MT mammalian tissue extraction buffer (section 2.6). Then tota l protein 
determination was assessed by the BCA assay (section 2.7). Quantitative two colour 
western blotting was done fo r all samples by electrophoresis of 20pg protein followed 
by electro-transfer onto a nitrocellulose membrane. The membrane was then blocked, 
incubated w ith primary and secondary antibodies before it was scanned on the 
Odyssey infrared imaging system (section 2.8).
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4.3 Results
4.3.1 Relative mRNA and protein expression of SGKl
The SGKl mRNA level in TLE-HS, TLE-STG and PMC samples was determined by qRT- 
PCR. Data showed a significant up regulation of SGKl mRNA in the TLE-HS samples 
compared to both TLE-STG and PMC specimens as in figure 4.1. The densitometric 
analysis of WBs bands of SGKl and ACTB in TLE-HS and TLE-STG samples revealed that 
the relative SGKl protein level was higher in TLE-HS than in TLE-STG samples, though it 
was not statistically significant as in figure 4.2.
qRT-PCR SGKl
PMC TLE-STG TLE-HS
Figure 4.1 qRT-PCR data showing the relative mRNA expression of SGKl in TLE-HS,
TLE-STG and PMC
qRT-PCR data shows that SGKl mRNA level in TLE-HS was significantly up regulated 
compared to both PMC and TLE-STG samples. Statistical analysis: Kruskal-Wallis w ith 
Conover-lnman post hoc analysis test was used to identify significant differences 
between samples (* P < 0.05, * *  P < 0.01, * * *  P < 0.001). Number of samples: TLE-HS 
(n =10), TLE-STG (n = 5) and PMC (n = 8). Data presented as mean ± S.E.M.
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Figure 4.2 Quantitative western blotting of SGKl in TLE-HS and TLE-STG
(a) Two-colour WBs showing expression of SGKl and ACTB revealed by IRDye 680 and 
800 secondary antibodies, (b) Quantitative expression of SGKl relative to ACTB 
expression. SGKl protein expression was higher in TLE-HS compared to TLE-STG. The 
quantification of the bands was done using Odyssey (1.2) and Image Studio Lite (4.0) 
software. Statistical analysis: Kruskal-Wallis w ith Conover-lnman post hoc analysis test 
was used to identify significant differences between samples (* P < 0.05). Number of 
samples: TLE-HS (n = 7) and TLE-STG (n = 4). Data presented as mean ± S.E.M.
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4.3.2 Relative mRNA and protein expression o f SCN4B
The SCN4B mRNA expression was investigated by qRT-PCR in TLE-HS, TLE-STG and PMC 
samples. The data demonstrated that, SCN4B subunit transcript was significantly up 
regulated in TLE-HS compared to PMC. On the other hand, SCN4B mRNA expression 
was significantly reduced in TLE-HS compared to  TLE-STG samples as in figure 4.3.
The protein level of SCN4B in TLE-HS and TLE-STG was investigated by quantitative WB. 
The WB bands analysis revealed the same trend, SCN4B protein expression in TLE-HS 
was also significantly reduced in TLE-HS compared to TLE-STG samples as in figure 4.4. 
The SCN4B protein expression was mirroring the mRNA expression in TLE-HS and TLE- 
STG samples.
4.3.3 Relative mRNA expression of IP3R1 receptor
The IP3R1 mRNA expression was investigated by qRT-PCR in TLE-HS, TLE-STG and PMC 
samples. The data demonstrated that, mRNA expression of IP3R1 receptor was 
significantly increased in TLE-HS compared to PMC. On the other hand, IP3R1 mRNA 
expression was significant reduced in TLE-HS compared to TLE-STG samples as in figure 
4.5.
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Figure 4.3 qRT-PCR data showing the relative mRNA expression of SCN4B in TLE-HS,
TLE-STG and PMC
The SCN4B mRNA level in TLE-HS was significantly up regulated compared to PMC but 
it was significantly down regulated compared to TLE-STG. qRT-PCR data analysis was 
done using 2‘ACT method. Statistical analysis: Kruskal-Wallis w ith Conover-lnman post 
hoc analysis test was used to identify significant differences between samples (* P < 
0.05, * *  P < 0.01, * * *  P < 0.001). Number of samples: TLE-HS (n = 10), TLE-STG (n = 5) 
and PMC (n = 8). Data presented as mean ± S.E.M.
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Figure 4.4 Quantitative western blotting of SCN4B in TLE-HS and TLE-STG
(a) Two-colour WBs showing expression of SCN4B and ACTB revealed by IRDye 680 and 
800 secondary antibodies, (b) Quantitative expression of SCN4B relative to ACTB 
expression. The protein expression of SCN4B was significantly reduced in TLE-HS 
compared to TLE-STG. The quantification of the bands was done using the Odyssey 
(1.2) and Image Studio Lite (4.0) software. Statistical analysis: Kruskal-Wallis w ith 
Conover-lnman post hoc analysis test was used to identify significant differences 
between samples (* P < 0.05, * *  P < 0.01, * * *  P < 0.001). Number of samples: TLE-HS 
(n = 7) and TLE-STG (n = 4). Data presented as mean ± S.E.M.
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Figure 4.5 qRT-PCR data showing the relative mRNA expression of IP3R1 in TLE-HS,
TLE-STG and PMC
The IP3R1 mRNA level in TLE-HS was significantly up regulated compared to PMC but it 
was significantly down regulated compared to TLE-STG. qRT-PCR data analysis was 
done using 2 ACT method. Statistical analysis: Kruskal-Wallis w ith Conover-lnman post 
hoc analysis test was used to identify significant differences between samples (* P < 
0.05, * *  P < 0.01, * * *  P < 0.001). Number of samples: TLE-HS (n = 10), TLE-STG (n = 5) 
and PMC (n = 8). Data presented as mean ± S.E.M.
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4.3.4 Relative mRNA and protein expression of SYNPR
The synaptic vesicle SYNPR mRNA expression was investigated by qRT-PCR in TLE-HS, 
TLE-STG and PMC samples. The data demonstrated that, SYNPR transcript was 
significantly up regulated in TLE-HS compared to PMC. In contrast, SYNPR mRNA 
expression was significant down regulated in TLE-HS compared to TLE-STG samples as 
in figure 4.6.
The protein expression o f SYNPR in TLE-HS and TLE-STG was investigated by 
quantitative WB. The densitometric analysis of WBs bands showed that SYNPR protein 
expression in TLE-HS was also significantly reduced in TLE-HS compared to  TLE-STG 
samples as in figure 4.7.
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Figure 4.6 qRT-PCR data showing the relative mRNA expression of SYNPR in TLE-HS,
TLE-STG and PMC
The SYNPR mRNA level in TLE-HS was significantly up regulated compared to  PMC but 
it was significantly down regulated compared to TLE-STG. The qRT-PCR data analysis 
was done using 2“ACT method. Statistical analysis: Kruskal-Wallis w ith Conover-lnman 
post hoc analysis test was used to identify significant differences between samples (* P 
< 0.05, * *  P < 0.01, * * *  P < 0.001). Number of samples: TLE-HS (n = 10), TLE-STG (n = 5) 
and PMC (n = 8). Data presented as mean ± S.E.M.
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Figure 4.7 Quantitative western blotting of SYNPR in TLE-HS and TLE-STG
(a) Two-colour WBs showing expression of SYNPR and ACTB revealed by IRDye 680 and 
800 secondary antibodies, (b) Quantitative expression of SYNPR relative to ACTB 
expression. The protein expression of SYNPR was significantly decreased in TLE-HS 
compared to TLE-STG. The bands quantification was done using Odyssey (1.2) and 
Image Studio Lite (4.0) software. Statistical analysis: Kruskal-Wallis w ith Conover- 
Inman post hoc analysis test was used to identify significant differences between 
samples (* P < 0.05, **  P < 0.01). Number of samples: TLE-HS (n = 7) and TLE-STG (n = 
4). Data presented as mean ± S.E.M.
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4.4 Discussion
Previous studies in animal models indicated that changes in SGKl (Lang et al., 2006; 
Wang et al., 2010), SCN4B (Borges et al., 2007; Miyazaki et al., 2014), SYNPR (Singec et 
al., 2002; Lee et al., 2013) and IP3R1 (Cai et al., 2004; Nicolay et al., 2007) could be 
implicated in the pathophysiology of pharmacoresistant TLE associated w ith HS. The 
key findings of this study were: 1) the SGKl, SCN4B, SYNPR and IP3R1 mRNA levels 
were significantly altered in drug resistant TLE-HS hippocampi compared to  TLE-STG 
and PMC hippocampi; 2) the quantification of SGKl, SCN4B and SYNPR protein levels 
were also altered in TLE-HS compared to TLE-STG samples.
4.4.1 SGKl expression in TLE-HS
The SGKl has a role in regulating neurone excitability; it up regulates glutamate 
transporters and activates VGKCs. This suggests that it could have a role in TLE 
(Boehmer et al., 2006; Wang et al., 2010). In this study we found that there was a 
significant up regulation of SGKl mRNA level in the sclerotic hippocampi of refractory 
TLE-HS compared to both TLE-STG and PMC. This corroborates Wang et al., 2010 
research as they have investigated SGKl expression in the anterior temporal neocortex 
tissue of drug resistant epilepsy patients. They found that SGKl mRNA and protein 
were significantly up regulated compared to PMC. In the present study the SGKl 
protein level was increased in TLE-HS compared to TLE-STG, though it was not 
significant which could be attributed to the variability and low numbers o f TLE-STG 
samples. However, it still supports our data as SGKl showed the same trend of 
increased expression in the high frequency seizure experiencing tissue.
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In a lithium-pilocarpine rat model of epilepsy, SGKl and EAAT3 mRNA and protein 
expression were investigated at d ifferent time points (6 hrs - 2 months) after the onset 
of status epilepticus. They found that SGKl expression was significantly up regulated at 
all-time points after the onset of status epilepticus. This increase in SGKl was also 
accompanied by the significant up regulation of the glutamate transporter EAAT3 
suggesting the neuroprotective role of SGKl after seizures (Wang et al., 2010).
It is recognised that SGKl expression was increased after neuronal injury and neuronal 
excitotoxicity (Imaizumi et al., 1994; Hollister et al., 1997) and it was found that 
seizures of status epilepticus induce neuronal injury in animal models (Torolira et al., 
2016). Therefore, SGKl up regulation in drug resistant TLE-HS patients might play a 
neuroprotective role in response to recurrent seizures.
4.4.2 SCN4B expression in TLE-HS
For the first time, this study reports that SCN4B mRNA was significantly up regulated in
TLE-HS compared to PMC. It also reports that both mRNA and protein expression of
SCN4B subunit were significantly down regulated in the drug resistant TLE-HS
compared to TLE-STG obtained from patients undergoing surgical resection. The VGSCs
3 subunits have multiple functions; they modulate the gating kinetics and voltage
dependence of VGSCs and regulate cell adhesion, migration and neurite outgrowth.
They regulate action potential firing and therefore are vital for controlling neuronal
excitability (Cannon and Bean, 2010; Catterall et al., 2010; Miyazaki et al., 2014). The
altered expression of 3 1 / 3 2  and 33 subunits have been previously reported in human
TLE-HS hippocampi and TLE animal models but not 34 subunit (Gastaldi et al., 1998;
Aronica et al., 2003; van Gassen et al., 2008; 2009).
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The 34 subunit facilitates the action potential firing in the neurons making them more 
sensitive to excitatory stimuli (Amen et al., 2009). Therefore, the significant up 
regulation of SCN4B mRNA in TLE-HS compared to  PMC could explain partially the 
increased seizure susceptibility of the sclerotic hippocampi in TLE patients. Miyazaki et 
al. (2014) found that in response to repetitive stimulation, mice that are deficient in 
Scn4b showed a decrease in repetitive firing frequency of action potentials as well as a 
significant reduction in resurgent Na+ currents. W hether the significant down 
regulation of SCN4B in TLE-HS compared to TLE-STG is a compensatory mechanism or 
not, it needs to be further investigated. In conclusion, the altered expression of SCN4B 
subunit indicates that it does seem to be involved in TLE pathophysiology.
4.4.3 IP3R1 expression in TLE-HS
In this study we found that there was a significant up regulation of calcium channel 
receptor IP3R1 mRNA level in the sclerotic hippocampi of refractory TLE-HS compared 
to PMC and IP3R1 was significantly down regulated in TLE-HS compared to TLE-STG.
The calcium signalling has been increasingly recognised in having a role in the 
development of epilepsy (epileptogenesis). The intracellular Ca2+ level affects neuronal 
excitability and neurotransm itter release. Therefore IP3R1 is essential in regulating 
intracellular Ca2+ homeostasis and hence neuronal excitability and neurotransm itter 
release (Matsumoto and Nagata, 1999; Pal et al., 2001; Cai et al., 2004; Steinlein, 2014).
It was found that the expression of IP3R1 in hippocampal neurons is regulated by 
synaptic activity (Cai et al., 2004). In hippocampal neurons, IP3R1 expression was 
increased by the activation of NMDA receptors and VGCCs (Greaf et al., 1999). On the
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other hand, chronic activation of mGluRs as well as other plasma membrane receptors 
linked to IP3 production down regulated the IP3R1 expression in cerebellar granule 
cells (Cai et o l,  2004).
In conditions such as refractory TLE there is a chronic over activation of NMDA 
receptors by glutamate, and as a consequence this is accompanied by excessive influx 
of calcium into the neurons making them more prone to seizures. In this study, 
sclerotic hippocampi, which are the seizure's focus, from refractory TLE showed a 
significant up regulation of IP3R1 expression, compared to PMC; this could be a 
contributing factor to the increased neuronal excitability seen in TLE-HS. On the other 
hand there was a significant down regulation of IP3R1 expression in TLE-HS compared 
to TLE-STG, suggesting that this reduction could be a compensatory mechanism to 
reduce the intracellular calcium. However, in conclusion there does seem to  be 
impairment in the intracellular Ca2+ homeostasis mechanism that plays a major role in 
imbalance between inhibitory and excitatory state in epilepsy. Therefore, further 
research into IP3R1 role in TLE pathophysiology may provide new drug targets fo r the 
development of AEDS.
4.4.4 SYNPR expression in TLE-HS
In this study, for the first time, the SYNPR mRNA and protein were investigated in TLE- 
HS and TLE-STG obtained from patients undergoing surgical resection as well as in PMC 
hippocampi. We found that SYNPR mRNA was significantly up regulated in TLE-HS 
compared to PMC. On the other hand, both mRNA and protein expression of SYNPR 
were significantly down regulated in the TLE-HS compared to TLE-STG.
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Synaptoporin is used as a marker for mossy fibres in many studies investigating TLE 
pathogenesis in animal models (Wilczynski et al., 2008; Volz et al., 2011; Haussler et al., 
2015). Mossy fiber-CA3 synapses in the hippocampus are essential in preventing the 
seizure generation in the CA3 network. The presynaptic synaptoporin in the mossy 
fibre- CA3 synapses is vital for maintaining the homeostatic synaptic plasticity and 
reducing excitation (Lee et al., 2013). In CA3 the down regulation of synaptoporin 
increased the recurrent CA3 excitation and thus enhances seizure susceptibility 
(Lawrence and McBain 2003; Queenan and Pak et al., 2013). Synaptoporin was also 
found to be expressed in the inhibitory GABAergic nerve terminals in the different 
hippocampal layers (Singec et al., 2002). In this study there was an increase in 
synaptoporin expression in TLE-HS compared to PMC, which could be an indicator o f a 
compensatory increase in inhibitory GABAergic synapses. In contrast the down 
regulation of synaptoporin in TLE-HS compared to TLE-STG, seem to enhance 
excitation and seizure susceptibility in TLE -HS samples. Therefore, alteration in 
synaptoporin expression needs to be further exploited in order to  provide a new 
insight into TLE-HS pathophysiology.
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4.5 Conclusion
In epileptic brains, specifically refractory TLE hippocampus there are frequent 
uncontrolled seizures that are affecting neuronal activity and overwhelming many of 
the homeostatic mechanisms such as intracellular calcium homeostasis and 
homeostatic synaptic plasticity. All of the genes investigated in this study play a vital 
role in regulating neuronal excitability. Their expression was significantly altered in 
TLE-HS patients indicating the complexity of drug resistant TLE pathophysiology. 
Therefore a vast amount of research is still needed to unravel the epileptogenesis and 
pathophysiology involved in TLE-HS.
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Chapter 5
Transcriptome analysis of sclerotic TLE 
hippocampi from refractory TLE-HS
patients
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5 Transcriptome analysis of sclerotic TLE hippocampi from  
refractory TLE-HS patients
5.1 Introduction
Transcriptome analysis is the examination of expression levels of mRNAs, transcribed 
in a given cell population or tissue. It is also known as expression profiling analysis 
because it reflects only the actively expressed genes in a tissue at a given time. This 
analysis often uses high-throughput techniques based on microarray technology. They 
provide a vital screening tool to investigate many disease pathologies (Wang et al., 
2009). The transcriptional profiles obtained could also provide predictive biomarkers 
of the disease (Trevino et al., 2007).
In TLE-HS there is a need to develop new AEDs that also have anti-epileptogenic effect 
to stop the progression of TLE. However, TLE-HS pathophysiology remains poorly 
understood despite the vast amount of research done, and deciphering its 
pathophysiology will help in the development of new anti-epileptogenic drugs. 
Therefore, the transcriptome analysis is a powerful tool to investigate TLE-HS 
pathophysiology as it assesses the gene expression in a comprehensive and unbiased 
fashion.
There are a limited numbers of studies that investigated human TLE specimens by 
microarray analysis. Becker et al. (2002) found that 21 genes (from total of 588) that 
are involved in cell death, gliosis and neuronal plasticity were significantly altered in 
surgical TLE-HS samples compared to Non-HS from patients w ith extra-hippocampal
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mass lesion. Lee et al. (2007) investigated gene expression in the CA1 region and 
found that 137 genes (from total of 14,500) were significantly altered in TLE-HS 
compared to Non-HS. Those genes were involved in gliosis and immune response. In 
another study, the transcriptome profiles of spiking and non-spiking specimens from 
TLE temporal cortex found that; 76 genes (from total of 14,500) were significantly 
altered. Those genes were involved in GABA signalling, iron metabolism and MAPK 
pathway (Arion et al., 2006).
On the other hand; the transcriptome analysis of entorhinal cortex from TLE patients 
w ith dual pathology (HS and cortical atrophy) investigated by cDNA microarray analysis 
found that only 6 genes (from 2400 genes) were differentially expressed in TLE 
compared to autopsy controls. These genes were involved in complement cascade and 
synaptic transmission (Jamali et al., 2006). The previous studies are lim ited by the use 
of cDNA arrays that have less target specificity and only represent a small fraction of 
the human transcriptome. Recently two transcriptome studies have used the new 
oligonucleotide microarrays that are more representative of the whole human 
transcriptome. The oligonucleotide microarrays also have higher target specificity that 
provides better discrimination of highly similar genes and splice variants (Kreil et al., 
2006). In the van Gassen et al. (2008) study, hippocampal specimens from TLE patients 
w ith and w ithout HS and autopsy controls (n = 4 per group) were investigated. They 
found that most of the 618 (from 21,329) differentially expressed genes identified 
were implicated in innate immunity. While, Venugopal et al. (2012) performed 
microarray analysis on spiking and non-spiking hippocampal specimens from TLE
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patients (n = 10 per group). They identified 413 genes that were differentially 
expressed; some of them were GABA-associated and astrocyte-associated genes.
The analysis approach by the previous transcriptome studies focused primarily on the 
list of genes tha t are differentially expressed in TLE compared to control, these lists of 
genes are relatively large and according to  (Mirza et al., 2011) only a small proportion 
of those genes are consistent across the different studies. This may be due to the small 
number of samples, different microarray platform used and different methods of 
analysis (Ahmed et al., 2004). However, TLE is a multifactorial condition where many 
genes are simultaneously affected and contributing to TLE-HS phenotype. In order for 
the transcriptome analysis to have significant impact on our understanding of TLE 
pathophysiology, we ought to look at the biological processs and pathways that are 
affected rather than single genes.
5.1.1 Aims o f the study
The aim of this study was to do transcriptome analysis o f TLE-HS and TLE-STG from  TLE 
patients w ith hippocampal sclerosis, in addition to post-mortem hippocampi samples. 
This was followed by transcriptome enrichment analysis of microarray data, where 
genes are functionally clustered based on their cellular component, molecular function, 
biological process and pathways they are involved in. This will give us more 
understanding of pathways and biological processes affected in TLE-HS 
pathophysiology.
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5.2 Materials and methods
5.2.1 Patient clinical inform ation
For microarray analysis, only TLE patients w ith hippocampal sclerosis were included 
and any patients with cortical dysplasia or neoplastic TLE lesion were excluded from 
the study. In total the number o f patients used fo r microarray analysis study were 
seven TLE patients (2M + 5F) the ir age at surgery was 36 ± 11 years, age at onset of 
first non-febrile seizure 10 ± 8 years and duration of epilepsy 26 ± 15 years. Five post­
mortem (2M + 3F) hippocampi from individuals w ith no known brain disease were 
used fo r transcriptome analysis; the ir age 78 ± 5 years and PMI 42 ± 12 hrs. The full 
clinical information for TLE-STG and TLE-HS samples investigated in this chapter is 
described in Appendix I.
5.2.2 Study design
The transcriptome profiling of TLE-STG (n = 7), TLE-HS (n = 7) and PMC (n = 5) samples 
was done by microarray analysis (MA) then it was followed by the enrichment analysis 
of dysregulated genes that were identified by Rank Product test. The validation of MA 
data was done by qRT-PCR for 11 genes in TLE-STG (n = 10), TLE-HS (n = 22) and PMC (n 
= 7) samples. Significant difference between the samples was identified by Kruskal- 
Wallis w ith Conover-lnman post hoc analysis test.
5.2.3 M icroarray experim ent (MA)
Briefly the total RNA was extracted by SV Total RNA Isolation System (section 2.4.1).
Then cDNA samples were synthesized and labelled w ith Cy3 or Cy5 using the Two-
colour Low Input Quick Amp Labelling Kit (Agilent Technologies, 5190-2306). Following
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the labelling of TLE-HS hippocampi w ith Cy5 and TLE-STG samples with Cy3, equal 
amounts of each samples were co-hybridized onto SurePrint G3 Human Gene 
Expression 8x60K microarrays (Agilent Technologies, G4851A). The microarray was 
washed and then scanned using Agilent Technologies SureScan microarray Scanner 
(section 2.9).
5.2.4 MA data analysis
There are three main stages in microarray data analysis: raw data processing and 
normalization, identification of differentially expressed genes (DEGs) and DAVID 
enrichment analysis of the DEGs as shown in figure 5.1.
Raw data 
processing and normalization
Log Ratio = Epileptic/Control
_
Identify Differentially Expressed Genes (DEGs)
Rank Products (RP) test (P-value £ 0.0001)
TM4 MeV software
Functional annotation clustering analysis
DAVID bioinformatics software 
(Database for Annotation, Visualisation and Integrated Discovery)
Cluster the genes based on their 
molecular function, biological process, 
cellular components and pathways
Functional Enrichment Score indicates 
the relative significance of gene cluster 
among other clusters
Figure 5.1 Schematic diagram presenting main steps in microarray data analysis
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5.2.4.1 Raw data processing and normalization
The raw data is extracted using Agilent feature extraction software. A feature is the 
gene specific probe that is printed on the microarray slide. The feature's local 
background signal is subtracted and the dye bias between the 2 dyes is corrected by 
using linear and locally weighted scatter plot smoothing (LOWESS) normalization 
methods. The LOWESS dye normalization factor is calculated by fitting  the locally 
weighted linear regression curve to  the chosen normalization features. The processed 
signal is then calculated by multiplying the background-subtracted signal by the 
LOWESS dye normalization factor (Agilent Technologies, G4460-90052). For every 
probe or gene, the differential expression between 2 samples (labelled w ith either 
green or red dye) is calculated as a Log ratio as follows:
Log ratio = Logi0 (red processed signal/ green processed signal)
5.2.4.2 Identification of differentially expressed genes (DEGs) in TLE-HS by RP
The Rank Product (RP) method is a robust, sensitive and highly specific microarray 
analysis method that is powerful in identifying biologically relevant gene expression 
changes (Breitling et al., 2004; Koziol, 2010). Therefore in the present study, RP 
method is used to identify differentially expressed genes between TLE-STG, PMC and 
epileptic TLE-HS samples. The RP test w ith false discovery rate (FDR) < 0.1 was done 
using TM4 Multi-Experiment Viewer (MeV) software, version 4.9 (Saeed et al., 2003). 
Only genes w ith FDR < 0.1 and P < 0.05 were considered differentially expressed and 
were used for functional enrichment analysis.
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5 .2 .4 .3  Functional e n ric h m e n t analysis o f DEGs by D A VID
The functional enrichment analysis is done using the Database fo r Annotation, 
Visualisation and Integrated Discovery (DAVID) bioinformatics resources v6.7 
(http://david.abcc.ncifcrf.gov). The DAVID database consists o f an integrated 
biological knowledge database and analytical tools. It provides functional annotation 
tools fo r understanding the biological meaning behind a large list o f genes (Huang et 
al., 2009a; 2009b).
The functional annotation clustering analysis in DAVID, groups genes w ith similar 
annotations together into clusters and then links them to an annotation term. The 
term enrichment P -value represents the association of genes to an annotation term  in 
a cluster. Then every cluster is given an enrichment score, which is a geometric mean 
(in -logio scale) of member's P-values in that cluster. The enrichment score helps to 
rank the overall importance of a cluster among others. A cluster is considered of 
significant biological importance if the enrichment score is more than 1.3 (P -  0.05) 
(Huang et al., 2009b).
In the present study, the analysis was done by following the method in Huang et al., 
(2009b). The gene lists (Agilent probe ID list) of differentially expressed genes were 
uploaded into DAVID separately. They were mapped to DAVID default gene IDs and the 
background annotation was set to Homo sapiens. All submitted gene lists were 
analysed by the functional annotation clustering method using the annotation search 
categories in table 5.1. The functional classification stringency was set to medium with 
enrichment threshold of 0.05 (enrichment P - value).
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Table 5.1 Annotation search categories used in functional enrichment analysis of 
DEGs
Functional categories
COG_Ontology Clusters of Orthologous Groups of proteins database
SP_PIR .KEYWORDS
SwissProt protein knowledgebase and Protein Information 
Resource combined annotations
UP.SEQ^feature Uniprot Sequence annotations
Gene Ontology
GOTERM_BP_FAT Gene ontology term: Biological Processes
GOTERM_CC_FAT Gene ontology term : Cellular Components
GOTERM_MF_FAT Gene ontology term: Molecular Functions
Pathways
BBID Biological Biochemical Image Database
BIOCARTA Biological pathways resource
KEGG_pathway Kyoto Encyclopaedia of Genes and Genomes pathways
Protein. Domains
INTERPRO Protein sequence analysis and classification resource
PIR.SUPERFAMILY Protein Information Resource -Superfamily protein annotation
SMART Simple Modular Architecture Research Tool
5.2.5 qRT-PCR
In brief, the total RNA extracted was reverse transcribed using Superscript™ III first 
strand synthesis system (section 2.4). Stable housekeeping genes were selected fo r the 
normalization of target gene expression (section 2.5.3) then followed by the qRT-PCR 
using TaqMan® gene expression assays (section 2.5.5). qRT-PCR statistical analysis: 
Kruskal-Wallis w ith Conover-lnman post hoc analysis test was used to identify 
significant differences between samples (* P < 0.05).
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5.3 Results
5.3.1 Microarray quality control (QC)
The Agilent feature extraction software generates a detailed quality control report for 
every microarray analysed to evaluate its quality. In order for the microarray to be 
considered for further analysis it should be w ith in the range of the 16 metrics 
parameters. The percentage of outlier features that are non-uniform should be less 
than 1%. The average of background-subtracted signal of the negative control should 
be -20 to 4 and its standard deviation < 15 for both channels.
In the present study all of the microarrays that were run were w ith in the range of the 
above parameters as in table 5.2. This indicates good hybridization w ith minimum 
outlier probes and no non-specific binding. The reproducibility metrics of MA include 
calculating signal coefficient of variation (CV)% for replicated non-control probes and 
Agilent spike-in positive control (E1A) probes. The median of CV% for replicated probes 
should be 0 - 18 (both channels). This indicates a good reproducibility between 
replicates. The median of CV% of the Agilent spike-in positive control (E1A) probes 
should also be 0 - 18 (both channels). In our study all microarrays are w ithin the ideal 
range as in table 5.3 and this indicates good and reliable reproducibility.
The Spike-in linearity is also checked by plotting the observed log ratio against the 
expected log ratio. The plot slope and regression coefficient (R2) should be more than 
0.85 and 0.86 respectively. In this study all the microarrays had R2 more than 0.96 
indicating high reproducibility and an excellent quality (table 5.4).
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Tab le  5 .2  M ic ro a rra y  q u a lity  co n tro l m etrics 1
MA
% of feature 
outliers in both 
channels
Green negative 
control metrics
Red negative 
control metrics
Average
Signal
Std. Dev Average
Signal
Std. Dev
1 E l C l 0.003 -2.52 1.52 -3.55 2.63
2 E2 C2 0.035 -2.67 1.46 -3.78 2.65
3 E3 C3 0.003 -2.47 1.41 -3.58 2.52
4 E4 C4 0.016 -2.51 1.44 -4.09 2.76
5 E5 C5 0.030 -3.33 1.67 -3.78 2.77
6 E6 C6 0.014 -3.36 1.58 -3.73 2.53
7 E8 C8 0.025 -3.29 1.65 -4.00 2.64
8 C3 E3 0.017 -2.82 1.58 -3.74 2.63
9 E l PM1 0.033 -2.10 1.29 -2.29 2.30
10 E2 PM2 0.003 -2.57 1.40 -2.64 2.49
11 E3 PM3 0.008 -2.25 1.38 -2.56 2.47
12 E4 PM4 0.008 -2.48 1.50 -2.58 2.50
13 E5 PM6 0.014 -2.56 1.41 -2.51 2.36
14 E6 PM6 0.021 -2.07 1.39 -2.65 2.59
15 E8 PM3 0.027 -3.29 1.38 -2.78 2.41
16 PM1 E l 0.022 -1.76 1.25 -3.48 2.61
QC range < 1 % -20 to 10 <15 -20 to 4 < 6
C: Non-spiking superior temporal gyrus TLE-STG from TLE patients. E: sclerotic 
hippocampi from TLE patients. MA: Microarray. PM: post-mortem  hippocampi. Signal: 
background subtracted signal.
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T ab le  5 .3  M ic ro a rra y  q u a lity  co n tro l m etrics  2
MA
Median % CV 
Non-Control probe Signal
Median % CV 
spike-in E1A probe Signal
Green Red Green Red
1 E l C l 10.7 11.8 10.2 10.7
2 E2 C2 11.2 11.0 10.8 9.7
3 E3 C3 11.0 10.4 10.0 9.8
4 E4 C4 11.2 9.9 10.4 9.6
5 E5 C5 12.3 14.9 10.9 14.9
6 E6 C6 11.8 12.1 10.6 10.6
7 E8 C8 11.5 10.8 10.7 9.6
8 C3 E3 11.8 12.6 10.8 12.1
9 E l PM1 10.6 12.9 10.0 10.6
10 E2 PM2 10.3 11.9 9.5 9.2
11 E3 PM3 11.3 13.6 9.8 11.6
12 E4 PM4 10.6 13.3 9.1 9.4
13 E5 PM6 11.4 12.5 10.1 11.0
14 E6 PM6 11.6 12.6 10.2 11.8
15 E8 PM3 11.4 14.0 11.2 12.0
16 PM1 E l 12.1 13.7 10.3 12.9
QC range Oto 18 Oto 18 Oto 18 Oto 18
C: Non-spiking superior temporal gyrus TLE-STG from TLE patients. E: sclerotic 
hippocampi from TLE patients. MA: Microarray. PM: post-mortem  hippocampi. Signal: 
background subtracted signal.
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T ab le  5 .4  M ic ro a rra y  q u a lity  co n tro l m etrics  3
MA
E1A Spike-in Observed log 
ratio Vs expected plot
Direction dependent 
noise
R2 Slope Green Red
1 E l C l 0.98 0.86 3 -8
2 E2 C2 0.98 0.84 3 -8
3 E3 C3 0.98 0.84 3 -8
4 E4 C4 0.99 0.85 3 -8
5 E5 C5 0.98 0.82 3 -8
6 E6 C6 0.99 0.85 3 -8
7 E8 C8 0.98 0.86 3 -8
8 C3 E3 0.98 0.85 3 -8
9 E l PM1 0.97 0.84 3 -8
10 E2 PM2 0.98 0.84 3 -8
11 E3 PM3 0.97 0.86 3 -8
12 E4 PM4 0.98 0.86 3 -8
13 E5 PM6 0.98 0.83 3 -8
14 E6 PM6 0.98 0.84 3 -8
15 E8 PM3 0.97 0.85 3 -8
16 PM1E1 0.98 0.86 3 -8
QC range >0.86 >0.85 -15 to 15 -15 to 15
The direction dependent noise (DDN) metric is measured for every channel, to  check 
for noise during scanning. Our microarray scanning DNN noise was w ith in the range of 
a good quality array. C: Non-spiking superior temporal gyrus TLE-STG from TLE patients. 
E: sclerotic hippocampi from TLE patients. MA: Microarray. PM: post-mortem  
hippocampi.
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5 .3 .2  Id e n tific a tio n  o f d iffe re n tia lly  expressed genes (DEGs) in TLE-HS using RP
In comparing epileptic TLE-HS transcriptome to TLE-STG, there were 1821 genes that 
were significantly up regulated, while 1511 genes were significantly down regulated. 
In comparing TLE-HS to PMC samples, the transcriptome analysis revealed that there 
were; 1961 significantly up regulated genes and 2867 significantly down regulated 
genes as in TLE-HS tissue figure 5.2.
The comparison of TLE-HS transcriptome to both TLE-STG and PMC, showed that there 
were an overlapping 464 genes that are up regulated and 350 genes down regulated in 
TLE-HS as in figure 5.3. The functional enrichment analysis was done fo r those 
overlapping differentially expressed genes.
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5.3.3 Functional enrichm ent analysis of DEGs by DAVID
5.3.3.1 Functional enrichment analysis of all DEGs
The function annotation clustering analysis fo r both the up and down DEGs produced 
34 significantly enriched clusters (enrichment score > 1.3) w ith the first cluster having 
6.72 enrichment score.
The DEGs in clusters 1, 2 and 3 with high enrichment score 6.72, 5.96, and 5.51 
respectively, were closely related to  signal, glycoprotein and cytokine activity terms. 
They were mainly related to the extracellular region of the cellular component and 
were significantly associated with the biological process of inflammatory and defence 
response as in table 5.5. The association of individual genes to the annotation term  in 
cluster 3 is shown in figure 5.4.
The DEGs in clusters 4, w ith enrichment score 3.79, were associated w ith biological 
processes such as inflammatory response, cytokine activity, cytokine-cytokine receptor 
interaction, chemotaxis and chemokine activity as in table 5.6. The association of 
genes to the annotation term in cluster 4 is shown in figure 5.5. The DEGs in clusters 5 
w ith enrichment score 2.82; were related to neuropeptide signalling pathway and 
nuclear pore complex interacting proteins as in table 5.6. (See appendix IV fo r all 34 
clusters).
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T ab le  5 .5  Functional a n n o ta tio n  c lustering  o f DEGs: C luster 1-3
Annotation Cluster 1 Enrichment Score: 6.72
Category Term Count P Value
SP_PIR_KEYWORDS signal 97 4.44E-09
SP_PIR_KEYWORDS disulphide bond 90 4.90E-09
UP_SEQ_FEATURE signal peptide 97 6.18E-09
UP_SEQ_FEATURE disulphide bond 87 1.20E-08
UP_SEQ_FEATURE glycosylation site: N-linked (GlcNAc...) 98 1.72E-04
SP_PIR_KEYWORDS glycoprotein 101 1.76E-04
Annotation Cluster 2 Enrichment Score: 5.96
Category Term Count P Value
SP_PIR_KEYWORDS signal 97 4.44E-09
UP_SEQ_FEATURE signal peptide 97 6.18E-09
SP_PIR_KEYWORDS Secreted 55 2.51E-06
GOTERM_CC_FAT G0:0044421~extracellular region part 39 3.49E-06
GOTERM_CC_FAT G0:0005576~extracellular region 64 4.44E-06
GOTERMMFFAT G0:0005125~cytokine activity 15 1.02E-05
SP_PIR_KEY WORDS cytokine 14 1.15E-05
GOTERM_CC_FAT G0:0005615~extracellular space 30 1.67E-05
Annotation Cluster 3 Enrichment Score: 5.51
Category Term Count P Value
GOTERM_BP_FAT G0:0006954~inflammatory response 22 8.58E-07
GOTERM_BP_FAT G0:0006952~defense response 31 1.59E-06
GOTERMBPFAT G0:0009611~response to wounding 26 2.18E-05
BP: Biological Processes. CC: Cellular Components. GO: Gene ontology. GOTERM: Gene 
ontology term. INTERPRO: protein sequence analysis & classification resource. KEGG: Kyoto 
Encyclopaedia of Genes and Genomes. MF: Molecular Functions. PIR: Protein Information 
Resource annotation. SMART: Simple Modular Architecture Research Tool. SP: SwissProt 
Protein Knowledgebase. UP_SEQ_FEATURE: Uniprot Sequence annotations.
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Tab le  5 .6  Functional a n n o ta tio n  c lustering  o f DEGs: C luster 4  and 5
Annotation Cluster 4 Enrichment Score: 3.79
Category Term Count P Value
GOTERM_BP_FAT G0:0007610~behavior 27 8.00E-07
GOTERM_BP_FAT G0:0006954~inflammatory response 22 8.58E-07
SP_PIR_KEYWORDS inflammation 7 2.79E-06
GOTERM_MF_FAT G0:0005125~cytokine activity 15 1.02E-05
SP_PIR_KEYWORDS cytokine 14 1.15E-05
KEGG_PATHWAY
hsa04060:Cytokine-cytokine receptor 
interaction 18 1.21E-05
GOTERM_CC_FAT G0:0005615~extracellular space 30 1.67E-05
PIR_SUPERFAMILY
PIRSF500569:macrophage 
inflammatory protein 1, alpha/beta 4 2.97E-05
SP_PIR_KEYWORDS inflammatory response 9 4.27E-05
SP_PIR_KEYWORDS chemotaxis 8 1.96E-04
GOTERM_BP_FAT G0:0006935~chemotaxis 12 2.17E-04
G OTE R M_B P_F AT G0:0042330~taxis 12 2.17E-04
INTERPRO
IPR001811:Small chemokine, 
interleukin-8-like 6 6.40E-04
GOTERM_BP_FAT G0:0007626~locomotory behaviour 15 6.84E-04
INTERPRO
IPR000827:Small chemokine, C-C 
group, conserved site 5 7.99E-04
SMART SM00199:SCY 6 9.42E-04
PIR_SUPERFAMILY
PIRSF001950:small inducible 
chemokine, C/CC types 5 9.63E-04
GOTERM_MF_FAT G0:0008009~chemokine activity 6 0.00129
G OTE R M_M F_F AT
G0:0042379~chemokine receptor 
binding 6 0.00172
GOTERM BP FAT G0:0006928~cell motion 18 0.00828
Annotation Cluster 5 Enrichment Score: 2.<32
Category Term Count P Value
G OTE R M_B P_F AT
G0:0007218~neuropeptide signalling 
pathway 10 6.13E-05
INTERPRO
IPR009443:Nuclear pore complex 
interacting 4 9.54E-05
INTERPRO IPR000203: GPCR proteolytic site 4 0.0269
SMART SM00303: GPCR proteolytic site 4 0.03371
BP: Biological Processes. CC: Cellular Components. GO: Gene ontology. GOTERM: Gene 
ontology term. INTERPRO: protein sequence analysis & classification resource. KEGG: Kyoto 
Encyclopaedia of Genes and Genomes. MF: Molecular Functions. PIR: Protein Information 
Resource annotation. SMART: Simple Modular Architecture Research Tool. SP: SwissProt 
Protein Knowledgebase. UP_SEQ_FEATURE: Uniprot Sequence annotations.
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Figure 5.4 Genes in functional annotation cluster 3
Functional annotation cluster 3: the association of genes to annotation terms in the 
cluster w ith an enrichment score of 5.51.
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Figure 5.5 Genes in functional annotation cluster 4
Functional annotation cluster 4: the association of genes to some annotation terms in 
the cluster 4 w ith an enrichment score of 3.79.
5 .3 .3 .2  Functional e n ric h m e n t analysis o f up and  d ow n  reg u la ted  genes
Following the functional analysis of all DEGs, the up regulated and down regulated 
genes functional analysis was done separately. The functional analysis of the up 
regulated genes generated 21 clusters that are significantly enriched (enrichment 
score > 1.3). The analysis of the down regulated genes generated 6 significantly 
enriched clusters as in figure 5.6.
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Figure 5.6 Enrichment scores of annotation clusters obtained by functional
enrichment analysis
(a) Up regulated genes had 21 significantly enriched clusters w ith enrichment score 
from 7.45 to 1.46. (b) Down regulated genes only had 6 significantly enriched clusters 
w ith enrichment score from 2.85 to 1.55.
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Functional a n n o ta tio n  clusters o f up reg u la ted  genes
The first cluster of up regulated genes demonstrated that 82 genes with enrichment P- 
value 4.2 X 10 12 were significantly associated with signalling and glycoprotein terms; 
the ir cellular component was in the extracellular space or region. The genes in the 
second cluster were significantly associated w ith biological processes of inflammatory 
and defence responses and chemotaxis. They were also enriched in cytokine-cytokine 
receptor interaction pathway in addition to molecular function such as chemokine 
activity and chemokine receptor binding. The genes in annotation cluster 5 were 
associated with neuropeptide signalling pathway as in table 5.7.
Functional annotation clusters of down regulated genes
The annotation cluster 1 of down regulated genes demonstrated that those genes 
were associated w ith calmodulin and actin binding molecular functions; the ir cellular 
component was in the actin cytoskeleton region and they were associated w ith 
biological processes of actin and actomyosin cytoskeleton organization as well as 
regulation of cellular component biogenesis as in table 5.8. Furthermore; the genes in 
annotation cluster 3 were associated w ith cellular components such as synapse, cell 
junction, dendrite, postsynaptic membrane and postsynaptic density. In addition, the 
down regulated genes in annotation cluster 5 were associated w ith biological 
processes such as ligand- and voltage-gated channel activity, ion transport, calcium 
transport and calcium signalling pathway. They were also involved in the regulation of 
cellular localization, synapse organization and regulation of synaptic plasticity as in 
table 5.8.
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Tab le  5 .7  Functional a n n o ta tio n  c lustering  o f up reg u la ted  genes
Annotation Cluster 1 Enrichment Score: 7.48
Category Term Count P Value
SP_PIR_KEYWORDS signal 82 4.21E-12
UP_SEQ_FEATURE signal peptide 82 5.88E-12
SP_PIR_KEYWORDS disulphide bond 72 5.60E-10
UP SEQ FEATURE disulphide bond 70 1.02E-09
SP_PIR_KEYWORDS Secreted 50 2.25E-09
GOTERM_CC_FAT G0:0005576~extracellular region 58 3.76E-09
GOTERM_CC_FAT G0:0044421~extracellular region part 37 6.99E-09
GOTERM_CC_FAT G0:0005615~extracellular space 28 2.73E-07
UP SEQ FEATURE glycosylation site: N-linked (GlcNAc...) 74 1.15E-04
SP PIR KEYWORDS glycoprotein 76 1.29E-04
UP SEQ FEATURE topological domain:Cytoplasmic 54 0.01577
Annotation Cluster 2 Enrichment Score: 4.12
Category Term Count PValue
G OTE R M_B P_F AT G0:0006952~defense response 27 2.55E-07
G OTE R M_B P_F AT G0:0006954~inflammatory response 19 4.62E-07
GOTERM BP FAT G0:0009611~response to wounding 23 3.13E-06
SP PIR KEYWORDS inflammatory response 9 3.36E-06
GOTERM BP FAT G0:0007610~behavior 21 6.08E-06
KEGGPATHWAY
hsa04060:Cytokine-cytokine receptor 
interaction
16 7.48E-06
GOTERM MF FAT G0:0005125~cytokine activity 13 8.07E-06
SP PIR KEYWORDS inflammation 6 9.40E-06
SP_PIR_KEYWORDS cytokine 12 1.01E-05
PIR_SUPERFAMILY
PIRSF500569:macrophage inflammatory 
protein 1, alpha/beta
4 1.23E-05
INTERPRO
IPR001811:Small chemokine, 
interleukin-8-like
6 1.31E-04
SMART SM00199:SCY 6 1.56E-04
SP PIR KEYWORDS chemotaxis 7 2.01E-04
INTERPRO
IPR000827:Small chemokine, C-C group, 
conserved site
5 2.17E-04
GOTERM_MF_FAT G0:0008009~chemokine activity 6 2.97E-04
PIR_SUPERFAMILY
PIRSF001950:small inducible chemokine, 
C/CC types
5 3.18E-04
G OTE R M_B P_F AT G0:0042330~taxis 10 3.38E-04
GOTERM BP FAT G0:0006935~chemotaxis 10 3.38E-04
GOTERM_MF_FAT
G0:0042379~chemokine receptor 
binding
6 4.00E-04
GOTERM_BP_FAT G0:0006928~cell motion 16 0.00213
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Tab le  5 .7  Functional a n n o ta tio n  clustering  o f up reg u la ted  genes (c o n tin u e d )
Annotation Cluster 3 Enrichment Score: 3.29
Category Term Count P Value
GOTERM_BP_FAT
G0:0009991~response to extracellular 
stimulus
14 9.74E-06
G OTE R M_B P_F AT
G0:0010033~response to organic 
substance
25 4.39E-05
GOTERM_BP_FAT
G0:0009725~response to hormone 
stimulus
16 1.49E-04
GOTERM_BP_FAT G0:0033273~response to vitamin 7 2.69E-04
GOTERM_BP_FAT
G0:0048545~response to steroid 
hormone stimulus
11 2.97E-04
GOTERM_BP_FAT G0:0031667~response to nutrient levels 11 3.64E-04
GOTERM_BP_FAT
G0:0009719~response to endogenous 
stimulus
16 4.28E-04
GOTERM_BP_FAT G0:0007584~response to nutrient 9 6.52E-04
GOTERM_BP_FAT
G0:0051384~response to glucocorticoid 
stimulus
7 6.66E-04
GOTERM_BP_FAT
G0:0031960~response to corticosteroid 
stimulus
7 0.00105
GOTERMBPFAT
G0:0043434~response to peptide 
hormone stimulus
9 0.00121
GOTERMBPFAT
G0:0043627~response to estrogen 
stimulus
6 0.01427
GOTERMBPFAT
G0:0032570~response to progesterone 
stimulus
3 0.02977
Annotation Cluster 4 Enrichment Score: 2.64
Category Term Count P Value
GOTERM_BP_FAT
G0:0009628~response to abiotic 
stimulus
15 5.11E-04
GOTERM_BP_FAT
G0:0009612~response to mechanical 
stimulus
6 9.60E-04
GOTERM_BP_FAT
G0:0014070~response to organic cyclic 
substance
7 0.00617
GOTERM BP FAT G0:0042493~response to drug 9 0.00946
Annotation Cluster 5 Enrichment Score: 2.54
Category Term Count P Value
SP_PIR_KEYWORDS cleavage on pair of basic residues 13 9.07E-05
GOTERM_BP_FAT
G0:0007218's'neuropeptide signalling 
pathway
7 0.00167
GOTERM_MF_FAT G0:0005179~hormone activity 6 0.01278
GOTERM_MF_FAT
G0:0005184~neuropeptide hormone 
activity
3 0.03487
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Tab le  5 .8  Functional a n n o ta tio n  c lustering  o f d o w n  reg u la ted  genes
Annotation Cluster 1 Enrichment Score: 2.85
Category Term Count P Value
GOTERM MF FAT G0:0005516~calmodulin binding 9 4.0E-07
SP PIR KEYWORDS calmodulin-binding 7 2.9E-05
SP PIR KEYWORDS actin binding 5 4.5E-05
GOTERM_BP_FAT
G0:0031032~actomyosin structure 
organization
4 4.0E-04
GOTERM_MF_FAT
G0:0008092~cytoskeletal protein 
binding
10 7.7E-04
GOTERM_MF_FAT G0:0003779~actin binding 8 1.1E-03
GOTERM CC FAT G0:0015629~actin cytoskeleton 7 2.0E-03
SP PIR KEYWORDS actin-binding 6 7.6E-03
GOTERM CC FAT G0:0005856~cytoskeleton 14 1.6E-02
GOTERM_BP_FAT
G0:0030036~actin cytoskeleton 
organization
5 3.0E-02
GOTERM_BP_FAT
G0:0044087~regulation of cellular 
component biogenesis
4 3.7E-02
INTERPRO IPR001715:Calponin-like actin-binding 3 4.8E-02
Annotation Cluster 2 Enrichment Score: 2.67
Category Term Count P Value
INTERPRO
IPR009443:Nuclear pore complex 
interacting
4 2.4E-06
INTERPRO IPR001024:Lipoxygenase, LH2 3 6.3E-03
INTERPRO IPR000203:GPS 3 1.5E-02
SMART SM00303:GPS 3 2.2E-02
Annotation Cluster 3 Enrichment Score: 2.50
Category Term Count P Value
GOTERM CC FAT G0:0045211~postsynaptic membrane 6 5.2E-04
GOTERM CC FAT G0:0030054~cell junction 10 9.2E-04
GOTERM CC FAT G0:0044456~synapse part 7 1.3E-03
SP PIR KEYWORDS postsynaptic cell membrane 5 2.2E-03
SP PIR KEYWORDS cell junction 8 3.6E-03
SP PIR KEYWORDS synapse 6 4.1E-03
GOTERM CC FAT G0:0014069~postsynaptic density 4 5.1E-03
GOTERM CC FAT G0:0045202~synapse 7 7.9E-03
G OTE R M_CC_F AT G0:0030425~dendrite 5 8.5E-03
GOTERM CC FAT G0:0043197~dendritic spine 3 1.5E-02
Annotation Cluster 4 Enrichment Score: 2.40
Category Term Count P Value
GOTERM CC FAT G0:0015629~actin cytoskeleton 7 0.0020
GOTERM CC FAT G0:0044449~contractile fibre part 5 0.0023
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Tab le  5 .8  Functional a n n o ta tio n  c lustering  o f d o w n  reg u la ted  genes (co n tin u ed )
Annotation Cluster 5 Enrichment Score: 2.15
Category Term Count P Value
GOTERM_MF_FAT G0:0005516~calmodulin binding 9 4.0E-07
GOTERM MF FAT G0:0022836~gated channel activity 8 8.0E-04
GOTERM BP FAT G0:0006816~calcium ion transport 6 8.3E-04
SP PIR KEYWORDS ionic channel 8 1.0E-03
GOTERM_BP_FAT
G0:0044057~regulation of system 
process
8 1.1E-03
GOTERM_MF_FAT
G0:0046873~metal ion transmembrane 
transporter activity
8 1.1E-03
GOTERM BP FAT G0:0006811~ion transport 12 1.8E-03
GOTERM_BP_FAT
G0:0015674~di-, tri-valent inorganic 
cation transport
6 2.2E-03
SP PIR KEYWORDS ion transport 10 2.2E-03
GOTERM BP FAT G0:0030001~metal ion transport 9 2.7E-03
GOTERM MF FAT G0:0005216~ion channel activity 8 2.8E-03
GOTERM_MF_FAT
G0:0022838~substrate specific channel 
activity
8 3.3E-03
GOTERM MF FAT G0:0015267~channel activity 8 4.0E-03
GOTERM_MF_FAT
G0:0022803~passive transmembrane 
transporter activity
8 4.1E-03
KEGG_PATHWAY hsa04020:Calcium signalling pathway 5 6.2E-03
GOTERM MF FAT G0:0005262~calcium channel activity 4 6.9E-03
GOTERM BP FAT G0:0006812~cation transport 9 7.5E-03
GOTERM CC FAT G0:0034704~calcium channel complex 3 7.8E-03
GOTERM CC FAT G0:0030425~dendrite 5 8.5E-03
SP PIR KEYWORDS calcium transport 4 8.6E-03
G OTE R M_B P_F AT
G0:0043062~extracellular structure 
organization
5 1.0E-02
GOTERM MF FAT G0:0005261~cation channel activity 6 1.1E-02
GOTERM_BP_FAT
G0:0022037~metencephalon
development
3 1.4E-02
GOTERM CC FAT G0:0034702~ion channel complex 5 1.8E-02
GOTERM_MF_FAT
G0:0022834~ligand-gated channel 
activity
4 2.5E-02
GOTERM CC FAT G0:0034703~cation channel complex 4 2.7E-02
GOTERM_BP_FAT
G0:0050804~regulation of synaptic 
transmission
4 3.3E-02
GOTERM_MF_FAT
G0:0022843~voltage-gated cation 
channel activity
4 3.6E-02
SP_PIR_KEYWORDS calcium channel 3 3.7E-02
SP_PIR_KEYWORDS voltage-gated channel 4 3.8E-02
G OTE R M B  P_F AT G0:0030902~hindbrain development 3 3.9E-02
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T ab le  5 .8  Functional a n n o ta tio n  c lustering  o f d ow n  reg u la ted  genes (c o n tin u ed )
Annotation Cluster 5 Enrichment Score: 2.15
Category Term Count P Value
GOTERM_BP_FAT
G0:0060341~regulation of cellular 
localization
5 3.9E-02
GOTERM BP FAT G0:0050808~synapse organization 3 4.0E-02
GOTERM_BP_FAT
G0:0051969~regulation of transmission 
of nerve impulse
4 4.1E-02
GOTERM BP FAT G0:0050905~neuromuscular process 3 4.1E-02
GOTERM_BP_FAT
G0:0048167~regulation of synaptic 
plasticity
3 4.3E-02
GOTERM_BP_FAT
G0:0031644~regulation o f neurological 
system process
4 4.5E-02
GOTERM_MF_FAT
G0:0005230~extracellular ligand-gated 
ion channel activity
3 4.9E-02
160
5.3.3.3 The KEGG pathway enrichment analysis of DEGs
The KEGG pathway enrichment analysis of up regulated genes, displayed in table 5.9, 
showed that the genes were most significantly associated w ith cytokine-cytokine 
receptor interaction pathway (P = 7.5 X 10'6), Toll-like receptor signalling pathway (P =
4.3 X 10"3) and MAPK signalling pathway [P = 2.0 X 1 0 2). While the KEGG pathway 
enrichment analysis of down regulated genes showed that the genes were significantly 
associated w ith the calcium signalling pathway (P = 0.006) as displayed in table 5.10.
5.3.4 The mRNA expression o f cytokines in TLE-HS
The KEGG pathway functional enrichment analysis of DEGs showed that cytokine- 
cytokine receptor interaction pathway (16 genes) had the highest enrichment P - value. 
In addition, the functional annotation analysis o f up regulated genes showed that 
these cytokine genes were in the first and second highest clusters o f functional 
enrichment analysis. Therefore, the mRNA expression of IL-lp, IL-18, Fas, ICAM-1, 
CCL2, CCL4, CXCL1, CXCL2, CXCL12, CXCR4 and CX3CR1 from MA analysis were further 
validated by qRT-PCR (Gene names are fully described in section 2.5, table 2.4).
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Tab le  5 .9  KEGG p a th w a y  e n ric h m e n t analysis o f up reg u la ted  DEGs
KEGG_PATHWAY Count P Value
hsa04060: Cytokine-cytokine receptor interaction 16 7.5E-06
hsa04620: Toll-like receptor signalling pathway 7 4.3E-03
hsa04640: Hematopoietic cell lineage 6 9.9E-03
hsa05330: Allograft rejection 4 1.7E-02
hsa04010: MAPK signalling pathway 10 2.0E-02
hsa05332: Graft-versus-host disease 4 2.1E-02
hsa04940: Type 1 diabetes mellitus 4 2.6E-02
hsa04672: Intestinal immune network for IgA production 4 3.9E-02
hsa05320: Autoimmune thyroid disease 4 4.3E-02
hsa04350: TGF-beta signalling pathway 5 4.4E-02
hsa04623: Cytosolic DNA-sensing pathway 4 5.2E-02
hsa04062: Chemokine signalling pathway 7 6.6E-02
hsa04621: NOD-like receptor signalling pathway 4 6.9E-02
hsa05310: Asthma 3 7.2E-02
hsa03320: PPAR signalling pathway 4 8.9E-02
hsa05020: Prion diseases 3 1.0E-01
Table 5.10 KEGG pathway enrichment analysis of down regulated DEGs
KEGG_PATHWAY Count P Value
hsa04260: Cardiac muscle contraction 4 0.00433
hsa04020: Calcium signalling pathway 5 0.00622
hsa05410: Hypertrophic cardiomyopathy (HCM) 3 0.05139
hsa05414: Dilated cardiomyopathy 3 0.05918
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5.1.1.1 IL-ip, IL-18, Fas and ICAM-1 mRNA expression
The MA and qRT-PCR data demonstrated that gene expression of inflammatory 
cytokines IL-1|3, IL-18 and Fas were significantly increased in TLE-HS compared to both 
PMC and TLE-STG. The intracellular adhesion molecule 1 (ICAM-1) gene expression in 
TLE-HS was significantly increased compared to TLE-STG. However compared to PMC, 
only MA data show a significant increased expression of ICAM-1 as shown in figure 5.7.
5.1.1.2 CCL2, CCL4, CXCL1 and CXCL2 mRNA expression
The gene expression of chemokines CCL2, CCL4 and CXCL2 determined by both MA and 
qRT-PCR, were significantly up regulated in TLE-HS compared to both PMC and TLE-STG. 
The MA gene expression of CXCL1 was significantly up regulated in TLE-HS compared 
to  PMC; while the CXCL1 qRT-PCR data showed a significant up regulation in TLE-HS 
compared to both PMC and TLE-STG as shown in figure 5.8.
5.1.1.3 CXCL12, CXCR4 and CX3CR1 mRNA expression
The gene expression of the chemokine CXCL12 and its receptor CXCR4 determined by 
both MA and qRT-PCR; showed a significant up regulation in TLE-HS compared to both 
TLE-STG and PMC. The CX3CR1 expression in TLE-HS investigated by MA showed a 
slight increase in expression compared to TLE-STG and a significant increased 
expression compared to PMC. On the other hand, CX3CR1 expression in TLE-HS 
investigated by qRT-PCR revealed a significant up regulation compared to both PMC 
and TLE-STG as shown in figure 5.9.
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5.4 Discussion
In the few microarray studies done the analysis focused on the list of genes that are 
differentially expressed. In addition, there was only a small proportion o f genes that 
overlap between these studies. In physiological conditions a biological process is done 
by a group of genes that work together simultaneously. Hence in a pathological 
condition it is more rational to investigate the abnormal genes in a group-based 
analysis. Therefore in the present study, enrichment analysis of microarray data was 
performed as group-oriented analysis, rather than gene-oriented analysis. The 
differentially expressed genes are clustered into groups based on the ir cellular 
component, molecular function, biological processes and pathways. This will provide a 
better understanding of molecular functions and biological processes that are affected 
in the intractable TLE-HS pathology and thus providing new aspects for developing 
effective treatments for the pharmacoresistant TLE patients.
As a result of comparing the transcriptome profile of the epileptogenic TLE-HS tissue to 
TLE-STG and PMC samples, a total of 464 up regulated and 350 down regulated DEGs 
were identified. According to DAVID enrichment analysis of these genes, the up 
regulated gene clusters had higher enrichment scores than the down regulated 
clusters. Interestingly, the up regulated genes in TLE-HS tissue were significantly 
enriched in cytokine activity molecular functions and biological processes of 
inflammatory and defence responses. Furthermore the KEGG pathway analysis o f up 
regulated DEGs showed that the cytokine-cytokine receptor interaction, Toll-like
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receptor and MAPK signalling pathways were significantly enriched in epileptogenic 
TLE-HS tissue. Recent evidence suggested that these pathways have a role in the 
neuropathology of epilepsy (Ravizza et al., 2008; Vezzani et al., 2008; Maroso et al., 
2011; Lopes et al., 2012).
The enrichment of down regulated genes in TLE-HS tissue was significantly associated 
w ith synaptic, cell junction, dendritic, postsynaptic membrane and ion transport genes; 
which are one of the characteristics of epileptic sclerotic hippocampi. One of the novel 
findings of this study; we report that GABAa receptor, epsilon subunit is down 
regulated in TLE-HS. However, its down regulation needs to be further validated and its 
role in TLE pathophysiology needs to be further explored.
5.4.1 Role o f cytokines in TLE-HS
In this study, the enrichment analysis of microarray data revealed that 27 genes 
associated w ith inflammatory and defence responses were significantly up regulated in 
TLE-HS tissue (Table 5.7). From those 27 significantly up regulated genes, 16 were 
cytokines. The mRNA up regulation of inflammatory cytokines IL-1|3, IL-18 and Fas as 
well as the intercellular adhesion molecule 1 (ICAM-1) were validated by qRT-PCR 
analysis.
IL-lp expression in TLE-HS
In this study there was a significant up regulation of pro-inflammatory IL-lp  in 
epileptogenic TLE-HS tissue compared to TLE-STG and PMC, that further supports the 
data obtained from other studies done on TLE patients (Ravizza et al., 2008; Maroso et
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al., 2011). However, in addition to the classical role of cytokines in inflammation, 
cytokines also play a role in neuronal excitability. Recent evidence found that binding 
of IL-1(3 to its neuronal IL-1B receptor leads to the phosphorylation and activation of 
the NMDA receptor. Thus increasing the NMDA receptor induced Ca2+ influx into 
neurons, and enhancing seizure susceptibility and excitotoxicity (Viviani et al., 2003; 
Vezzani et al., 2008). Furthermore, it was reported that IL-1J3 and TNF-a inhibited the 
astrocytic glutamate uptake and thus promoting glutamate excitotoxicity in TLE-HS (Hu 
et al., 2000). Moreover, IL-1(3 inhibited the GABAa receptor current in surgically 
resected hippocampal tissue obtained from TLE patients (Wang et al., 2000; Roseti et 
al., 2015). In many animal models of epilepsy, the administration of IL-1(3 receptor 
antagonist or caspase-1 inhibitor had an anticonvulsive effect (Maroso et al., 2011). 
Therefore, blocking the action of IL-1(3 appears as a good drug target fo r treatm ent of 
refractory TLE-HS patients.
IL-18 expression in TLE-HS
IL-18 also known as interferon-gamma (IFN-y) inducing factor is a potent cytokine that 
belongs to IL-1 family of pro-inflammatory cytokines. It has many immunological and 
inflammatory roles such as induction of chemokines and growth factors (Kanno et al., 
2004; Felderhoff-Muese et al., 2005). IL-18 is expressed in the brain constitutively but 
its expression is increased significantly in neurons, microglia, astrocytes and 
endothelial cells in response to brain injury (Johnson et al., 2015).
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IL-18 has a key role in neuroinflammation and neurodegeneration; it induces the 
production of pro-inflammatory IL-1(3, TNF-a and matrix metalloproteinases (MMPs) 
from activated microglia. It also amplifies the effect of leukocyte extravasation by 
inducing chemokine production from activated microglia and the up regulation of 
ICAM-1 on endothelial cells. In inflammatory conditions, IL-18 increases Fas-mediated 
neuronal apoptosis via the induction of IFN-y secretion (Gerdes et al., 2002; 
Felderhoff-Muese et al., 2005; Johnson et al., 2015). Furthermore, it was reported that 
IL-18 affects hippocampal synaptic transmission where it stimulated synaptic 
glutamate release and enhances the currents of AMPA receptors in CA1 pyramidal 
neurons of a mouse hippocampal slice (Kanno et al., 2004).
In a rat model of SE, the expression o f IL-18 was significantly up regulated in DG 
neurons, pyramidal cells of CA1-3, astrocytes and microglia 1-3 days following SE , 
while IFN-y was only up regulated in astrocytes (Ryu et al., 2010) . In addition, they 
found that administration of IL-18 or IFN-y reduced the neuronal damage caused by SE. 
Therefore, suggesting that both IL-18 and IFN-y may have a protective role on neurons 
(Ryu et al., 2010). The IL-18 expression was significantly up regulated in hippocampus 
following SE in a rat model of sustained SE. Flowever, IL-18 showed the highest 
expression in endothelial cells where there was vasculature injury. Thus, indicating 
that IL-18 might also play a role in angiogenesis (Johnson et al., 2015). In addition, the 
mRNA expression of IL-18 was also up regulated in microvascular endothelial cells 
derived from the sclerotic hippocampus from TLE patients (Lachos et al., 2011).
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In the present study we report, for the first time, the up regulation of IL-18 in 
epileptogenic tissue from TLE-HS patients supporting the previous experimental data 
(Ryu et al., 2010). Taking into consideration: (1) the excitatory effect o f IL-18 on 
hippocampal synaptic transmission reported by Kanno et al. (2004); (2) the 
anticonvulsant VX-765 drug which is an inhibitor of interleukin converting enzyme 
(ICE)/caspase-l that affects both IL-lp  and IL-18, is showing promising results in phase 
II clinical trials (Walker and Sills, 2012; Vezzani, 2015). We hypothesize that this up- 
regulation in IL-18 is contributing to TLE-HS pathophysiology and represents a novel 
drug target to develop new AEDs.
Fas expression in TLE-HS
Fas (CD95) is the prototypical cell death receptor that belongs to the TNF receptor 
superfamily. It induces the extrinsic or receptor-mediated apoptotic pathway by 
binding to Fas ligand receptor and recruiting the cytoplasmic Fas-associated protein 
w ith Death Domain (FADD). FADD also has a Death Effector Domain that activates 
caspase 8 and 9 and starts the caspase cascade leading to apoptosis (Vermeulen et al., 
2005). Many experimental animal models and human studies o f TLE-HS reported 
neuronal loss connected to apoptosis in TLE tissue (Bengzon et al., 2002; Pitkanen and 
Sutula, 2002; Henshall, and Simon, 2005: Xu et al., 2007). In a rat model o f TLE, there 
was an increase in Fas expression indicating Fas-mediated apoptosis in TLE (Tan et al., 
2002). Furthermore, there was also overexpression of Fas in sclerotic hippocampi 
obtained from drug resistant TLE patients (Xu et al., 2007).
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In addition to the role of Fas in apoptosis, accumulating evidence supports Fas pro- 
inflammatory role (Choi et al., 2001; 2003; Chorpade et al., 2003; Park et al., 2003). It 
was found that Fas can initiate an inflammatory response by the inducing the release 
of pro-inflammatory cytokines such as TNF-a from monocytes and macrophages (Park 
et al., 2003). It was also reported that Fas increased the expression of ICAM-1 in 
human astroglioma cells (Choi et al., 2003). In addition, it was found tha t IL-1(3 induces 
the astrocytic expression of Fas (Chorpade et al., 2003). In the present study, there was 
a significant increase in Fas expression in TLE-HS further corroborating the Fas- 
mediated apoptosis demonstrated by previous studies. However, the Fas up regulation 
could also be implicated in the inflammatory aspect o f TLE-HS pathophysiology.
ICAM-1 expression in TLE-HS
Cell adhesion molecules such as ICAM-1 play a major role in inflammation as they are 
responsible for T-cells activation and leukocyte recruitment to sites o f inflammation 
(Ren et al., 2010). The pro-inflammatory cytokines Fas, IL-1(3 and TNF-a significantly 
enhance the expression of ICAM-1 (Kuppner et al., 1990). As mentioned earlier IL-18 
also increased the expression of ICAM-1 on endothelial cells (Gerdes et al., 2002). 
Interestingly it was found that increased expression of ICAM-1 causes an enhanced 
translation of IL-l(3 mRNA (Allan et al., 2005).
In the hippocampi of experimental models of TLE, there was an up regulation o f ICAM- 
1 expression on the endothelial cells that was followed by the infiltration of leukocytes 
(Akiyama et al., 1994; Zattoni et al., 2011). It was also reported that there was an up
172
regulation of ICAM-1 expression in the endothelial cells in sclerotic hippocampi (n = 4) 
from TLE patients (Nakahara et al., 2010). This supports our finding of significant 
increase in ICAM-1 mRNA level in TLE-HS. Regarding the T-lymphocyte infiltra tion in 
sclerotic hippocampi from TLE-HS, there were more cytotoxic T-cells (CD8+) than Th- 
cells (CD4+) suggesting that it might be contributing to the neurodegeneration in TLE- 
HS (Nakahara et al., 2010). Therefore, we suggest that ICAM-1 overexpression plays a 
vital role in triggering and aggravating leukocyte infiltration and thus further 
contributes to  TLE-HS neuropathology.
5.4.2 Role o f chemokines in TLE-HS
In the present study, the enrichment analysis of microarray data revealed that 27 
significantly up regulated genes in TLE-HS tissue were associated with inflammatory 
and defence responses (Table 5.7). From those, 16 cytokine genes including 6 
chemokines were significantly altered. The transcript up regulation of inflammatory 
chemokines CCL2, CCL4, CXCL1, CXCL2, CXCL12, as well as chemokine receptors CXCR4 
and CX3CR were validated by qRT-PCR analysis. Chemokines are a class of cytokines. 
They are small secreted proteins that play an important role in inflammation. One of 
the ir main functions is leukocyte chemoattraction but they are also involved in 
angiogenesis, proliferation and apoptosis. The primary sources o f chemokines 
following CNS injury are microglia and astrocytes (Mantovani et al., 2006). Recent 
evidence highlighted the role of pro-inflammatory chemokines such as CCL2, CCL3 and 
CCL4 in TLE neuropathology (Van Gassen et al., 2008; Kan et al., 2012; Arisi et al.,
2015).
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CCL2 and  CCL4 expression in TLE-HS
In animal models of TLE, there was a significant up regulation of CCL2, CCL3 and CCL4 
chemokines in the hippocampus during the acute and early phases of SE indicating 
their role in early stages of epileptogenesis (Gorter et al., 2006; Arisi et al., 2015). A 
study of sclerotic hippocampus from drug resistant TLE patients also showed high 
expression levels of CCL3 and CCL4 that are consistent w ith our results and further 
implicate their role in chronic stages of epileptogenesis. CCL2, CCL3 and CCL4 affect 
endothelial cells and increase the permeability of the BBB, thus facilitating the 
infiltration of leukocytes into the brain. Once w ithin the brain they activate microglia 
and astrocytes, which participate in cytokine-mediated neuroinflammation 
(Stamatovic et al, 2005; Louboutin et al., 2011). In addition, it was found that CCL2 and 
CCL4 are involved in neuronal damage and excitotoxicity following SE (Kalehua et al., 
2004; Sheehan et al., 2007; Louboutin et al., 2011). Therefore, the ir up regulation is a 
contributing factor to the TLE-HS pathology.
CXCL1 and CXCL2 expression in TLE-HS
The inflammatory chemokines CXCL1 and CXCL2 hippocampal expression were found 
to be up regulated following SE in animal models (Kalehua et al., 2004; Kim et al., 
2010; Johnson et al., 2011). The secretion of CXCL1 and CXCL2 by microglia, astrocytes, 
neurons and endothelial cells is essential for leukocyte recruitment and neutrophil 
in filtration during neuroinflammation (Wu et al., 2015). The neutrophil infiltration 
further amplifies the inflammatory response by releasing proteolytic enzymes and 
inducing pro-inflammatory cytokines production (Kim et al., 2010). In addition, in vitro
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and in vivo studies found that high levels of CXCL2 induced hippocampal neuronal 
damage via apoptotic pathways (Kalehua et al., 2004). Therefore, the significant up 
regulation of CXCL1 and 2 in the epileptogenic tissue from TLE-HS patients seem to be 
implicated in its neuropathology. Thus, blocking the ir receptor CXCR2 might have a 
beneficial effect in ameliorating neuroinflammation in TLE-HS.
CXCL12 and CXCR4 expression in TLE-HS
In TLE animal models, the homeostatic chemokine CXCL12 was up regulated in the 
hippocampus in response to KA-induced seizures (Hartmen et o i, 2010; Song et al.,
2016). In adults, CXCL12 plays a role in neuroinflammation by leukocytes 
chemoattraction and in filtration (Guyon, 2014). In addition, CXCL12 and its receptor 
CXCR4 play a vital role in hippocampal neurogenesis. CXCL12 regulates the migration, 
differentiation and functional integration of newly formed neurons into the existing 
neuronal networks (Marquez-Curtis et al., 2013). In drug refractory TLE-HS, there is an 
abnormal hippocampal neurogenesis that seem to contribute to TLE-HS 
neuropathology. In a TLE animal model, the administration of CXCR4 antagonist 
(AMD3100) showed anticonvulsant activity where it suppressed long-term seizure 
activity and altered neurogenesis (Song et al., 2016). In the present study there was a 
significant up regulation of CXCL12 and CXCR4 in sclerotic hippocampus from  TLE 
patients further supporting its role in TLE-HS pathophysiology. However, further 
studies are still needed to confirm the beneficial role of CXCR4 antagonists in TLE 
patients.
175
CX3CR1 expression in TLE-HS
The inflammatory chemokine receptor CX3CR1 is expressed primarily on microglia and 
it regulates microglia activation and phagocytic activity (Ali et al., 2015). In animal 
models, microglia activation preceded SE-induced neuronal death and it was found 
that microglia activation plays an important factor in TLE epileptogenesis (Kang et al., 
2006; Abiega et al., 2016).
The CX3CR1 ligand, CX3CL1, expression was significantly increased in neurons and 
astrocytes in the hippocampus following SE in animal models (Yeo et al., 2011). It was 
also up regulated in tissue obtained from drug resistant TLE patients (Xu et al., 2012). 
In addition, it was found that CX3CL1 reduced GABA currents in neurons obtained from 
TLE-HS patients and the increased expression of CX3CR1 further affected the GABA 
inhibitory current (Roseti et al., 2013).
The expression of CX3CR1 was investigated in rat hippocampus following SE and its 
expression was found to be up regulated following seizures (Yeo et al., 2011; Ali et al., 
2015). The high expression of CX3CR1 was associated with SE-induced neuronal death 
and blocking CX3CR1 led to  a reduction in SE-induced neuronal damage (Yeo et al., 
2011). In the present study, there was a significant up regulation of CX3CR1 in the 
epileptogenic TLE-HS tissue from drug resistant TLE patients. This further supports the 
pathological role of CX3CR1 up regulation in TLE-HS as it contributes to  elevated 
microglia activation and GABAergic activity reduction. Therefore, CX3CR1 might be a 
potential new drug target for TLE-HS.
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5.5 Conclusion
The enrichment analysis of TLE-HS transcriptome provided an overview of molecular 
functions and biological processes that are affected and possibly contributing to TLE- 
HS. The up regulated cytokine and chemokine genes in cluster 1 and 2 (Table 5.7), 
which had the highest enrichment scores associating them to TLE-HS pathology. In the 
present study, we had further corroborated the pathological role of some thoroughly 
investigated cytokines such as IL-1(3 and Fas in TLE epilepsy. In addition, the 
expression of some cytokines and their receptors such as IL-18, CXCL1, CXCL2, CXCL12, 
CXCR4 and CX3CR1 are reported for the first time in human TLE-HS tissue, implicating 
them in TLE-HS pathophysiology. However, further research to investigate the spatial 
and temporal pattern of these cytokines and chemokines during TLE will help in 
developing new AEDs for refractory TLE-HS.
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Chapter 6
Expression of Aquaporins in sclerotic 
hippocampi from refractory
TLE-HS patients
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6 Expression of AQPs in sclerotic hippocampi from refractory 
TLE-HS patients
6.1 Introduction
The excitability of the hippocampus was found to be affected by alteration in water 
movement and osmotic changes. It was reported that hypo-osmolality promoted 
epileptiform activity in hippocampal brain slices and induced seizures (Andrew, 1990). 
Imaging studies in TLE-HS patients did demonstrate that there is water accumulation in 
the sclerotic hippocampi, compared to non-sclerotic ones. Magnetic resonance 
imaging (MRI) of the TLE-HS shows an increase in T2 and T2-weighted signal indicating 
higher free water content in sclerotic hippocampi tissue (Bronen et o/., 1991; Dawe et 
al., 2014). In addition, diffusion-weighted imaging also demonstrated higher diffusion 
coefficient in TLE-HS hippocampi. This supports the T2 MRI findings as the diffusion 
coefficient is a measure of water movement w ithin tissues determined by MRI (Hugg 
et al., 1999; Heuser et al., 2010). Therefore the roles of aquaporins were investigated 
in TLE-HS as they are important regulators of transcellular water flow  in the brain.
6.1.1 Aquaporins (AQPs)
AQPs are a family of small membrane transporter proteins. They form  channels by
assembling into stable tetramers in the membrane (Nielsen et al., 1993; Tait et al.,
2008). AQPs mainly regulate the bidirectional water movement across cell membranes
in response to osmotic gradients. In humans there are 13 AQPs that are initia lly divided
into 2 subfamilies: orthodox aquaporins and the aquaglyceroporins. The orthodox
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aquaporins such as AQP1, AQP4, AQP5 and AQP8 selectively transport water. The 
aquaglyceroporins such as AQP3, AQP7 and AQP9 transport glycerol, urea and other 
small solutes, in addition to water (Amiry-Moghaddam and Ottersen, 2003; Tait et o/., 
2008; Papadopoulos and Verkmen, 2013; Day et al., 2014). Recently a th ird subfamily 
of AQPs called superaquaporins, such as AQP11 and AQP12, was identified and 
thought to play a role in intracellular water transport (Gorelick et al., 2006; Ishibashi et 
al., 2014).
6.1.2 AQP expression in the brain
The AQPs that are expressed in rodent brain are AQP1, AQP3, AQP4, AQP5, AQP8 and 
AQP9 (Badaut et al., 2014). In human brain, AQP4 is the most abundant aquaporin and 
it is widely expressed in all brain structures in contact w ith the cerebral vascular 
compartment. In the human hippocampus, AQP4 is found in CA1 and DG areas. It is 
highly expressed in the astrocyte end-feet that ensheath the glutamatergic synapses. 
However, it shows the highest expression at the astrocyte perivascular end-feet 
processes, which is known as AQP4 polarized expression (Eid et al., 2005; Lee et al.,
2004).
AQP1 is expressed in the epithelial cells of the choroid plexus. In physiological 
conditions AQP1 is not expressed in cerebrovascular endothelium, AQP1 expression is 
induced only in pathological situations where there is a disruption in BBB 
(Papadopoulos and Verkmen, 2013; Badaut et al., 2014). AQP9 is weakly expressed in 
the brain; it has been reported in some neurons and astrocytes (Papadopoulos and 
Verkmen, 2013). In the rodent hippocampus, AQP9 is expressed in the astrocyte cell
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bodies and processes but it is not polarized (Badaut and Regli, 2004; Yang et al., 2011). 
It is also found in some catecholaminergic neurons (Badaut et al., 2014). In rat 
hippocampus, AQP3, AQP5 and AQP8 are expressed in the DG area. They were found 
in both astrocytes and neurons as their expression was co-localized w ith GFAP and 
NeuN positive cells in the DG (Yang et al., 2009). AQP11 is an intracellular AQP 
expressed on the ER membrane (Morishita et al., 2005). In rat brain, AQP11 is 
expressed in the cerebral cortex neurons and in CA1 and CA2 hippocampal neurons 
(Gorelick et al., 2006).
6.1.3 AQPs in TLE
It is well-known that water and ion homeostasis are important factors tha t modulate 
seizure susceptibility (Andrew, 1990; Schwartzkroin et al., 1998; Lee et al., 2012). The 
role of AQP1, -4 and -9 in TLE pathophysiology has been studied as they are key players 
in maintaining water homeostasis in the brain (Lee et al., 2004; Eid et al., 2005; Bebek 
et al., 2013). Alterations in AQP expression were observed in epileptic animal models 
as AQP1, AQP4 and AQP9 were investigated in chronic pilocarpine -induced SE rat 
model (Kim et al., 2009). AQP4 expression was also investigated in a kainic acid- 
induced SE mouse model (Lee et al., 2012).
In human TLE-HS specimens, alterations of AQP1 and AQP4 expression were observed 
in a few studies (Lee et al., 2004; Eid et al., 2005; Bebek et al., 2013). The expression of 
AQP1 and AQP4 were studied in sclerotic hippocampi obtained from TLE patients and 
was compared to non-sclerotic hippocampi obtained from mass associated- and 
paradoxical TLE patients (Lee et al., 2004). AQP1 transcript was slightly increased and
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AQP4 expression was significantly up regulated in TLE-HS specimens compared to Non- 
HS (Lee et al., 2004). The overall AQP4 protein expression was also significantly up 
regulated in TLE-HS compared to Non-HS; however, there was also a mislocalization of 
AQP4 expression and a significant loss in perivascular expression in TLE-HS (Eid et al., 
2005). The loss o f perivascular AQP4 causes a perturbed flux of water through 
astrocytes which is accompanied w ith an impaired extracellular K+ homeostasis. This 
altered K+ homeostasis leads to prolonged and aggravated epileptic seizures (Eid et al.,
2005). The gene expression o f AQP1 and AQ.P4 investigated in TLE-HS, showed no 
significant alterations in the ir expression when compared with autopsy hippocampi as 
a control (Bebek et al., 2013).
6.1.4 Aims of the study
The expression of AQP1 and AQP4 has been investigated in human TLE-HS specimens 
and were found to be involved in pathology of TLE-HS. Nevertheless, little  is known 
about the expression of other AQPs such as AQP3, AQP5 AQP8, AQP9 and AQP11. Thus, 
the aim of this study was to investigate the expression of AQP3, AQP5 AQP8, AQP9 and 
AQP11 in human TLE-HS hippocampi to see if they play a role in the pathophysiology of 
TLE-HS.
6.2 Materials and methods
6.2.1 Patient clinical information
Clinical information for TLE-STG and TLE-HS samples investigated in this chapter is 
described in Appendix I.
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6.2.2 Study design
The mRNA level of AQP1, AQP3, AQP4, AQP5 AQP8, AQP9 and AQP11 as well as NeuN 
and GFAP were investigated by microarray analysis (n = 7) and qRT-PCR in TLE-STG (n = 
5) and TLE-HS (n = 10) samples.
6.2.3 Methods
Microarray analysis (MA): Briefly the total RNA was extracted by SV Total RNA 
Isolation System (section 2.3.1). Then cDNA samples were synthesized and labelled 
w ith Cy3 or Cy5 using the Two-colour Low Input Quick Amp Labeling Kit (Agilent 
Technologies, 5190-2306). Following the labelling of TLE-HS hippocampi w ith Cy5 and 
TLE-STG samples with Cy3, equal amounts of the two samples were co-hybridized onto 
SurePrint G3 Human Gene Expression 8x60K Microarrays (Agilent Technologies, 
G4851A). The microarray array was washed and then scanned on Agilent Technologies 
SureScan Microarray Scanner (section 2.9). Raw data was extracted using Agilent 
feature extraction software and analysis was done on Multi-experiment Viewer (MeV) 
software (section 5.2.4). MA statistical analysis: rank products test was used to 
identify significant differences between samples ( * * *  P < 0.0001).
qRT-PCR: In brief, the total RNA extracted was reverse transcribed using Superscript™
III first strand synthesis system (section 2.4). Stable housekeeping genes were selected
for the normalization of target gene expression (section 2.5.3) then followed by the
qRT-PCR using TaqMan® gene expression assays (section 2.5.5). qRT-PCR statistical
analysis: Kruskal-Wallis w ith Conover-lnman post hoc analysis test was used to  identify
significant differences between samples (* P< 0.05).
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6.3 Results
6.3.1 NeuN and GFAP mRNA expression
The neuronal marker, NeuN mRNA expression obtained from microarray analysis 
showed a significant decrease in TLE-HS tissue compared to  TLE-STG. The NeuN mRNA 
expression determined by qRT-PCR analysis also showed the same trend of a reduced 
expression in TLE-HS tissue though it was not significant as in figure 6.1.
The mRNA expression of GFAP, which is an astrocyte marker determined by microarray 
analysis and qRT-PCR showed a significant up regulation in TLE-HS samples compared 
to TLE-STG as in figure 6.1. The expression level of NeuN and GFAP does confirm the 
hallmarks of TLE-HS which are neuronal loss and gliosis.
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Figure 6.1 NeuN and GFAP mRNA expression in TLE-HS and TLE-STG
The neuronal marker, NeuN, mRNA level investigated by MA (a) and qRT-PCR (c) 
showed a reduced expression in TLE-HS. The astrocyte marker, GFAP, mRNA level 
investigated by MA (b) and qRT-PCR (d) showed a significant higher expression in TLE- 
HS. MA statistical analysis: rank products test was used to identify significant 
differences between samples (* * *  P < 0.0001). MA number of samples: TLE-STG (n = 
7); TLE-HS (n = 7). qRT-PCR statistical analysis: Kruskal-Wallis w ith Conover-lnman post 
hoc analysis test was used to identify significant differences between samples (* P < 
0.05); qRT-PCR number of samples: TLE-STG (n = 5); TLE-HS (n = 10). All data presented 
as mean ± S.E.M. MA: Microarray analysis; Rn: Normalized fluorescence intensity.
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6.3.2 The AQP abundance in TLE-STG samples
The transcript expression of AQPs was investigated in the non-spiking TLE-STG samples 
by both MA and qRT-PCR. The data demonstrate that AQP4 was the most abundant 
aquaporin, showing highest expression, and then there was AQP5 and AQP11 that 
were moderately expressed. Followed by AQP1, AQP3, AQP8 and AQP9 that were less 
abundant and showing lowest expression compared to  AQP4 as shown in figure 6.2.
6.3.3 AQP1 and AQP4 mRNA expression in TLE-HS
The microarray analysis revealed that AQP1 and AQP4 expression was significantly up 
regulated in TLE-HS samples. The qRT-PCR data showed an increase in AQP1 and AQP4 
expression; even though it was not significant but it was still the same trend as MA 
data as shown in figure 6.3.
6.3.4 AQP3 and AQP5 mRNA expression in TLE-HS
The data obtained from MA and qRT-PCR demonstrated that there was an increase in 
AQP3 transcript level in TLE-HS compared to TLE-STG. In contrast, AQP5 transcript level 
revealed a reduced expression in TLE-HS compared to TLE-STG as shown in figure 6.4.
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Figure 6.2 mRNA expression of AQPs in TLE-STG
AQPs expression in TLE-STG investigated by (a) MA and (b) qRT-PCR showed that AQP4 
has highest expression, AQP5 and AQP11 showed moderate expression and AQP1, 
AQP3, AQP8 and AQP9 showed the lowest expression in the TLE-STG specimens. 
Number of TLE-STG samples: MA (n = 5); qRT-PCR (n = 7). All data presented as mean ± 
S.E.M. MA: Microarray analysis; Rn: Normalized fluorescence intensity.
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Figure 6.3 AQP1 and AQP4 mRNA expression in TLE-HS and TLE-STG
MA data showed that mRNA levels o f AQP1 (a) and AQP4 (b) were significantly up 
regulated in TLE-HS. qRT-PCR data also showed that both AQP1 (c) and AQP4 (d) 
expression was higher in TLE-HS compared to  TLE-STG but it was not significant. MA 
statistical analysis: rank products test was used to identify significant differences 
between samples ( * * *  P < 0.0001). MA number of samples: TLE-STG (n = 7); TLE-HS (n 
= 7). qRT-PCR statistical analysis: Kruskal-Wallis w ith Conover-lnman post hoc analysis 
test was used to identify significant differences between samples (* P < 0.05). qRT-PCR 
number of samples: TLE-STG (n = 5); TLE-HS (n = 10). All data presented as mean ± 
S.E.M. MA: Microarray analysis; Rn: Normalized fluorescence fluorescence intensity.
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Figure 6.4 AQP3 and AQP5 mRNA expression in TLE-HS and TLE-STG
AQP3 mRNA level explored by MA (a) and qRT-PCR (c), showed an increased 
expression in TLE-HS. While AQP5 mRNA level investigated by MA (b) and qRT-PCR (d), 
showed a reduced expression in TLE-HS compared with TLE-STG. MA statistical 
analysis: rank products test was used to identify significant differences between 
samples. MA number of samples: TLE-STG (n = 7), TLE-HS (n = 7). qRT-PCR statistical 
analysis: Kruskal-Wallis w ith Conover-lnman post hoc analysis test was used to  identify 
significant differences between samples. No significant differences were detected. 
qRT-PCR number of samples: TLE-STG (n = 5); TLE-HS (n = 10). All data presented as 
mean ± S.E.M. MA: Microarray analysis; Rn: Normalized fluorescence intensity.
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6.3.5 AQP8 and AQP9 mRNA expression in TLE-HS
The mRNA expression data obtained from MA and qRT-PCR demonstrate that there 
was a slight reduction in AQP8 transcript level in TLE-HS samples. In TLE-STG samples, 
there was more variability seen in AQP8 expression compared to TLE-HS. The data also 
showed a reduced level of AQP9 mRNA expression in TLE-HS compared w ith TLE-STG 
as shown in figure 6.5.
6.3.6 AQP11 mRNA expression in TLE-HS
The MA data revealed a modest reduction in AQP11 mRNA expression in TLE-HS 
compared to TLE-STG. Nevertheless, the qRT-PCR data showed a significant down 
regulation in TLE-HS compared to TLE-STG as shown in figure 6.6.
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Figure 6.5 AQP8 and AQP9 mRNA expression in TLE-HS and TLE-STG
AQP8 mRNA level data obtained from MA (a) and qRT-PCR (c), showed a slight 
decreased expression in TLE-HS. AQP9 mRNA level investigated by MA (b) and qRT-PCR 
(d) also showed a reduced expression in TLE-HS compared with TLE-STG. MA statistical 
analysis: rank products test was used to identify significant differences between 
samples. MA number of samples: TLE-STG (n = 7), TLE-HS (n = 7). qRT-PCR statistical 
analysis: Kruskal-Wallis w ith Conover-lnman post hoc analysis test was used to identify 
significant differences between samples. No significant differences were detected. 
qRT-PCR number of samples: TLE-STG (n = 5); TLE-HS (n = 10). All data presented as 
Mean ± S.E.M. MA: Microarray analysis; Rn: Normalized fluorescence intensity.
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Figure 6.6 AQP11 mRNA expression in TLE-HS and TLE-STG
AQP11 mRNA level obtained from MA (a) showed a slight decreased expression in TLE- 
HS. While expression data obtained from qRT-PCR (b) showed a significant reduction of 
AQP11 in TLE-HS compared to TLE-STG. MA statistical analysis: rank products test was 
used to identify significant differences between samples. MA number of samples: TLE- 
STG (n = 7), TLE-HS (n = 7). qRT-PCR statistical analysis: Kruskal-Wallis w ith Conover- 
Inman post hoc analysis test was used to identify significant differences between 
samples (* P < 0.05). qRT-PCR number o f samples: TLE-STG (n = 5); TLE-HS (n = 10). All 
data presented as mean ± S.E.M. MA: Microarray analysis; Rn: Normalized 
fluorescence intensity.
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6.4 Discussion
As pointed out in the introduction, there is evidence of impaired water homeostasis in 
sclerotic hippocampi resected from TLE patients (Bronen et al., 1991; Lee et al., 2004; 
Heuser et al., 2010; Dawe et al., 2014). Previous studies in human TLE-HS specimens 
indicated that changes in AQP4 expression (Lee et al., 2004; Eid et al., 2005) is 
implicated in the pathophysiology of pharmacoresistant TLE associated w ith HS. In 
summary the novel findings of this study were: 1) Reporting the transcript expression 
of AQP3, AQP5 AQP8, AQP9 and AQP11 in human hippocampus; 2) the expression of 
AQ1 is significantly increased in TLE-HS hippocampi; 3) the expression of AQP11 is 
significantly reduced in TLE-HS; 4) there was a slight increase in AQP3 expression and a 
small decreases in AQP5, AQP8 and AQP9 expression in TLE-HS compared to TLE-STG.
6.4.1 AQP transcript abundance in TLE-HS
AQP3, AQP5 AQP8, AQP9 and AQP11 were previously reported to be expressed in 
rodent hippocampus (Badaut and Regli, 2004; Gorelick et al., 2006; Yang et al., 2009). 
However, fo r the first time the presence of AQP3, AQP5 AQP8, AQP9 and AQP11 
transcripts are described in human hippocampi. This indicates that these AQPs also 
play a physiological role in maintaining water and ion homeostasis in the hippocampus, 
in addition to AQP1 and 4 that are widely studied.
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6.4.2 AQP4 expression in TLE-HS
AQP4 is widely expressed in astrocytes and it was one of the first AQPs studied in 
human TLE hippocampi by Lee et al., (2004). In the present study AQP4 was used as a 
positive control, its total mRNA expression was increased in TLE-HS compared to  TLE- 
STG supporting the findings of Lee et al., (2004) and Eid et al., (2005).
6.4.3 AQP1 expression in TLE-HS
In the present study, AQP1 mRNA is significantly up regulated in TLE-HS compared to 
TLE-STG. Normally in the hippocampus, the water transporting AQP1 is not observed in 
astrocytes or cerebrovascular endothelial cells. However, in a chronic model of SE, 
AQP1 expression was observed in astrocytes at 4 weeks after SE and became 
significantly up regulated at 6 weeks compared to control that was followed by a 
sustained up regulation of AQP1 in epileptic hippocampi (Kim et a I., 2009). This is 
supporting our data and indicates that AQP1 astrocyte expression is increased as the 
number of uncontrolled seizures increases, which could be a compensatory 
mechanism to overcome the loss in perivascular AQP4 expression.
In addition, AQP1 expression in cerebrovascular endothelial cells is only seen in
conditions where the BBB is disrupted such as malignant brain tumours (Papadopoulos
and Verkmen, 2013). In chronic seizures there is transient opening of BBB during
seizures in the epileptogenic foci that plays a role in the epileptogenic process (Kovacs
et al., 2012; Gorter et al., 2015). Therefore in drug resistant TLE hippocampi, the AQP1
expression could be induced in endothelial cells to facilitate water movement across
BBB. In summary the up regulation of AQP1 seen in TLE-HS tissue seems to be the
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result of AQP1 induced expression in astrocytes and endothelial cells, in response to 
the uncontrolled seizures. Therefore, this data suggests that AQP1 does have a role in 
water homeostasis in the drug resistant sclerotic hippocampi from TLE patients.
6.4.4 AQP3 and AQP9 expression in TLE-HS
Seizures represent a massive metabolic burden to neurons and glia as the restoration 
of the ion gradients requires energy and an enhanced oxygen and glucose 
consumption (Kovacs et al., 2012; Ullah et al., 2015). It was found that during epileptic 
activity there is a reduction in the level of glucose and ATP in the tissue as well as an 
increase in the level of lactate (Kovacs et al., 2012). In order for the neurons to meet 
this enormous metabolic demand they use glycerol and lactate as a source of energy 
(Magistretti et al., 1999; Badaut and Regli, 2004). The aquaglyceroporins, AQP3 and 
AQP9, are expressed in both astrocytes and neurons in the brain. They act as a 
metabolite channel that transports glycerol and other solutes such as lactate to 
astrocytes and neurons. Therefore they play a vital role in astrocyte and neuronal 
energy metabolism (Amiry-Moghaddam and Ottersen, 2003, Badaut et al., 2004).
In the present study, the total AQP9 transcript level is reduced in TLE-HS compared to
TLE-STG. In chronic epileptic rats, the metabolic disturbance was manifested by
accumulation of C02 and lactic acid in the extracellular space that lead to extracellular
lactic acidosis in CA1 (Kim et al., 2009). There was also an up regulation of AQP9
expression in CA1 area in the chronic epilepsy rats after 6 weeks from SE. This
increased AQP9 expression in the astrocytes enabled the uptake of excess lactate, due
to AQP9 permeability to lactate. Therefore suggesting that AQP9 up regulation is very
195
important in inhibiting the extracellular lactic acidosis induced by repeated 
spontaneous seizures (Ribeiro et al., 2006; Kim et al., 2009). Therefore, the reduced 
AQP9 level seen in this study indicates that AQP9 might be one of the many 
contributing factors to the pathophysiology of TLE-HS.
In the present study, AQP3 expression was not significantly up regulated in TLE-HS 
tissue compared to TLE-STG. AQP3 expression investigated in rat hippocampus showed 
that AQP3 mRNA and protein are expressed in CA1, CA2 and CA3 hippocampal 
subregions. AQP3 is expressed in both astrocytes and neurons (Yang et al., 2009; 
2011). So far there are no studies that investigate the role of AQP3 in epilepsy. 
However in ischemia, similarly to seizure, there is massive metabolic burden on 
neurons as they need energy to restore the ion gradient across the cell membrane 
(Kim et al., 2009; Ullah et al., 2015). In a rat model of focal ischemia, AQP3 expression 
was significantly increased in the hippocampus following ischemia to cope with the 
increased energy demand (Yang et al., 2011). Therefore, the non-significant up 
regulation of AQP3 seen in this study in the TLE-HS tissue, which is the site o f repeated 
spontaneous seizures, indicates an impaired neuronal energy metabolism in TLE-HS 
that might be contributing to its pathophysiology.
6.4.5 AQP5 and AQP8 expression in TLE-HS
In rat hippocampus AQP5 and AQP8 are expressed in neurons and astrocytes. They
both have very similar distribution in CA1, CA2 and CA3 areas suggesting tha t they may
co-operate w ith each other to regulate water homeostasis in neurons and astrocytes
(Yang et al., 2011). To date, there are no studies that investigate the role o f AQP5 and
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AQP8 in the epileptogenic process. In the present study, there is a slight non­
significant reduction in the expression of AQP5 and AQP8 in the TLE-HS samples. This 
finding suggests that AQP5 and AQP8 do seem to have a role in neuronal water 
homeostasis. However, whether they have a role in TLE pathophysiology needs to  be 
investigated by further research.
6.4.6 AQP11 expression in TLE-HS
AQP11 is one of the recently described superaquaporin that have a relatively low 
homology with the other AQPs (Gorelick et al., 2006; Yakata et al., 2011). It has low but 
constant water permeability (Yakata et al., 2011). In the kidneys, AQP11 has an 
intracellular localization as it was expressed on the endoplasmic reticulum membrane 
(Morishita et al., 2005). It has an important role in ER function as the kidney cells from 
AQP11 knockout mice show an up regulation of both apoptosis and ER stress genes 
(Ishibashi et al., 2014).
It is proposed that AQP11 has a distinct role in CNS function. In rat brain AQP11 has a 
unique intracellular expression in Purkinje cell dendrites, while having a membrane 
expression in the neurons of the cerebral cortex and hippocampal CA1 and CA2 
neurons (Gorelick et al., 2006). AQP11 is also expressed in cerebral endothelial cells, 
suggesting it might have a protective role in brain oedema (Ishibashi et al., 2014). 
However, the exact biological function of AQP11 in the brain still needs to be 
elucidated and so far, the role of AQP11 in TLE-HS have not been investigated.
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In the present study, there was a significant reduction in AQP11 expression in the 
epileptogenic foci of TLE-HS compared to TLE-STG. This indicates that AQP11 down 
regulation might also be linked to the neuroinflammation in seizure foci. A recent 
study revealed that AQP11 is expressed in retina glial cells. It also found that, in a 
chronic inflammatory retinal disease, the down regulation of AQP11 was linked to 
neuroinflammation in the retina (Deeg et al., 2016). In pharmacoresistant epilepsies 
such as TLE-HS, many clinical and experimental studies demonstrate that there is 
neuroinflammation in the epileptogenic foci contributing to its pathophysiology 
(Walker and Sills, 2012; Vezzani et al., 2013; 2015). Therefore, the novel and vital role 
of AQP11 in TLE-HS pathophysiology needs to be further explored.
6.5 Conclusion
In the sclerotic epileptic hippocampus all AQPs investigated showed an altered 
expression compared to TLE-STG. The different AQPs have distinct roles involving 
neuronal excitability, neuronal and astrocytic ion and water homeostasis, neuronal and 
astrocytic energy metabolism and neuroinflammation. Therefore, the selective 
regulation of the different AQPs may provide new therapeutic approaches to  TLE-HS 
epilepsy treatment.
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7 General discussion and conclusions
7.1 General discussion
Temporal lobe epilepsy is a common type of adult epilepsy. The AEDs available 
modulate and control seizures in 70% of TLE patients. However, there is a need to 
develop new AEDs as 30% of TLE patients do not respond to the available AEDs. Those 
patients experience recurrent uncontrolled seizures that cause a decline in their 
cognitive functions and affect the ir quality of life (Pitkanen and Sutula, 2002; Blumcke 
et al., 2012). In addition, TLE-HS surgical treatment, by the resection of the epileptic 
focus, causes memory impairments and psychopathological disturbances. Furthermore, 
surgical resection is only effective in controlling seizures in 60% of refractory TLE 
patients (Blumcke et al., 2012; Cleary et al., 2012; Coras and Blumcke, 2015). Therefore 
it is a necessity to further understand TLE-HS pathophysiology so new AEDs could be 
developed fo r treatm ent of refractory TLE-HS patients.
In the present study the expression of many genes were investigated in TLE-HS, TLE- 
STG and PMC specimens, in order to further understand TLE-HS pathophysiology and 
identify potential drug targets. The use of the surgically resected non-sclerotic, non­
spiking TLE-STG samples from TLE patients (Lee et al., 2006; Ravizza et al., 2008; 
Teichgraber et al., 2009; Bartolomei et al., 2010; Rocha et al., 2015) has many 
advantages. The samples do not have the post-mortem  confounding factors such as 
post-mortem  interval time and method of collection (Preece and Carins, 2003; Tomita 
et al., 2004). They have less inter-individual variation as samples are from the same
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TLE patient so they are age matched and have the same AED history. However, the 
epileptogenicity of non-spiking TLE-STG could not be excluded. Even though the TLE- 
STG sample is a non-spiking tissue, and we cannot exclude that it might be 
epileptogenic, it is still less epileptogenic compared to chronic epileptogenic TLE-HS 
tissue which is the seizure focus.
7.1.1 Dysregulation o f GABAB receptor in TLE-HS
In the present study, we found that there was a dysregulation in GABAb receptor 
subunits B1 and B2 expression that seem to be contributing to the impaired GABAergic 
inhibition in TLE-HS patients (Figure 3.10 and 3.13). The total GABABi and GABAB2 
subunits expression in TLE-HS showed an apparent elevation compared to PMC. On the 
other hand, comparing epileptogenic TLE-HS to  TLE-STG, we found a significant down 
regulation of GABAB2 subunit. This affects the formation of a functional heterodimeric 
GABAb receptor and contributes to the slow GABAergic inhibition impairment in 
epileptogenic TLE-HS. Therefore, drugs that target and increase GABAb2 subunit 
expression could promote and prolong the late inhibitory postsynaptic potential in the 
seizure foci tissue and counteracts the excitatory hyperactivity in TLE-HS.
7.1.2 Dysregulation of SGK1 and SCN4B in TLE-HS
In the present study, we found that there was an up regulation of SGK1 in the 
epileptogenic TLE-HS tissue compared to non-spiking TLE-STG and PMC samples 
(Figure 4.1 and 4.2). SGK1 is a potent regulator of neuronal excitability (Lang et al., 
2006; 2010) and its increased expression may have a protective role in TLE as it induces
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$prolonged IPSP by the activation and up regulation of VGKCs. It also plays a role in the 
neuronal and glial re-uptake of glutamate by the up regulation o f sodium-dependent 
glutamate transporters (Lang et al., 2006; Boehmer et al., 2006). Therefore, the 
activation of SGK1 might be a potential drug target fo r controlling excessive neuronal 
excitability.
In addition, this study reports for the first time the expression of SCN4B subunit in TLE. 
There was a significant up regulation of SCN4B mRNA level in the drug resistant TLE-HS 
compared to PMC (Figure 4.3 and 4.4). This elevated expression of SCN4B seems to 
contribute to the increased seizure susceptibility of the sclerotic hippocampi in TLE 
patients, as p4 subunit favours the Na+ channel activation and facilitates the action 
potential firing in neurons. The up regulation of SCN4B may also be contributing to the 
drug resistance in TLE-HS patients; hence they were resistant to sodium channels 
blockers such as phenytoin and lamotrigine that stabilize the inactive form of VGSCs. 
On the other hand, SCN4B subunit was significantly down regulated in the 
epileptogenic TLE-HS compared to TLE-STG obtained from drug resistant TLE patients. 
However, whether this down regulation of SCN4B is a compensatory mechanism in 
response to increased number o f seizures, still needs to be further investigated. 
Nevertheless, modulating VGSCs via targeting SCN4B subunit seem to be a potential 
drug target fo r TLE-HS treatment.
7.1.3 Dysregulation o f IP3R1 and SYNPR in TLE-HS
In this study we found that there was a significant up regulation o f intracellular calcium
channel receptor IP3R1 transcript in the sclerotic hippocampi of refractory TLE-HS
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compared to PMC (Figure 4.5). The up regulation of IP3R1 increases the intracellular 
Ca2+ concentration, neuronal excitability and neurotransm itter release (Cai et al., 2004; 
Steinlein, 2014). Therefore, IP3R1 up regulation seems to be an additional contributing 
factor to the increased neuronal excitability seen in TLE-HS as there is already 
excessive influx of calcium into the neurons caused by excessive glutamate release and 
chronic NMDA receptor activation. On the other hand, IP3R1 was significantly down 
regulated in high seizure-frequency TLE-HS tissue compared to TLE-STG indicating an 
alteration in intracellular Ca2+ homeostasis. In conclusion, impairment in Ca2+ 
homeostasis seems to play a role in TLE-HS pathophysiology and IP3R1 may be a 
potential drug targets for the development of new AEDs.
This study also found that presynaptic SYNPR that is involved in calcium dependent 
neurotransm itter release was significantly up regulated in TLE-HS compared to PMC 
(Figure 4.6 and 4.7). SYNPR is found in the inhibitory GABAergic nerve terminals in the 
hippocampus (Singec et al., 2002). Therefore, SYNPR up regulation in TLE-HS compared 
to PMC may be an indicator o f a compensatory increase in inhibitory GABAergic 
synapses. On the other hand, both mRNA and protein expression of SYNPR were 
significantly down regulated in the TLE-HS compared to TLE-STG. This SYNPR down 
regulation seem to be contributing to the enhanced seizure susceptibility of TLE -HS 
samples. Nevertheless, role of synaptoporin dysregulation in TLE-HS pathophysiology 
needs to be further exploited as it might represent a good drug target fo r TLE-HS 
patients.
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7.1.4 Up regulation of cytokines and chemokines in TLE-HS
The enrichment analysis of TLE-HS transcriptome done in this study presented an 
overview of molecular functions and biological processes that are affected and 
possibly contributing to TLE-HS pathophysiology. The clusters of up regulated genes 
had higher enrichment analysis than the down regulated clusters (Figure 5.6). The up 
regulated cytokine and chemokine genes were in both the first and second clusters 
(Table 5.7) and they had the highest enrichment analysis scores associating them to 
TLE-HS pathophysiology. In addition to the thoroughly investigated cytokines such as 
IL-lp, and Fas, this study reports fo r the first time the up regulation of some cytokines 
and the ir receptors such as IL-18, CXCL1, CXCL2, CXCL12, CXCR4 and CX3CR1 in TLE-HS, 
implicating them in TLE pathophysiology (Figure 5.7 - 5.9). The up regulated cytokines 
are mediating and aggravating neuroinflammation in the epileptogenic TLE-HS tissue. 
Furthermore, the up regulation of cytokines IL-lp  and IL-18 enhances neuronal 
excitability either via activation of NMDA, AMPA receptors or reduction in inhibitory 
GABAa currents (Kanno et al., 2004; Vezzani et al., 2008; Roseti et al., 2015). Therefore, 
inhibiting the cytokines' effect by means of receptor antagonists or drugs that inhibit 
the ir activation provides a worthy therapeutic approach for treatm ent o f refractory 
TLE-HS.
The up regulation of chemokines CCL2, CCL4, CXCL1, CXCL2 and CXCL12 and the up 
regulation of chemokine receptors CXCR4 and CX3CR1 (Figure 5.8 and 5.9) are also 
contributing to the neuroinflammation in the epileptogenic TLE-HS tissue. As they 
increase the BBB permeability and thus facilitate the infiltra tion of leukocytes into the
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brain. The infiltrated leukocytes further amplify the inflammatory response by 
releasing proteolytic enzymes and inducing pro-inflammatory cytokines production 
(Kim et al., 2010; Wu et al., 2015). In addition, the high expression of CCL2, CCL4, 
CXCL2 and CX3CR1 is probably contributing to the neuronal loss in TLE-HS hence their 
up regulation was associated w ith neuronal death in SE animal models (Kalehua et al., 
2004; Yeo et al., 2011). Furthermore, high expression of CX3CR1 contributes to 
increased neuronal hyperactivity via the reduction in inhibitory GABAa currents (Roseti 
et al., 2013). Therefore, inhibiting the chemokine effect by means of antagonists fo r 
CCR2, CCR5, CXCR2, CXCR4, CX3CR1 receptors or RNA interference therapy might 
provide a new viable therapeutic approach for treatm ent of refractory TLE-HS.
It is also important to point out that, activated microglia are the main source of many 
inflammatory cytokines that are up regulated in TLE-HS such as IL-lp, IL-18, CCL2, CCL4, 
CXCL1, CXCL2, CXCL12 and CX3CL1. Therefore, drugs that target microglial activation 
would halt the cycle of recurrent cytokine secretion and microglial autoactivation that 
causes neuronal damage. Thus they would represent a novel approach fo r treatm ent 
of refractory TLE-HS.
7.1.5 Up regulation of ICAM-1 in TLE-HS
In the present study there was an up regulation of ICAM-1 expression in the
epileptogenic TLE-HS tissue (Figure 5.7). This increase in ICAM-1 expression in TLE-HS
causes leukocyte recruitment and T-lymphocyte infiltration that contributes to the
neurodegeneration and neuroinflammation in TLE-HS. Therefore, targeting ICAM-1
would help in reducing neuroinflammatory response in TLE-HS.
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7.1.6 Dysregulation of AQPs in TLE-HS
The present study demonstrates an altered expression of AQP1, AQP3, AQP4, AQP5 
AQP8, AQP9 and AQP11 in TLE-HS compared to TLE-STG. There was an up regulation of 
AQP1 and AQP4 in the seizure foci tissue (TLE-HS) that seems to play a role in astrocyte 
and epithelial cell water homeostasis (Figure 6.3). There was also an elevation in AQP3 
expression in TLE-HS tissue that is experiencing high frequency seizures (Figure 6.4). 
AQP3 is vital fo r astrocyte and neuronal energy metabolism and its increased 
expression in TLE-HS samples might be a way of coping w ith the massive metabolic 
burden caused by seizures. On the other hand, there was a down regulation in 
neuronal AQPs such as AQP5, AQP8, AQP9 and AQP11 in the TLE-HS tissue (Figure 6.4 - 
6.6). This indicates that there is impairment in the neuronal ion and water homeostasis, 
thus making the neurons more vulnerable to water changes in the TLE-HS tissues. 
Therefore, the selective targeting of the different AQPs may provide new therapeutic 
approaches to TLE-HS epilepsy treatment.
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7.2 Conclusion and future directions
In this thesis, there was an alteration in expression of many genes in the epileptogenic 
TLE-HS specimens compared to TLE-STG and PMC as shown in the summary table 7.1. 
The genes investigated were involved in d ifferent biological processes; some were 
involved in neuronal excitability, neuroinflammation, neuronal and astrocytic energy 
metabolism. Other genes were involved in neurogenesis, apoptosis, intracellular 
calcium and water homeostasis. Furthermore the investigated genes and the 
associated proteins produced that were dysregulated in TLE-HS, were expressed or 
released by neurons, astrocytes, activated microglia and BBB endothelial cells. This 
highlights that TLE-HS pathophysiology is a complex condition that is caused by 
combination of astrocytic, microglial and endothelial cells dysfunction, in addition to 
the neuronal dysfunction. Therefore, developing drugs that address the dysfunction of 
all cells involved in TLE-HS pathophysiology gives hope for anti-epileptogenic drugs 
rather than just anti-seizure drugs. In conclusion, many of dysregulated genes 
identified by this study gave us more insight in TLE-HS pathophysiology and they 
represent potential drug targets for TLE-HS treatment. However, further research is 
needed to understand the temporal and spatial changes of those genes and the ir 
proteins in TLE-HS.
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Tab le  7 .1  S um m ary  o f thesis key find ings on gene and  p ro te in  expression in TLE-HS
Target
TLE-HS mRNA expression TLE-HS protein expression
vs TLE-STG VS PMC vs TLE-STG VS PMC
GABAb1 1 No change 4 t *
g a b aB2 1 ‘ I 1 * t  *
SGK1 t * t * t —
SCN4B 1 * l  * 1 * —
IP3R1 1 * t * — —
SYNPR 4 * t * 1 * —
Target
TLE-HS mRNA expression (MA] TLE-HS mRNA expression (qRT-PCR)
vs TLE-STG vs PMC vs TLE-STG vs PMC
IL-10 t * f  * ■# * ■# *
IL-18 ♦ * ♦ * f  * t  *
Fas ♦ * f  * t ♦ *
ICAM-1 ♦  * ♦  * ♦  * t
CCL2 ♦  * f  * ♦  * ♦  *
CCL4 t  * ♦  * ♦  * ♦  *
CXCL1 t t  * ♦  * t  *
CXCL2 ♦  * ♦  * ♦  * ♦  #
CXCL12 ♦  * ♦  * * ♦  «
CXCR4 f  * ♦  * f  * T  *
CX3CR1 t ♦  * ♦  * ♦  *
AQP1 ♦  * ---- t —
AQP3 t ---- t —
AQP4 f  * ---- —
AQPS 4 ---- 4 —
AQP8 4 ---- 4 —
AQP9 4 ---- 4 —
AQP11 4 ---- L * —
J. Down regulated f  Up regulated —  Not available
* Significant P <0.05
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Appendix II: Regression analysis between the age at death, post-mortem interval and 
GABAb subunits expression:
Linear regression Linear regression
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Appendix III: Suppliers:
Abeam, 330 Cambridge Science Park, Cambridge, CB4 OFL, UK; Agilent Technologies, 
610 Wharfedale Road, IQ Winnersh, Wokingham, Berkshire, RG41 5TP, UK; Applied 
Biosystems, Lingley House, 120 Birchwood Boulevard, Warrington, WA3 7QH, UK; Cell 
Signaling Technology, Inc. 3 Trask Lane, Danvers, MA, 01923, USA; Fisher Scientific 
Inc, Bishop Meadow Rd., Loughborough, Leicestershire, LE11 5RG, UK; Invitrogen, 3 
Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF, UK; LI-COR Biotechnology 
(UK) Ltd, St. John's Innovation Centre, Cowley Road, Cambridge, CB4 OWS, UK; Life 
Technologies Ltd., (Invitrogen, Arcturus) 3 Fountain Drive, Inchinnan Business Park, 
Paisley, PA4 9RF, UK; Merck Millipore® (UK) Limited, Suite 21, Building 6, Croxley 
Green Business Park, Watford, Hertfordshire, WD18 8YH, UK; New England BioLab, 
75-77 Knowl Piece, W ilbury Way, Hitchin, Herts, SG4 OTY, UK; Promega UK Ltd, Delta 
House, Southampton Science Park, Southampton, Hampshire, S016 7NS, UK; QIAGEN 
Ltd, Skelton House, Lloyd Street North, Manchester, M15 6SH, UK; Santa Cruz 
Biotechnology, Inc., Bergheimer Str. 89-2, 69115, Heidelberg, Germany; Sigma-Aldrich, 
The Old Brickyard, New Road, Gillingham, Dorset, SP8 4XT, UK; STARLAB (UK), Ltd, 5 
Tanners Drive, Blakelands, M ilton Keynes, MK14 5BU, UK.
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Appendix IV: Functional Annotation Clustering analysis of both up and down
differentially regulated genes:
Annotation Cluster 1 Enrichment Score: 6.718867155915662
Category Term Count P-Value
SP PIR KEYWORDS signal 97 4.44E-09
SP PIR KEYWORDS disulfide bond 90 4.90E-09
UP SEQ FEATURE signal peptide 97 6.18E-09
UP SEQ FEATURE disulfide bond 87 1.20E-08
UP SEQ FEATURE glycosylation site:N-linked (GlcNAc...) 98 1.72E-04
SP_PIR_KEYWORDS glycoprotein 101 1.76E-04
Annotation Cluster 2 Enrichment Score: 5.9600103646605636
Category Term Count P-Value
SP PIR KEYWORDS signal 97 4.44E-09
UP_SEQ_FEATURE signal peptide 97 6.18E-09
SP_PIR_KEYWORDS Secreted 55 2.51E-06
GOTERM CC FAT G0:0044421~extracellular region part 39 3.49E-06
GOTERM CC FAT G0:0005576~extracellular region 64 4.44E-06
GOTERM MF FAT G0:0005125~cytokine activity 15 1.02E-05
SP PIR KEYWORDS cytokine 14 1.15E-05
GOTERM_CC_FAT G0:0005615~extracellular space 30 1.67E-05
Annotation Cluster 3 Enrichment Score: 5.509099942728049
Category Term Count P-Value
GOTERM BP FAT G0:0006954~inflammatory response 22 8.58E-07
GOTERM BP FAT G0:0006952~defense response 31 1.59E-06
GOTERM_BP_FAT G0:0009611~response to wounding 26 2.18E-05
Annotation Cluster 4 Enrichment Score: 3.785753187273131
Category Term Count P-Value
GOTERM BP FAT G0:0007610~behaviour 27 8.00E-07
GOTERM BP FAT G0:0006954~inflammatory response 22 8.58E-07
SP PIR KEYWORDS inflammation 7 2.79E-06
GOTERM MF FAT G0:0005125~cytokine activity 15 1.02E-05
SP_PIR_KEYWORDS cytokine 14 1.15E-05
KEGG_PATHWAY
hsa04060:Cytokine-cytokine receptor 
interaction 18 1.21E-05
GOTERM CC FAT G0:0005615~extracellular space 30 1.67E-05
PIR_SUPERFAMILY
PIRSF500569:macrophage 
inflammatory protein 1, alpha/beta 
types 4 2.97E-05
SP PIR KEYWORDS inflammatory response 9 4.27E-05
SP PIR KEYWORDS chemotaxis 8 1.96E-04
GOTERM BP FAT G0:0006935~chemotaxis 12 2.17E-04
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GOTERM BP FAT G0:0042330~taxis 12 2.17E-04
INTERPRO
IPR001811:Small chemokine, 
interleukin-8-like 6 6.40E-04
GOTERM BP FAT G0:0007626~locomotory behaviour 15 6.84E-04
INTERPRO
IPR000827:Small chemokine, C-C 
group, conserved site 5 7.99E-04
SMART SM00199:SCY 6 9.42E-04
PIRSUPERFAMILY
PIRSF001950:small inducible 
chemokine, C/CC types 5 9.63E-04
GOTERM MF FAT G0:0008009~chemokine activity 6 0.001292
GOTERM_MF_FAT
G0:0042379~chemokine receptor 
binding 6 0.001721
GOTERM_BP_FAT G0:0006928~cell motion 18 0.008276
GOTERM BP FAT G0:0019079~viral genome replication 3 0.035438
G OTE R M_B P_F AT G0:0019058~viral infectious cycle 4 0.046561
Annotation Cluster 5 Enrichment Score: 2.8189143^197033533
Category Term Count P-Value
G OTE R M_B P_F AT
G0:0007218~neuropeptide signalling 
pathway 10 6.13E-05
INTERPRO
IPR009443:Nuclear pore complex 
interacting 4 9.54E-05
INTERPRO IPR000203:GPS 4 0.0269
SMART SM00303:GPS 4 0.033711
Annotation Cluster 6 Enrichment Score: 2.7386591027193132
Category Term Count P-Value
GOTERMBPFAT
G0:0009991~response to 
extracellular stimulus 16 1.77E-05
GOTERM_BP_FAT
G0:0010033~response to organic 
substance 28 4.89E-04
GOTERM_BP_FAT
G0:0031667~response to nutrient 
levels 12 0.001253
GOTERM BP FAT G0:0007584~response to nutrient 10 0.001302
GOTERM BP FAT G0:0033273~response to vitamin 7 0.001463
GOTERM_BP_FAT
G0:0009725~response to hormone 
stimulus 17 0.001567
GOTERMBPFAT
G0:0009719~response to 
endogenous stimulus 18 0.001678
GOTERM_BP_FAT
G0:0048545~response to steroid 
hormone stimulus 11 0.003416
GOTERM_BP_FAT
G0:0051384~response to 
glucocorticoid stimulus 7 0.003433
GOTERM_BP_FAT
G0:0031960~response to 
corticosteroid stimulus 7 0.005246
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GOTERM_BP_FAT
G0:0043434~response to peptide 
hormone stimulus 9 0.008606
GOTERM_BP_FAT
G0:0043627~response to estrogen 
stimulus 6 0.047747
Annotation Cluster 7 Enrichment Score: 2.653103007394828
Category Term Count P-Value
GOTERM_BP_FAT
G0:0045944~positive regulation of 
transcription from RNA polymerase II 
promoter 20 7.48E-05
GOTERM_BP_FAT
G0:0045893~positive regulation of 
transcription, DNA-dependent 21 6.86E-04
GOTERM_BP_FAT
G0:0051254~positive regulation of 
RNA metabolic process 21 7.68E-04
GOTERM_BP_FAT
G0:0010557~positive regulation of 
macromolecule biosynthetic process 25 0.001337
GOTERM_BP_FAT
G0:0010628~positive regulation of 
gene expression 23 0.001422
GOTERM_BP_FAT
G0:0045941~positive regulation of 
transcription 22 0.002233
GOTERM_BP_FAT
G0:0051173~positive regulation of 
nitrogen compound metabolic 
process 24 0.0024
GOTERM_BP_FAT
G0:0031328~positive regulation of 
cellular biosynthetic process 25 0.002479
GOTERMBPFAT
G0:0009891~positive regulation of 
biosynthetic process 25 0.002967
GOTERM_BP_FAT
G0:0010604~positive regulation of 
macromolecule metabolic process 29 0.002998
GOTERM_BP_FAT
G0:0045935~positive regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process 23 0.003427
GOTERM_BP_FAT
G0:0051094~positive regulation of 
developmental process 13 0.006331
GOTERM_BP_FAT
G0:0045597~positive regulation of 
cell differentiation 11 0.0114
GOTERM_BP_FAT
G0:0006357~regulation of 
transcription from RNA polymerase II 
promoter 22 0.032847
Annotation Cluster 8 Enrichment Score: 2.3801544678193176
Category Term Count P-Value
GOTERM_MF_FAT
G0:0008092~cytoskeletal protein 
binding 20 0.001675
GOTERM MF FAT G0:0003779~actin binding 15 0.002121
GOTERM CC FAT G0:0015629~actin cytoskeleton 13 0.00362
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SP PIR KEYWORDS actin-binding 10 0.023435
Annotation Cluster 9 Enrichment Score: 2.243004058494122
Category Term Count P-Value
GOTERM_BP_FAT
G0:0031032~actomyosin structure 
organization 6 1.55E-04
GOTERM_BP_FAT
G0:0010927~cellular component 
assembly involved in morphogenesis 5 0.004459
GOTERM BP FAT G0:0030239~myofibril assembly 4 0.006774
GOTERM_BP_FAT
G0:0055002~striated muscle cell 
development 5 0.016242
GOTERM_BP_FAT
G0:0055001~muscle cell 
development 5 0.020798
GOTERM_BP_FAT
G0:0048738~cardiac muscle tissue 
development 5 0.022048
Annotation Cluster 10 Enrichment Score: 2.22151090895036
Category Term Count P-Value
GOTERM_BP_FAT
G0:0007178~transmembrane 
receptor protein serine/threonine 
kinase signalling pathway 8 0.00325
GOTERM_BP_FAT
G0:0007179~transforming growth 
factor beta receptor signalling 
pathway 6 0.005287
GOTERM_BP_FAT
G0:0007167~enzyme linked receptor 
protein signalling pathway 14 0.012601
Annotation Cluster 11 Enrichment Score: 2.204384901915561
Category Term Count P-Value
GOTERM_BP_FAT
G0:0044057~regulation of system 
process 16 7.51E-04
GOTERM_BP_FAT
G0:0048168~regulation of neuronal 
synaptic plasticity 5 0.004459
GOTERM BP FAT G0:0007611~learning or memory 8 0.004912
GOTERM_BP_FAT
G0:0051969~regulation of 
transmission of nerve impulse 9 0.006569
GOTERM_BP_FAT
G0:0048167~regulation of synaptic 
plasticity 6 0.006948
GOTERM_BP_FAT
G0:0031644~regulation of 
neurological system process 9 0.008289
GOTERM_BP_FAT
G0:0050804~regulation of synaptic 
transmission 8 0.014272
GOTERM BP FAT G0:0030902~hindbrain development 5 0.026068
Annotation Cluster 12 Enrichment Score: 2.2042064385802975
Category Term Count P-Value
GOTERM CC FAT G0:0031982~vesicle 24 0.00236
GOTERM_CC_FAT G0:0031410~cytoplasmic vesicle 23 0.00297
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GOTERM_CC_FAT
G0:0031988~membrane-bounded
vesicle 20 0.00729
GOTERM_CC_FAT
G0:0016023~cytoplasmic membrane- 
bounded vesicle 19 0.01115
GOTERM CC FAT G0:0030141~secretory granule 9 0.01668
Annotation Cluster 13 Enrichment Score: 2.1989123311431285
Category Term Count P-Value
GOTERM MF FAT G0:0030246~carbohydrate binding 16 0.00179
GOTERM_MF_FAT
G0:0005539~glycosaminoglycan
binding 9 0.00355
GOTERM MF FAT G0:0030247~polysaccharide binding 9 0.00622
GOTERM MF FAT G0:0001871~pattern binding 9 0.00622
GOTERM_MF_FAT G0:0008201~heparin binding 7 0.01012
GOTERM_BP_FAT
G0:0045785~positive regulation of 
cell adhesion 5 0.02608
Annotation Cluster 14 Enrichment Score: 2.1739754579500272
Category Term Count P-Value
GOTERM BP FAT G0:0003012~muscle system process 13 7.85E-05
GOTERM BP FAT G0:0006936~muscle contraction 12 1.47E-04
GOTERM CC FAT G0:0015629~actin cytoskeleton 13 0.00362
GOTERM CC FAT G0:0044449~contractile fibre part 8 0.00433
GOTERM CC FAT G0:0043292~contractile fibre 8 0.00636
GOTERMBPFAT
G0:0006941~striated muscle 
contraction 5 0.01069
SP PIR KEYWORDS muscle protein 5 0.01785
GOTERMBPFAT
G0:0048738~cardiac muscle tissue 
development 5 0.02208
G OTE R M_CC_F AT
G0:0005865~striated muscle thin 
filament 3 0.02929
GOTERM CC FAT G0:0030017~sarcomere 6 0.03235
GOTERM_MF_FAT
G0:0008307~structural constituent of 
muscle 4 0.03837
SP PIR KEYWORDS Cardiomyopathy 4 0.04588
Annotation Cluster 15 Enrichment Score: 2.01211341L42077866
Category Term Count P-Value
GOTERM BP FAT G0:0051591~response to cAMP 6 0.00102
INTERPRO
IPR004827:Basic-leucine zipper (bZIP) 
transcription factor 5 0.01276
SMART SM00338:BRLZ 5 0.01708
UP SEQ FEATURE domain:Leucine-zipper 6 0.03806
Annotation Cluster 16 Enrichment Score: 2.0057516111940923
Category Term Count P-Value
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GOTERM_BP_FAT
G0:0046888~negative regulation of 
hormone secretion 5 0.00131
GOTERM_BP_FAT
G0:0060341~regulation of cellular 
localization 12 0.00727
GOTERM BP FAT G0:0051046~regulation o f secretion 10 0.01417
GOTERM_BP_FAT
G0:0051048~negative regulation of 
secretion 5 0.01953
GOTERM_BP_FAT
G0:0046883~regulation o f hormone 
secretion 5 0.03535
Annotation Cluster 17 Enrichment Score: 1.948891880528446
Category Term Count P-Value
GOTERM BP FAT G0:0007626~locomotory behaviour 15 6.84E-04
GOTERM BP FAT G0:0019725~cellular homeostasis 20 0.00127
GOTERM_BP_FAT
G0:0055082~cellular chemical 
homeostasis 16 0.00557
GOTERM_BP_FAT
G0:0030003~cellular cation 
homeostasis 12 0.00868
GOTERM_BP_FAT
G0:0030005~cellular di-, tri-valent 
inorganic cation homeostasis 11 0.01075
GOTERM BP FAT G0:0006873~cellular ion homeostasis 15 0.01124
GOTERM_BP_FAT G0:0042592~homeostatic process 24 0.01445
GOTERM_BP_FAT
G0:0055066~di-, tri-valent inorganic 
cation homeostasis 11 0.01499
GOTERM BP FAT G0:0048878~chemical homeostasis 18 0.01665
GOTERM BP FAT G0:0055080~cation homeostasis 12 0.01947
GOTERM_BP_FAT
G0:0006874~cellular calcium ion 
homeostasis 9 0.02236
GOTERM BP FAT G0:0050801~ion homeostasis 15 0.02263
GOTERM BP FAT G0:0055074~calcium ion homeostasis 9 0.02579
GOTERM_BP_FAT
G0:0006875~cellular metal ion 
homeostasis 9 0.03167
GOTERM BP FAT G0:0055065~metal ion homeostasis 9 0.03981
Annotation Cluster 18 Enrichment Score: 1.9260615339996585
Category Term Count P-Value
GOTERM_BP_FAT
G0:0032101~regulation of response 
to external stimulus 9 0.01037
GOTERM_BP_FAT
G0:0048585~negative regulation of 
response to stimulus 7 0.01137
GOTERM_BP_FAT
G0:0032102~negative regulation of 
response to external stimulus 5 0.01422
Annotation Cluster 19 Enrichment Score: 1.9099746554025676
Category Term Count P-Value
GOTERM_CC_FAT
G0:0031226~intrinsic to plasma 
membrane 37 0.00206
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GOTERM_CC_FAT G0:0044459~plasma membrane part 58 0.00249
GOTERM_CC_FAT
G0:0005887~integral to plasma 
membrane 35 0.00473
SP PIR KEYWORDS transmembrane protein 20 0.01176
SP PIR KEYWORDS receptor 39 0.01459
UP SEQ FEATURE topological domain:Extracellular 60 0.021956
GOTERM_CC_FAT G0:0005886~plasma membrane 82 0.03896
UP SEQ FEATURE topological domain:Cytoplasmic 70 0.042817
SP PIR KEYWORDS cell membrane 48 0.04356
Annotation Cluster 20 Enrichment Score: 1.8740906263654176
Category Term Count P-Value
GOTERM CC FAT G0:0000267~cell fraction 33 0.003835
GOTERM CC FAT G0:0005624~membrane fraction 24 0.020742
GOTERM_CC_FAT GQ:0005626~insoluble fraction 24 0.030003
Annotation Cluster 21 Enrichment Score: 1.8540373271456263
Category Term Count P-Value
GOTERM_MF_FAT
G0:0022838~substrate specific 
channel activity 16 0.005108
GOTERM MF FAT G0:0015267~channel activity 16 0.006951
GOTERM_MF_FAT
G0:0022803~passive transmembrane 
transporter activity 16 0.007114
GOTERM MF FAT G0:0005216~ion channel activity 14 0.020878
SP PIR KEYWORDS ion transport 17 0.034047
SP PIR KEYWORDS ionic channel 11 0.041838
Annotation Cluster 22 Enrichment Score: 1.8385165551147895
Category Term Count P-Value
GOTERM_BP_FAT
G0:0048754~branching 
morphogenesis of a tube 6 0.007415
GOTERM_BP_FAT
G0:0001763~morphogenesis of a 
branching structure 6 0.012631
GOTERM BP FAT GQ:0035239~tube morphogenesis 7 0.032577
Annotation Cluster 23 Enrichment Score: 1.8029687642885472
Category Term Count P-Value
GOTERM_BP_FAT
G0:0010035~response to inorganic 
substance 11 0.005412
GOTERM_BP_FAT
G0:0000302~response to reactive 
oxygen species 6 0.013332
GOTERM_BP_FAT
G0:0034614~cellular response to 
reactive oxygen species 4 0.018276
GOTERM_BP_FAT
G0:0034599~cellular response to 
oxidative stress 4 0.046561
Annotation Cluster 24 Enrichment Score: 1.7646634444180525
Category Term Count P-Value
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INTERPRO IPR013151:lmmunoglobulin 10 0.008101
INTERPRO IPR003598:lmmunoglobulin subtype 2 10 0.008883
INTERPRO IPR003599:lmmunoglobulin subtype 13 0.011646
SP PIR KEYWORDS Immunoglobulin domain 16 0.012886
INTERPRO IPR013783:lmmunoglobulin-like fold 18 0.014611
SMART SM00408:IGc2 10 0.014824
SMART SM00409:IG 13 0.021059
INTERPRO IPR007110:lmmunoglobulin-like 16 0.025599
UP_SEQ_FEATURE domain:lg-like C2-type 1 8 0.041802
UP SEQ FEATURE domain:lg-like C2-type 2 8 0.042801
Annotation Cluster 25 Enrichment Score: 1.7469534 14787051
Category Term Count P-Value
SP PIR KEYWORDS postsynaptic cell membrane 7 0.010372
GOTERM CC FAT G0:0045211~postsynaptic membrane 8 0.011308
GOTERM CC FAT G0:0030054~cell junction 16 0.048969
Annotation Cluster 26 Enrichment Score: 1.6895442:L29153926
Category Term Count P-Value
GOTERM CC FAT G0:0000323~lytic vacuole 10 0.014577
GOTERM CC FAT G0:0005764~lysosome 10 0.014577
GOTERM CC FAT G0:0005773~vacuole 10 0.040181
Annotation Cluster 27 Enrichment Score: 1.6785307237329645
Category Term Count P-Value
GOTERM BP FAT G0:0051726~regulation of cell cycle 15 0.004006
GOTERM_BP_FAT
G0:0042325~regulation of 
phosphorylation 17 0.014868
GOTERMBPFAT
G0:0019220~regulation o f phosphate 
metabolic process 17 0.020987
GOTERM_BP_FAT
G0:0051174~regulation of 
phosphorus metabolic process 17 0.020987
GOTERM BP FAT G0:0007243~protein kinase cascade 14 0.022755
GOTERM_BP_FAT
G0:0045860~positive regulation of 
protein kinase activity 10 0.025141
GOTERMBPFAT
G0:0033674~positive regulation of 
kinase activity 10 0.030589
GOTERM_BP_FAT
G0:0051347~positive regulation of 
transferase activity 10 0.037925
GOTERM_BP_FAT
G0:0001932~regulation o f protein 
amino acid phosphorylation 8 0.044919
Annotation Cluster 28 Enrichment Score: 1.5955104866674612
Category Term Count P-Value
GOTERM_BP_FAT
G0:0001568~blood vessel 
development 11 0.017467
GOTERM_BP_FAT G0:0001944~vasculature 11 0.020372
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development
GOTERM_BP_FAT
G0:0048514~blood vessel 
morphogenesis 9 0.045942
Annotation Cluster 29 Enrichment Score: 1.5808777697129992
Category Term Count P-Value
BIOCARTA
h_bbcellPathway: Bystander B Cell 
Activation 3 0.015545
KEGG_PATHWAY hsa05330:Allograft rejection 4 0.033818
BIOCARTA
h_asbcellPathway: Antigen 
Dependent B Cell Activation 3 0.034406
Annotation Cluster 30 Enrichment Score: 1.560897193242292
Category Term Count P-Value
GOTERMBPFAT
G0:0002521~leukocyte
differentiation 8 0.011799
GOTERM_BP_FAT G0:0045321~leukocyte activation 10 0.039338
GOTERM BP FAT G0:0001775~cell activation 11 0.044736
Annotation Cluster 31 Enrichment Score: 1.5248021584253257
Category Term Count P-Value
G OTE R M_B P_F AT
G0:0019319~hexose biosynthetic 
process 4 0.019959
GOTERM_BP_FAT
G0:0006006~glucose metabolic 
process 8 0.025436
GOTERM_BP_FAT
G0:0046364~monosaccharide 
biosynthetic process 4 0.031795
GOTERMBPFAT
G0:0046165~alcohol biosynthetic 
process 4 0.049299
Annotation Cluster 32 Enrichment Score: 1.47270301L20557136
Category Term Count P-Value
GOTERM_BP_FAT
G0:0051249~regulation of 
lymphocyte activation 8 0.02168
GOTERM_BP_FAT
G0:0002694~regulation of leukocyte 
activation 8 0.037228
GOTERM_BP_FAT
G0:0050865~regulation of cell 
activation 8 0.047311
Annotation Cluster 33 Enrichment Score: 1.466199596760949
Category Term Count P-Value
GOTERM_BP_FAT
G0:0043065~positive regulation of 
apoptosis 15 0.03288
GOTERM_BP_FAT
G0:0043068~positive regulation of 
programmed cell death 15 0.034281
GOTERM_BP_FAT
G0:0010942~positive regulation of 
cell death 15 0.035433
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Annotation Cluster 34 Enrichment Score: 1.3847563772782288
Category Term Count P-Value
KEGG_PATHWAY hsa05330:Allograft rejection 4 0.033818
KEGG PATHWAY hsa05332:Graft-versus-host disease 4 0.04149
KEGG_PATHWAY hsa04940:Type 1 diabetes mellitus 4 0.049962
Appendix V: Functional Annotation Clustering analysis of up regulated genes:
Annotation Cluster 1 Enrichment Score: 7.48
Category Term Count P Value
SP PIR KEYWORDS signal 82 4.21E-12
UP SEQ FEATURE signal peptide 82 5.88E-12
SP PIR KEYWORDS disulfide bond 72 5.60E-10
UP SEQ FEATURE disulfide bond 70 1.02E-09
SP PIR KEYWORDS Secreted 50 2.25E-09
GOTERM CC FAT G0:0005576~extracellular region 58 3.76E-09
GOTERM CC FAT G0:0044421~extracellular region part 37 6.99E-09
GOTERM CC FAT G0:0005615~extracellular space 28 2.73E-07
UP SEQ FEATURE glycosylation site:N-linked (GlcNAc...) 74 1.15E-04
SP PIR KEYWORDS glycoprotein 76 1.29E-04
UP SEQ FEATURE topological domain:Cytoplasmic 54 0.01577
Annotation Cluster 2 Enrichment Score: 4.12
Category Term Count P Value
GOTERM BP FAT G0:0006952~defense response 27 2.55E-07
GOTERM BP FAT G0:0006954~inflammatory response 19 4.62E-07
GOTERM BP FAT G0:0009611~response to wounding 23 3.13E-06
SP PIR KEYWORDS inflammatory response 9 3.36E-06
GOTERM BP FAT G0:0007610~behaviour 21 6.08E-06
KEGG PATHWAY
hsa04060:Cytokine-cytokine receptor 
interaction
16 7.48E-06
GOTERM MF FAT G0:0005125~cytokine activity 13 8.07E-06
SP_PIR_KEYWORDS inflammation 6 9.40E-06
SP_PIR_KEYWORDS cytokine 12 1.01E-05
PIR_SUPERFAMILY
PIRSF500569:macrophage 
inflammatory protein 1, alpha/beta 
types
4 1.23E-05
INTERPRO
IPR001811:Small chemokine, 
interleukin-8-like
6 1.31E-04
SMART SM00199:SCY 6 1.56E-04
SP_PIR_KEYWORDS chemotaxis 7 2.01E-04
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INTERPRO
IPR000827:Small chemokine, C-C 
group, conserved site
5 2.17E-04
GOTERM_MF_FAT G0:0008009~chemokine activity 6 2.97E-04
PIRSUPERFAMILY
PIRSF001950:small inducible 
chemokine, C/CC types
5 3.18E-04
G OTE R M_B P_F AT G0:0042330~taxis 10 3.38E-04
GOTERM_BP_FAT G0:0006935~chemotaxis 10 3.38E-04
G OTE R M_M F_F AT
G0:0042379~chemokine receptor 
binding
6 4.00E-04
GOTERM_BP_FAT G0:0006928~cell motion 16 0.00213
G OTE R M_B P_F AT G0:0007626~locomotory behaviour 10 0.01274
GOTERM_BP_FAT G0:0019079~viral genome replication 3 0.01948
G OTE R M_B P_F AT G0:0019058~viral infectious cycle 4 0.02051
Annotation Cluster 3 Enrichment Score: 3.29
Category Term Count P Value
G OTE R M_B P_F AT
G0:0009991~response to extracellular 
stimulus
14 9.74E-06
GOTERM_BP_FAT
G0:0010033~response to organic 
substance
25 4.39E-05
GOTERM_BP_FAT
G0:0009725~response to hormone 
stimulus
16 1.49E-04
GOTERM_BP_FAT G0:0033273~response to vitamin 7 2.69E-04
GOTERM_BP_FAT
G0:0048545~response to steroid 
hormone stimulus
11 2.97E-04
GOTERMBPFAT
G0:0031667~response to nutrient 
levels
11 3.64E-04
GOTERM_BP_FAT
G0:0009719~response to endogenous 
stimulus
16 4.28E-04
GOTERM_BP_FAT G0:0007584~response to nutrient 9 6.52E-04
GOTERM_BP_FAT
G0:0051384~response to 
glucocorticoid stimulus
7 6.66E-04
GOTERM_BP_FAT
G0:0031960~response to 
corticosteroid stimulus
7 0.00105
GOTERM_BP_FAT
G0:0043434~response to peptide 
hormone stimulus
9 0.00121
GOTERM_BP_FAT G0:0043627~response to stimulus 6 0.01427
GOTERM_BP_FAT
G0:0032570~response to 
progesterone stimulus
3 0.02977
Annotation Cluster 4 Enrichment Score: 2.64
Category Term Count P Value
GOTERM_BP_FAT
G0:0009628~response to abiotic 
stimulus
15 5.11E-04
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GOTERM_BP_FAT
G0:0009612~response to mechanical 
stimulus
6 9.60E-04
GOTERMBPFAT
G0:0014070~response to organic cyclic 
substance
7 0.00617
GOTERMBPFAT G0:0042493~response to drug 9 0.00946
Annotation Cluster 5 Enrichment Score: 2.54
Category Term Count P Value
SP_PIR_KEYWORDS cleavage on pair of basic residues 13 9.07E-05
GOTERM_BP_FAT
G0:0007218~neuropeptide signalling 
pathway
7 0.00167
GOTERM_MF_FAT G0:0005179~hormone activity 6 0.01278
GOTERM_MF_FAT
G0:0005184~neuropeptide hormone 
activity
3 0.03487
Annotation Cluster 6 Enrichment Score: 2.53
Category Term Count P Value
GOTERM_MF_FAT G0:0030246~carbohydrate binding 14 6.59E-04
GOTERM_MF_FAT
G0:0005539~glycosaminoglycan
binding
8 0.00221
GOTERM_MF_FAT G0:0030247~polysaccharide binding 8 0.00376
GOTERM_MF_FAT G0:0001871~pattern binding 8 0.00376
G OTE R M_M F_F AT G0:0008201~heparin binding 6 0.01056
Annotation Cluster 7 Enrichment Score: 2.32
Category Term Count P Value
BIOCARTA
h_Ccr5Pathway:Pertussis toxin- 
insensitive CCR5 Signalling in 
Macrophage
5 1.01E-04
GOTERMBPFAT
G0:0007179~transforming growth 
factor beta receptor signalling pathway
5 0.00893
GOTERM_BP_FAT
G0:0007178~transmembrane receptor 
protein serine/threonine kinase 
signalling pathway
6 0.01322
GOTERM_BP_FAT
G0:0007167~enzyme linked receptor 
protein signalling pathway
10 0.04433
Annotation Cluster 8 Enrichment Score: 2.32
Category Term Count P Value
GOTERM_CC_FAT G0:0031982~vesicle 20 0.00128
G OTE R M_CC_F AT G0:0031410~cytoplasmic vesicle 19 0.00196
GOTERM_CC_FAT
G0:0031988~membrane-bounded
vesicle
16 0.00791
GOTERM_CC_FAT G0:0030141~secretory granule 8 0.0097
G OTE R M_CC_F AT
G0:0016023~cytoplasmic membrane- 
bounded vesicle
15 0.0137
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Annotation Cluster 9 Enrichment Score: 2.16
Category Term Count P Value
GOTERM_BP_FAT
G0:0045944~positive regulation of 
transcription from RNA polymerase II 
promoter
15 5.54E-04
GOTERM_BP_FAT
G0:0045597~positive regulation of cell 
differentiation 10
0.00413
GOTERM_BP_FAT
G0:0051094~positive regulation of 
developmental process
11 0.00476
GOTERM_BP_FAT
G0:0045893~positive regulation of 
transcription, DNA-dependent
15 0.00566
GOTERM_BP_FAT
G0:0010628~positive regulation of 
gene expression
17 0.00582
GOTERM_BP_FAT
G0:0051254~positive regulation of 
RNA metabolic process
15 0.00608
GOTERM_BP_FAT
G0:0010604~positive regulation of 
macromolecule metabolic process
22 0.00635
GOTERM_BP_FAT
G0:0051173~positive regulation of 
nitrogen compound metabolic process
18 0.00683
GOTERM_BP_FAT
G0:0010557~positive regulation of 
macromolecule biosynthetic process
18 0.00791
GOTERM_BP_FAT
G0:0045941~positive regulation of 
transcription
16 0.01015
GOTERMBPFAT
G0:0045935~positive regulation of 
nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process
17 0.01115
GOTERMBPFAT
G0:0031328~positive regulation of 
cellular biosynthetic process
18 0.01217
GOTERM_BP_FAT
G0:0009891~positive regulation of 
biosynthetic process
18 0.01387
G OTE R M_M F_F AT
G0:0043566~structure-specific DNA 
binding
6 0.0393
Annotation Cluster 10 Enrichment Score: 2.08
Category Term Count P Value
GOTERM_BP_FAT
G0:0009612~response to mechanical 
stimulus
6 9.60E-04
INTERPRO
IPR004827:Basic-leucine zipper (bZIP) 
transcription factor
5 0.00386
SMART SM00338:BRLZ 5 0.00444
UP_SEQ_FEATURE domain:Leucine-zipper 6 0.00993
UP_SEQ_FEATURE DNA-binding region:Basic m otif 7 0.01238
GOTERM_MF_FAT
G0:0043566~structure-specific DNA 
binding
6 0.0393
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Annotation Cluster 11 Enrichment Score: 1.98
Category Term Count P Value
GOTERM_BP_FAT G0:0019725~cellular homeostasis 16 0.00177
G OTE R M_B P_F AT G0:0042592~homeostatic process 20 0.00673
GOTERM_BP_FAT
G0:0055082~cellular chemical 
homeostasis
12 0.01492
GOTERM_BP_FAT G0:0048878~chemical homeostasis 14 0.02279
GOTERM_BP_FAT G0:0006873~cellular ion homeostasis 11 0.03198
Annotation Cluster 12 Enrichment Score: 1.89
Category Term Count P Value
GOTERM_BP_FAT
G0:0002673~regulation of acute 
inflammatory response
4 0.00275
GOTERM_BP_FAT
G0:0050727~regulation of 
inflammatory response
5 0.01989
GOTERM_BP_FAT G0:0045087~innate immune response 6 0.04024
Annotation Cluster 13 Enrichment Score: 1.83
Category Term Count P Value
GOTERM_BP_FAT G0:0002521~leukocyte differentiation 8 0.00208
GOTERM_BP_FAT G0:0030097~hemopoiesis 9 0.0155
GOTERM_BP_FAT G0:0001775~cell activation 10 0.01672
GOTERM_BP_FAT G0:0045321~leukocyte activation 9 0.01776
GOTERM_BP_FAT G0:0046649~lymphocyte activation 8 0.01905
GOTERMBPFAT
G0:0048534~hemopoietic or lymphoid 
organ development
9 0.02591
GOTERMBPFAT
G0:0002520~immune system 
development
9 0.03513
Annotation Cluster 14 Enrichment Score: 1.82
Category Term Count P Value
GOTERM_CC_FAT
G0:0031226~intrinsic to plasma 
membrane
27 0.00873
G OTE R M_CC_F AT
G0:0005887~integral to plasma 
membrane
26 0.01233
UP_SEQ_FEATURE topological domain:Cytoplasmic 54 0.01577
UP_SEQ_FEATURE topological domain:Extracellular 45 0.01772
SP_PIR_KEYWORDS receptor 29 0.01934
SP_PIR_KEYWORDS transmembrane protein 15 0.01988
Annotation Cluster 15 Enrichment Score: 1.80
Category Term Count P Value
GOTERM_BP_FAT
G0:0001568~blood vessel 
development
10 0.00636
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GOTERM_BP_FAT G0:0001944~vasculature development 10 0.00743
GOTERM_BP_FAT
G0:0048754~branching 
morphogenesis of a tube
5 0.01177
G OTE R M_B P_F AT G0:0001525~angiogenesis 7 0.01571
GOTERMBPFAT
G0:0001763~morphogenesis of a 
branching structure
5 0.01822
G OTE R M B  P_F AT
G0:0048514~blood vessel 
morphogenesis
8 0.0254
GOTERM_BP_FAT G0:0035239~tube morphogenesis 6 0.02967
GOTERM_BP_FAT
G0:0007389~pattern specification 
process
9 0.02971
Annotation Cluster 16 Enrichment Score: 1.68
Category Term Count P Value
INTERPRO IPR013151:lmmunoglobulin 8 0.01173
INTERPRO IPR003598:lmmunoglobulin subtype 2 8 0.01264
SMART SM00408:IGc2 8 0.0152
INTERPRO IPR013783:lmmunoglobulin-like fold 14 0.01755
SP_PIR_KEYWORDS Immunoglobulin domain 12 0.02352
INTERPRO IPR007110:lmmunoglobulin-like 12 0.04158
INTERPRO IPR003599:lmmunoglobulin subtype 9 0.04844
Annotation Cluster 17 Enrichment Score: 1.67
Category Term Count P Value
GOTERMBPFAT
G0:0019319~hexose biosynthetic 
process
4 0.00841
G OTE R M B  P_F AT
G0:0046364~monosaccharide 
biosynthetic process
4 0.0137
GOTERM_BP_FAT
G0:0006006~glucose metabolic 
process
7 0.01811
GOTERM_BP_FAT
G0:0046165~alcohol biosynthetic 
process
4 0.0218
GOTERM_BP_FAT G0:0006094~gluconeogenesis 3 0.04498
GOTERM_BP_FAT
G0:0019318~hexose metabolic 
process
7 0.0475
Annotation Cluster 18 Enrichment Score: 1.65
Category Term Count P Value
GOTERM_BP_FAT
G0:0051249~regulation of lymphocyte 
activation
8 0.00411
GOTERM_BP_FAT
G0:0002694~regulation of leukocyte 
activation
8 0.00758
GOTERM_BP_FAT
G0:0050865~regulation of cell 
activation
8 0.00997
GOTERM_BP_FAT
G0:0050670~regulation of lymphocyte 
proliferation
5 0.0265
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GOTERM_BP_FAT
G0:0070663~regulation of leukocyte 
proliferation
5 0.02754
GOTERM_BP_FAT
G0:0032944~regulation of 
mononuclear cell proliferation
5 0.02754
GOTERM_BP_FAT
G0:0050671~positive regulation of 
lymphocyte proliferation
4 0.03878
GOTERM_BP_FAT
G0:0032946~positive regulation of 
mononuclear cell proliferation
4 0.04057
GOTERM_BP_FAT
G0:0070665~positive regulation of 
leukocyte proliferation
4 0.04057
GOTERM_BP_FAT
G0:0051251~positive regulation of 
lymphocyte activation
5 0.04326
GOTERM_BP_FAT
G0:0002684~positive regulation of 
immune system process
8 0.04424
Annotation Cluster 19 Enrichment Score: 1.64
Category Term Count P Value
BIOCARTA
h_bbcell Pathway:Bystander B Cell 
Activation
3 0.00954
KEGG_PATHWAY hsa05330:Allograft rejection 4 0.01724
KEGG_PATHWAY hsa05332:Graft-versus-host disease 4 0.02136
BIOCARTA
h_asbcell Pathway:Antigen Dependent 
B Cell Activation
3 0.02143
GOTERM_CC_FAT
G0:0009897~extemal side of plasma 
membrane
7 0.02473
KEGG_PATHWAY hsa04940:Type 1 diabetes mellitus 4 0.02597
KEGG_PATHWAY
hsa04672:lntestinal immune network 
for IgA production
4 0.03863
KEGG_PATHWAY hsa05320:Autoimmune thyroid disease 4 0.04273
Annotation Cluster 20 Enrichment Score: 1.55
Category Term Count P Value
GOTERM_CC_FAT G0:0005764~lysosome 8 0.02148
G OTE R M_CC_F AT G0:0000323~lytic vacuole 8 0.02148
GOTERM CC FAT G0:0005773~vacuole 8 0.04882
Annotation Cluster 21 Enrichment Score: 1.46
Category Term Count P Value
G OTE R M_B P_F AT
G0:0043065~positive regulation of 
apoptosis
12 0.0332
GOTERM_BP_FAT
G0:0043068~positive regulation of 
programmed cell death
12 0.03465
GOTERM_BP_FAT
G0:0010942~positive regulation of cell 
death
12 0.03565
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Appendix VI: Functional Annotation Clustering analysis of down regulated genes:
Annotation Cluster 1 Enrichment Score: 2.85
Category Term Count P Value
GOTERM MF FAT G0:0005516~calmodulin binding 9 4.0E-07
SP PIR KEYWORDS calmodulin-binding 7 2.9E-05
SP PIR KEYWORDS actin binding 5 4.5E-05
GOTERM_BP_FAT
G0:0031032~actomyosin structure 
organization 4 4.0E-04
G OTE R M_M F_F AT
G0:0008092~cytoskeletal protein 
binding 10 7.7E-04
GOTERM MF FAT G0:0003779~actin binding 8 1.1E-03
GOTERM CC FAT G0:0015629~actin cytoskeleton 7 2.0E-03
SP PIR KEYWORDS actin-binding 6 7.6E-03
GOTERM CC FAT G0:0005856~cytoskeleton 14 1.6E-02
G OTE R M_B P_F AT
G0:0030036~actin cytoskeleton 
organization 5 3.0E-02
GOTERM_BP_FAT
G0:0030029~actin filament-based 
process 5 3.6E-02
GOTERM_BP_FAT
G0:0044087~regulation of cellular 
component biogenesis 4 3.7E-02
INTERPRO IPR001715:Calponin-like actin-binding 3 4.8E-02
Annotation Cluster 2 Enrichment Score: 2.67
Category Term Count P Value
INTERPRO
IPR009443:Nuclear pore complex 
interacting 4 2.4E-06
INTERPRO IPR001024:Lipoxygenase, LH2 3 6.3E-03
SMART SM00308:LH2 3 9.1E-03
INTERPRO IPR000203:GPS 3 1.5E-02
SMART SM00303:GPS 3 2.2E-02
Annotation Cluster 3 Enrichment Score: 2.50
Category Term Count P Value
GOTERM CC FAT G0:0045211~postsynaptic membrane 6 5.2E-04
GOTERM CC FAT G0:0030054~cell junction 10 9.2E-04
GOTERM CC FAT G0:0044456~synapse part 7 1.3E-03
SP PIR KEYWORDS postsynaptic cell membrane 5 2.2E-03
SP PIR KEYWORDS cell junction 8 3.6E-03
SP PIR KEYWORDS synapse 6 4.1E-03
GOTERM CC FAT G0:0014069~postsynaptic density 4 5.1E-03
GOTERM CC FAT G0:0045202~synapse 7 7.9E-03
GOTERM CC FAT G0:0030425~dendrite 5 8.5E-03
GOTERM_CC_FAT G0:0043197~dendritic spine 3 1.5E-02
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Annotation Cluster 4 Enrichment Score: 2.40
Category Term Count P Value
GOTERM CC FAT G0:0015629~actin cytoskeleton 7 0.0020
GOTERM CC FAT G0:0044449~contractile fibre part 5 0.0023
GOTERM CC FAT G0:0043292~contractile fibre 5 0.0030
SP PIR KEYWORDS muscle protein 4 0.0033
GOTERM BP FAT G0:0006936~muscle contraction 5 0.0081
GOTERM_BP_FAT G0:0003012~muscle system process 5 0.0111
Annotation Cluster 5 Enrichment Score: 2.15
Category Term Count P Value
GOTERM MF FAT G0:0005516~calmodulin binding 9 4.0E-07
GOTERM MF FAT G0:0022836~gated channel activity 8 8.0E-04
GOTERM_BP_FAT G0:0006816~calcium ion transport 6 8.3E-04
SP PIR KEYWORDS ionic channel 8 1.0E-03
GOTERM_BP_FAT
G0:0044057~regulation o f system 
process 8 1.1E-03
G OTE R M_M F_F AT
G0:0046873~metal ion 
transmembrane transporter activity 8 1.1E-03
GOTERM BP FAT G0:0006811~ion transport 12 1.8E-03
GOTERM_BP_FAT
G0:0015674~di-, tri-valent inorganic 
cation transport 6 2.2E-03
SP PIR KEYWORDS ion transport 10 2.2E-03
GOTERM_BP_FAT G0:0030001~metal ion transport 9 2.7E-03
GOTERM MF FAT G0:0005216~ion channel activity 8 2.8E-03
GOTERMMFFAT
G0:0022838~substrate specific 
channel activity 8 3.3E-03
GOTERM MF FAT G0:0015267~channel activity 8 4.0E-03
G OTE R M_M F_F AT
G0:0022803~passive transmembrane 
transporter activity 8 4.1E-03
KEGG PATHWAY hsa04020:Calcium signaling pathway 5 6.2E-03
G OTE R M_M F_F AT G0:0005262~calcium channel activity 4 6.9E-03
GOTERM BP FAT G0:0006812~cation transport 9 7.5E-03
GOTERM CC FAT G0:0034704~calcium channel complex 3 7.8E-03
GOTERM CC FAT G0:0030425~dendrite 5 8.5E-03
SP PIR KEYWORDS calcium transport 4 8.6E-03
GOTERM_BP_FAT
G0:0043062~extracellular structure 
organization 5 1.0E-02
GOTERM_MF_FAT G0:0005261~cation channel activity 6 1.1E-02
GOTERM_BP_FAT
G0:0022037~metencephalon
development 3 1.4E-02
GOTERM CC FAT G0:0034702~ion channel complex 5 1.8E-02
GOTERM_MF_FAT
G0:0022834~ligand-gated channel 
activity 4 2.5E-02
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GOTERM_MF_FAT
G0:0015276~ligand-gated ion channel 
activity 4 2.5E-02
G OTE R M_CC_F AT G0:0034703~cation channel complex 4 2.7E-02
GOTERM_BP_FAT
G0:0050804~regulation o f synaptic 
transmission 4 3.3E-02
GOTERM_MF_FAT G0:0022843~voltage-gated cation 
channel activity 4 3.6E-02
SP_PIR_KEYWORDS calcium channel 3 3.7E-02
SP_PIR_KEYWORDS voltage-gated channel 4 3.8E-02
GOTERM_BP_FAT G0:0030902~hindbrain development 3 3.9E-02
GOTERM_BP_FAT
G0:0060341~regulation o f cellular 
localization 5 3.9E-02
GOTERM_BP_FAT G0:0050808~synapse organization 3 4.0E-02
GOTERM_BP_FAT
G0:0051969~regulation of 
transmission of nerve impulse 4 4.1E-02
GOTERM_BP_FAT G0:0050905~neuromuscular process 3 4.1E-02
GOTERM_BP_FAT
G0:0048167~regulation of synaptic 
plasticity 3 4.3E-02
GOTERM_BP_FAT
G0:0031644~regulation of 
neurological system process 4 4.5E-02
G OTE R M_M F_F AT
G0:0005230~extracellular ligand-gated 
ion channel activity 3 4.9E-02
Annotation Cluster 6 Enrichment Score: 1.55
Category Term Count P Value
GOTERMBPFAT
G0:0007517~muscle organ 
development 5 0.0237
GOTERMBPFAT
G0:0014706~striated muscle tissue 
development 4 0.0237
GOTERM_BP_FAT
G0:0042692~muscle cell 
differentiation 4 0.0248
GOTERM_BP_FAT
G0:0060537~muscle tissue 
development 4 0.0269
GOTERM_BP_FAT
G0:0055002~striated muscle cell 
development 3 0.0296
GOTERM_BP_FAT G0:0055001~muscle cell development 3 0.0340
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